var title_f36_42_37536="Unraveled suture material";
var content_f36_42_37536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of unraveled suture material in a patient with a gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unraveled suture material associated with marginal ulceration after gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher S Huang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37536=[""].join("\n");
var outline_f36_42_37536=null;
var title_f36_42_37537="External rotation for shoulder reduction";
var content_f36_42_37537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External rotation technique for reduction of anterior shoulder dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the patient's arm adducted and the elbow flexed, the forearm is slowly and gently externally rotated. If pain or spasm is felt, the physician stops and allows the patient to relax. No longitudinal traction is necessary. In most cases, by the time the shoulder is fully externally rotated, the shoulder will have been reduced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott C Sherman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37537=[""].join("\n");
var outline_f36_42_37537=null;
var title_f36_42_37538="Urothelial CIS G";
var content_f36_42_37538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37538=[""].join("\n");
var outline_f36_42_37538=null;
var title_f36_42_37539="Generalized morphea - legs";
var content_f36_42_37539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68904%7EDERM%2F56113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68904%7EDERM%2F56113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized morphea on the legs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symmetric, hypopigmented, sclerotic plaques are present on the legs of this patient with generalized morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized morphea on the trunk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isomorphic, hyperpigmented, sclerotic plaques are present on the chest and abdomen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37539=[""].join("\n");
var outline_f36_42_37539=null;
var title_f36_42_37540="Trocar placement";
var content_f36_42_37540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Placement of laparoscopic trocars",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37540=[""].join("\n");
var outline_f36_42_37540=null;
var title_f36_42_37541="Rifampin (rifampicin): Patient drug information";
var content_f36_42_37541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rifampin (rifampicin): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     see \"Rifampin (rifampicin): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     see \"Rifampin (rifampicin): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rifadin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rifadin&reg;;",
"     </li>",
"     <li>",
"      Rofact&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692116",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis) and stop the spread of TB in those who carry the bacteria but are not sick with the disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rifampin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids to orange.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A long-lasting change in color of contact lenses. Do not wear contacts while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3654108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 28 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11184 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37541=[""].join("\n");
var outline_f36_42_37541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218187\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218188\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028254\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028256\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028255\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028260\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028261\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028263\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028258\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028259\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028264\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028265\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=related_link\">",
"      Rifampin (rifampicin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=related_link\">",
"      Rifampin (rifampicin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_42_37542="Pentazocine and acetaminophen: Drug information";
var content_f36_42_37542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentazocine and acetaminophen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/11/18613?source=see_link\">",
"    see \"Pentazocine and acetaminophen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13114311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid);",
"     </li>",
"     <li>",
"      Analgesic, Opioid Partial Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Maximum daily intake of acetaminophen from all sources should not exceed 4 g.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     Oral: One caplet (pentazocine 25 mg/acetaminophen 650 mg) every 4 hours as needed (maximum: 6 caplets/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12742888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; may be more sensitive to analgesic and sedative effects.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12742898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Manufacturer labeling does not provide specific dosing recommendations; less frequent administration may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12742899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Manufacturer labeling does not provide specific dosing recommendations; less frequent administration may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Pentazocine 25 mg and acetaminophen 650 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F208124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of mild-to-moderate pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Talacen may be confused with Timoptic&reg;, Tinactin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions attributed to pentazocine 50 mg. Frequency not defined. See Acetaminophen monograph for acetaminophen-related reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory depression, facial edema, flushing, hyper-/hypotension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills,  confusion, depression, disorientation, dizziness, drowsiness, euphoria, excitement,  hallucinations, headache, insomnia, intracranial pressure increased, irritability, lightheadedness, nightmares, sedation, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, erythema multiforme, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, anorexia, biliary spasm, constipation, diarrhea, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, WBCs decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, physical and psychological dependence, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentazocine, acetaminophen, or any component of the formulation; hypersensitivity to sulfites (contains metabisulfite)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Confusion, disorientation, and visual hallucinations have occurred in some patients, but usually clears within a few hours; observe patients closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, cholecystitis; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bowel disease: Use with caution in patients with inflammatory or obstructive bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution in patients with acute MI or MI with nausea/vomiting; hypertension may occur with pentazocine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with a history of porphyria; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture, especially when combined with medications that have anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Effects may be potentiated when used with other sedatives, including narcotics or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedatives, including narcotics or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Pentazocine clearance may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: May contain sodium metabisulfite; may cause allergic-type reactions including anaphylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms; taper dose to decrease risk of withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F208109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F208105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentazocine and acetaminophen enter breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F208106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5221787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pentazocine-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-650 mg (100): $113.56",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pentazocine: Agonist of kappa opiate receptors and partial agonist of mu opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces analgesia, respiratory depression and sedation similar to opioids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen: Inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/42/37542/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10258 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37542=[""].join("\n");
var outline_f36_42_37542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114311\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208122\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208113\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12742888\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208114\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12742898\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12742899\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208100\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208085\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208124\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208101\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208130\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208120\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208104\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208089\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299847\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222220\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208109\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208095\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208105\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208116\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208106\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5221787\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208088\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208103\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/11/18613?source=related_link\">",
"      Pentazocine and acetaminophen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_42_37543="Congenital anomalies of the larynx";
var content_f36_42_37543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital anomalies of the larynx",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37543/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37543/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37543/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37543/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/42/37543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies are the product of errors in embryogenesis (malformations) or the result of intrauterine events that affect embryonic and fetal growth (deformations and disruptions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/1\">",
"     1",
"    </a>",
"    ]. The more complex the formation of a structure, the more opportunities for malformation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Defects in the formation and growth of the larynx lead to a variety of malformations. The embryology, clinical features, and management of congenital anomalies of the larynx are reviewed here. Congenital anomalies of the intrathoracic airways are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of a median pharyngeal groove presages the appearance of the respiratory tract. At approximately 25 days of intrauterine life, the anlagen of the larynx, trachea, bronchi, and lungs arise from a ventromedial diverticulum of the foregut called the tracheobronchial groove. The cartilage of the trachea and connective tissue and muscle of the trachea and esophagus are derived from splanchnic mesenchyme. Lateral furrows develop on each side of the ventromedial diverticulum, deepen, and join to form the tracheoesophageal septum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distal esophagus can be distinguished from the stomach and the laryngeal primordia appear at approximately 33 days of intrauterine life. The T-shaped laryngeal slit (aditus) is formed anteriorly by the growth of the primordium of the epiglottis (from the hypobranchial eminence, arches III and IV) and laterally by the precursors of the arytenoid cartilages (ventral ends of arch VI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the fifth and sixth weeks, the tracheoesophageal septum extends to the first tracheal ring. By the time the embryo is 13 to 17 mm in length, laryngeal cartilage and muscle development are clearly identifiable, and lateral cricoid condensation is underway. By the seventh week of development, the cricoid ring is complete, and the cartilaginous hyoid is visible below the epiglottis (",
"    <a class=\"graphic graphic_picture graphicRef74038 \" href=\"mobipreview.htm?30/16/30983\">",
"     picture 1",
"    </a>",
"    ). Definitive tracheal cartilage appears at this stage, and the esophagus has four discrete layers. The larynx, trachea, and esophagus are well formed by the end of the embryologic period (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50788 \" href=\"mobipreview.htm?18/41/19090\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73785 \" href=\"mobipreview.htm?25/16/25871\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LARYNGOMALACIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngomalacia refers to collapse of the supraglottic structures during inspiration (",
"    <a class=\"graphic graphic_movie graphicRef77720 \" href=\"mobipreview.htm?24/21/24915\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79457 \" href=\"mobipreview.htm?27/21/27999\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It is the most common congenital anomaly of the larynx and is also called congenital laryngeal stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. It is distinct from tracheomalacia (an abnormally compliant trachea), which has a different clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link&amp;anchor=H11#H11\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheomalacia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of laryngomalacia is not clearly defined, and different mechanisms may apply in different infants. Proposed mechanisms include delayed maturation or \"hypotonia\" of the supporting cartilaginous structures of the larynx, redundant soft tissue in the supraglottis, a foreshortened or tight aryepiglottic fold, underlying neuromuscular disorders, and supraglottic edema (possibly related to gastroesophageal reflux) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In histologic studies, surgically excised supraglottic tissues from infants with laryngomalacia are not distinct from supraglottic tissues from infants without laryngomalacia, weakening the \"malacia\" or soft-cartilage theory. The frequent concurrence of gastroesophageal reflux, the variation in severity with state of consciousness, and the new onset of laryngomalacia after neurologic injuries support the hypothesis that it is a neuromuscular disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngomalacia manifests with intermittent low-pitched \"wet\" inspiratory stridor, usually in the neonatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7-9,11,12\">",
"     7-9,11,12",
"    </a>",
"    ]. In most children with laryngomalacia, stridor is loudest at four to eight months of age and resolves by 12 to 18 months. Stridor is more intense during upper respiratory tract infections. The stridor is often worse in the supine position and during crying or feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. It may be present only during sleep or relaxation (state-dependent laryngomalacia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Stridor may improve when prone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with mild forms of laryngomalacia breathe and feed well despite their noisy respiration. More severe forms result in suprasternal or substernal retractions; poor feeding; and failure to thrive.",
"   </p>",
"   <p>",
"    Up to 20 percent of infants with laryngomalacia have additional airway anomalies, but life-threatening anomalies are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. Laryngomalacia may be isolated or occur in association with congenital anomalies not affecting the airway or multiple congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5\">",
"     5",
"    </a>",
"    ]. Associated gastroesophageal reflux and laryngopharyngeal reflux (reflux beyond the esophagus to the larynx, oropharynx, or nasopharynx) are more common than in infants without laryngomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7,10,14\">",
"     7,10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of laryngomalacia is usually suspected based upon the history and physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7\">",
"     7",
"    </a>",
"    ]. It is confirmed with flexible fiberoptic laryngoscopy (",
"    <a class=\"graphic graphic_movie graphicRef77720 \" href=\"mobipreview.htm?24/21/24915\">",
"     movie 1",
"    </a>",
"    ). An experienced pediatric care provider need not refer every child with mild inspiratory stridor to a pediatric otolaryngologist. Children with significant or progressive stridor, apnea, cyanotic episodes, or failure to thrive require endoscopic confirmation. Numerous, potentially dangerous airway abnormalities have similar clinical presentations. Hoarseness is not characteristic of laryngomalacia and suggests vocal cord involvement.",
"   </p>",
"   <p>",
"    Other causes of stridor include subglottic stenosis, vocal cord paralysis, vascular ring, laryngeal mass (eg, cyst or hemangioma), subglottic hemangioma, and tracheomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severity &mdash; The severity of laryngomalacia is determined by the degree and sequelae of airway obstruction and the response to conservative interventions (eg, position change, feeding modifications, treatment for gastroesophageal reflux).",
"     </li>",
"     <li>",
"      Associated anomalies &mdash; The need for routine ancillary evaluation (eg, direct laryngoscopy and bronchoscopy or flexible fiberoptic bronchoscopy) for concurrent laryngotracheal malformations (eg, esophageal atresia, tracheoesophageal atresia) is controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5,13,15\">",
"       5,13,15",
"      </a>",
"      ]. There is general agreement that ancillary evaluation is necessary in infants with cyanosis, apnea, hoarseness, feeding difficulty, failure to thrive, or atypical stridor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation of infants with frequent episodes of regurgitation for gastroesophageal reflux is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=see_link&amp;anchor=H10#H10\">",
"     \"Gastroesophageal reflux in infants\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of laryngomalacia depends upon the severity. In the vast majority of otherwise normal children, laryngomalacia is not dangerous and resolves spontaneously.",
"   </p>",
"   <p>",
"    Infants with mild laryngomalacia (intermittent mild stridor with no other symptoms) may be followed clinically with frequent monitoring to make sure that weight gain is adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7\">",
"     7",
"    </a>",
"    ]. Infants known to have associated gastroesophageal reflux should be treated for reflux. There is no good scientific basis to guide the decision between a full diagnostic evaluation and empiric therapy for gastroesophageal reflux in the child with laryngomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=see_link&amp;anchor=H19#H19\">",
"     \"Gastroesophageal reflux in infants\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with moderate or severe laryngomalacia (stridor with feeding difficulty, dyspnea, tachypnea, cyanosis, apnea) should be referred to an otolaryngologist for full endoscopic evaluation and possible intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with severe laryngomalacia often benefit from surgery to remove redundant supraglottic tissue (",
"    <a class=\"graphic graphic_picture graphicRef56479 \" href=\"mobipreview.htm?2/20/2368\">",
"     picture 4",
"    </a>",
"    ). In experienced hands, this surgery can produce dramatic improvements in breathing, feeding, and growth with little morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5,7,20,21\">",
"     5,7,20,21",
"    </a>",
"    ]. Possible complications include supraglottic or glottic scarring and subsequent chronic aspiration or dysphonia, so surgery should not be undertaken for purely aesthetic reasons (ie, to ease parental anxiety about noisy breathing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complex structure of the larynx and its numerous folds and outpouchings predispose this region to congenital malformations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cysts",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Vallecular cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital vallecular cysts contain respiratory epithelium and mucous glands; they arise in the hypopharynx and are an uncommon cause of respiratory distress in infancy (",
"    <a class=\"graphic graphic_picture graphicRef79138 \" href=\"mobipreview.htm?0/57/912\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69715 \" href=\"mobipreview.htm?2/39/2672\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Infants with vallecular cysts typically present with feeding difficulty, failure to thrive, stridor, noisy breathing, respiratory distress, or a hoarse cry; laryngomalacia is an associated finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Diagnosis is confirmed with endoscopy of the hypopharynx.",
"   </p>",
"   <p>",
"    Definitive treatment requires adequate marsupialization, which can be performed transorally with microscissors or laser, or through a transhyoid resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/22,26,27\">",
"     22,26,27",
"    </a>",
"    ]. Aspiration or rupture may provide temporary improvement in symptoms but seldom provides permanent treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Laryngoceles and saccular cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital laryngoceles and saccular cysts are abnormal dilations of the laryngeal saccule and arise in the region of the laryngeal ventricle. Laryngoceles are outpouchings of the saccular mucosa. They may remain within the confines of the cartilaginous larynx (internal laryngoceles) or extend through the thyrohyoid membrane to present as neck masses (combined laryngoceles). Saccular cysts are fluid-filled submucosal cysts that are covered by a normal mucous membrane and isolated from the interior of the larynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These anomalies typically are asymptomatic; however, they may cause upper airway obstruction (particularly in the neonate), hoarseness, dysphagia, dyspnea, and laryngeal discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. The symptoms caused by laryngoceles are episodic because laryngoceles intermittently fill with air. In contrast, the symptoms produced by saccular cysts are constant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laryngoceles and saccular cysts usually are discovered incidentally during radiologic evaluation for unrelated symptoms. Laryngoceles are visualized as fluid- and air-containing cystic masses on plain radiography, ultrasound, or computed tomography (CT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/31\">",
"     31",
"    </a>",
"    ]. CT is preferred for determination of the full extent of the lesion and its relation to the larynx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atresia and stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal atresia is thought to be caused by the failure of epithelial growth and recanalization in the vestibule and subglottic regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33\">",
"     33",
"    </a>",
"    ]. The three types of laryngeal atresia are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 1 &mdash; Supraglottic obstruction, absent vestibule, and stenotic subglottis",
"     </li>",
"     <li>",
"      Type 2 &mdash; Supraglottic obstruction separates the primitive vestibule from the normal subglottis",
"     </li>",
"     <li>",
"      Type 3 &mdash; Perforated membrane partly obstructs the glottis (laryngeal web) (",
"      <a class=\"graphic graphic_picture graphicRef57415 \" href=\"mobipreview.htm?37/51/38719\">",
"       picture 7",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=see_link&amp;anchor=H20#H20\">",
"       \"Etiology and management of hoarseness in children\", section on 'Laryngeal webs'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most infants with laryngeal atresia present with asphyxia at the time of birth. Performing an emergent tracheotomy soon after delivery is necessary for survival because the imperforate larynx cannot be intubated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital subglottic stenosis is a narrowing of the lumen of the cricoid region possibly caused by incomplete canalization of the cricoid ring (diameter less than 4 mm in the term infant and 3 mm in the preterm infant) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33,37\">",
"     33,37",
"    </a>",
"    ]. It is differentiated from acquired subglottic stenosis by the absence of history of trauma or instrumentation and by less severe symptoms. Congenital subglottic stenosis typically improves as the larynx grows; fewer than one-half of the children with this disorder require tracheostomy. Depending upon the severity of the obstruction and the need for supplemental oxygen therapy, congenital subglottic stenosis also may be treated by anterior cricoid split or endoscopic laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33,38\">",
"     33,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laryngeal clefts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior laryngeal clefts are thought to result from failed fusion of the two lateral growth centers of the posterior cricoid cartilage at six to seven weeks of intrauterine life. Further aborted development of the tracheoesophageal septum may result in a laryngotracheoesophageal cleft that extends to the carina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laryngeal clefts occur in approximately 1 in 10,000 to 1 in 20,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/41\">",
"     41",
"    </a>",
"    ]. They are more common in boys than girls, with a male:female ratio of 5:3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with posterior laryngeal clefts may present with increased secretions, feeding difficulty, failure to thrive, wheezing, stridor, noisy breathing, aspiration, respiratory distress, recurrent pulmonary infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hoarseness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33,44,45\">",
"     33,44,45",
"    </a>",
"    ]. In one series of 41 children with posterior laryngeal clefts, the average age at onset of symptoms was five months, and the average age at diagnosis was three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/44\">",
"     44",
"    </a>",
"    ]. Children with posterior laryngeal clefts often have associated gastroesophageal reflux, tracheomalacia, developmental delay,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33,44-46\">",
"     33,44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=see_link&amp;anchor=H21#H21\">",
"     \"Etiology and management of hoarseness in children\", section on 'Laryngeal clefts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rigid endoscopy is the standard for diagnosis and should include palpation of the interarytenoid area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, contrast studies of the esophagus may show spillage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    into the airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33,45\">",
"     33,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posterior laryngeal clefts and laryngotracheoesophageal clefts may be classified according to anatomic or clinical criteria. The Benjamin classification describes five types (",
"    <a class=\"graphic graphic_figure graphicRef66067 \" href=\"mobipreview.htm?31/43/32437\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Occult clefts can be appreciated only by palpation and measurement of the interarytenoid height",
"     </li>",
"     <li>",
"      Type 1 clefts are limited to the supraglottic, interarytenoid area (",
"      <a class=\"graphic graphic_picture graphicRef74786 \" href=\"mobipreview.htm?5/24/5505\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Type 2 clefts show partial clefting of the posterior cricoid cartilage, sometimes with a mucosal bridge across the cartilaginous gap",
"     </li>",
"     <li>",
"      Type 3 clefts involve the entire cricoid and the cervical portion of the tracheoesophageal membrane, stopping above the thoracic inlet",
"     </li>",
"     <li>",
"      Type 4 clefts involve a major portion of the intrathoracic tracheoesophageal wall (",
"      <a class=\"graphic graphic_picture graphicRef67712 \" href=\"mobipreview.htm?22/61/23504\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment for these disorders depends upon the type of cleft and severity of associated symptoms. Alternatives to surgery for type 1 clefts may include endoscopic injection augmentation of the posterior glottis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/48-50\">",
"     48-50",
"    </a>",
"    ] and medical therapy to control gastroesophageal reflux and aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33,44\">",
"     33,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subglottic hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangiomas are congenital vascular lesions that undergo a phase of rapid growth that is initiated during the first few weeks to months of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/51\">",
"     51",
"    </a>",
"    ]. They may present as solitary lesions or as part of a segmental hemangioma syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The growth phase lasts for 12 to 18 months, after which the lesion stabilizes in size for a period of time. Finally, the lesion undergoes involution, typically with complete resolution of the lesion by age five in 50 percent of cases and age 12 in the remainder of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital subglottic hemangiomas are rare but potentially fatal lesions. They account for 1.5 percent of congenital laryngeal abnormalities. There is a higher prevalence in females with a female:male ratio of 2:1. Presentation may be similar to that of subglottic stenosis, with recurrent croup and biphasic stridor.",
"   </p>",
"   <p>",
"    Clinical diagnosis can be made based upon history and complete physical examination, including rigid endoscopy. Plain radiographs of the neck typically demonstrate asymmetric narrowing of the subglottis. Contrast computed tomography may be useful in delineating large hemangiomas or those extending beyond the confines of the larynx. Rigid endoscopy reveals a red to blue, compressible, sessile lesion that is most commonly located in the posterolateral subglottis (",
"    <a class=\"graphic graphic_picture graphicRef73275 \" href=\"mobipreview.htm?15/36/15937\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several options are available for the treatment of subglottic hemangiomas. A watchful waiting approach with or without a tracheotomy traditionally has been taken. Locally injected or systemic glucocorticoids may hasten resolution. Laser or open surgical resections have been advocated, with mixed results. Systemic therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    has produced dramatic results in case reports, and some have advocated propranolol as first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of infantile hemangiomas\", section on 'Airway hemangiomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subglottic hemangioma associated with cutaneous hemangiomas in a &ldquo;beard&rdquo; distribution may be seen in PHACE syndrome (",
"    <a class=\"graphic graphic_table graphicRef80245 \" href=\"mobipreview.htm?9/52/10059\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37543/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'PHACE syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laryngomalacia refers to collapse of the supraglottic structures during inspiration (",
"      <a class=\"graphic graphic_movie graphicRef77720 \" href=\"mobipreview.htm?24/21/24915\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79457 \" href=\"mobipreview.htm?27/21/27999\">",
"       picture 3",
"      </a>",
"      ). Clinical manifestations include stridor that worsens in the supine position and during crying, feeding, and upper respiratory infections. Laryngomalacia is suspected based upon the history and physical examination, and confirmed with flexible fiberoptic laryngoscopy. In most otherwise normal children, laryngomalacia resolves spontaneously. Infants who have hoarseness, atypical stridor, or stridor with feeding difficulty, dyspnea, tachypnea, cyanosis, or apnea should be referred to an otolaryngologist for full endoscopic evaluation and possible intervention. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Laryngomalacia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with vallecular cysts (",
"      <a class=\"graphic graphic_picture graphicRef79138 \" href=\"mobipreview.htm?0/57/912\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69715 \" href=\"mobipreview.htm?2/39/2672\">",
"       picture 6",
"      </a>",
"      ) typically present with feeding difficulty, failure to thrive, stridor, noisy breathing, respiratory distress, or a hoarse cry; laryngomalacia is an associated finding. Diagnosis is confirmed with endoscopy of the hypopharynx. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Vallecular cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital laryngoceles and saccular cysts typically are asymptomatic; however, they may cause upper airway obstruction (particularly in the neonate), hoarseness, dysphagia, dyspnea, and laryngeal discomfort. The symptoms caused by laryngoceles are episodic because laryngoceles intermittently fill with air; the symptoms produced by saccular cysts are constant. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laryngoceles and saccular cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infants with laryngeal atresia present with asphyxia at the time of birth; emergent tracheotomy is necessary for survival. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Atresia and stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with posterior laryngeal clefts may present with increased secretions, feeding difficulty, failure to thrive, wheezing, stridor, noisy breathing, aspiration, respiratory distress, recurrent pulmonary infections,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hoarseness. Contrast studies of the esophagus may show spillage of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      into the airway. Rigid endoscopy is the standard for diagnosis and should include palpation of the interarytenoid area (",
"      <a class=\"graphic graphic_picture graphicRef74786 \" href=\"mobipreview.htm?5/24/5505\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef67712 \" href=\"mobipreview.htm?22/61/23504\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laryngeal clefts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital subglottic hemangiomas are rare but potentially fatal lesions. The presentation may be similar to that of subglottic stenosis with recurrent croup and biphasic stridor. Plain radiographs typically demonstrate asymmetric narrowing of the subglottis. The diagnosis is confirmed endoscopically (",
"      <a class=\"graphic graphic_picture graphicRef73275 \" href=\"mobipreview.htm?15/36/15937\">",
"       picture 10",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Subglottic hemangiomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jones KL. Dysmorphology approach and classification. In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/2\">",
"      Hast MH. The developmental anatomy of the larynx. Otolaryngol Clin North Am 1970; 3:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/3\">",
"      O'Rahilly R, Tucker JA. The early development of the larynx in staged human embryos. I. Embryos of the first five weeks (to stage 15). Ann Otol Rhinol Laryngol 1973; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/4\">",
"      Tucker JA, Tucker GF. Some aspects of fetal laryngeal development. Ann Otol Rhinol Laryngol 1975; 84:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/5\">",
"      Olney DR, Greinwald JH Jr, Smith RJ, Bauman NM. Laryngomalacia and its treatment. Laryngoscope 1999; 109:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/6\">",
"      Shah UK, Wetmore RF. Laryngomalacia: a proposed classification form. Int J Pediatr Otorhinolaryngol 1998; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/7\">",
"      Richter GT, Thompson DM. The surgical management of laryngomalacia. Otolaryngol Clin North Am 2008; 41:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/8\">",
"      Kay DJ, Goldsmith AJ. Laryngomalacia: a classification system and surgical treatment strategy. Ear Nose Throat J 2006; 85:328.",
"     </a>",
"    </li>",
"    <li>",
"     Smith RJH, Cable BB. Laryngeal disorders. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1411.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/10\">",
"      Thompson DM. Abnormal sensorimotor integrative function of the larynx in congenital laryngomalacia: a new theory of etiology. Laryngoscope 2007; 117:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/11\">",
"      Smith JL 2nd, Sweeney DM, Smallman B, Mortelliti A. State-dependent laryngomalacia in sleeping children. Ann Otol Rhinol Laryngol 2005; 114:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/12\">",
"      Amin MR, Isaacson G. State-dependent laryngomalacia. Ann Otol Rhinol Laryngol 1997; 106:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/13\">",
"      Mancuso RF, Choi SS, Zalzal GH, Grundfast KM. Laryngomalacia. The search for the second lesion. Arch Otolaryngol Head Neck Surg 1996; 122:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/14\">",
"      Giannoni C, Sulek M, Friedman EM, Duncan NO 3rd. Gastroesophageal reflux association with laryngomalacia: a prospective study. Int J Pediatr Otorhinolaryngol 1998; 43:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/15\">",
"      Bluestone CD, Healy GB, Cotton RT. Diagnosis of laryngomalacia is not enough! Arch Otolaryngol Head Neck Surg 1996; 122:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/16\">",
"      Gilger MA. Pediatric otolaryngologic manifestations of gastroesophageal reflux disease. Curr Gastroenterol Rep 2003; 5:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/17\">",
"      Stavroulaki P. Diagnostic and management problems of laryngopharyngeal reflux disease in children. Int J Pediatr Otorhinolaryngol 2006; 70:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/18\">",
"      El-Serag HB, Gilger M, Kuebeler M, Rabeneck L. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001; 121:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/19\">",
"      Phillips B. Towards evidence based medicine for paediatricians. Arch Dis Child 2012; 97:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/20\">",
"      Friedman EM, Vastola AP, McGill TJ, Healy GB. Chronic pediatric stridor: etiology and outcome. Laryngoscope 1990; 100:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/21\">",
"      Meier JD, Nguyen SA, White DR. Improved growth curve measurements after supraglottoplasty. Laryngoscope 2011; 121:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/22\">",
"      Guti&eacute;rrez JP, Berkowitz RG, Robertson CF. Vallecular cysts in newborns and young infants. Pediatr Pulmonol 1999; 27:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/23\">",
"      Breysem L, Goosens V, Vander Poorten V, et al. Vallecular cyst as a cause of congenital stridor: report of five patients. Pediatr Radiol 2009; 39:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/24\">",
"      Ku AS. Vallecular cyst: report of four cases--one with co-existing laryngomalacia. J Laryngol Otol 2000; 114:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/25\">",
"      Hsieh WS, Yang PH, Wong KS, et al. Vallecular cyst: an uncommon cause of stridor in newborn infants. Eur J Pediatr 2000; 159:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/26\">",
"      Myer CM. Vallecular cyst in the newborn. Ear Nose Throat J 1988; 67:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/27\">",
"      Oluwole M. Congenital vallecular cyst: a cause of failure to thrive. Br J Clin Pract 1996; 50:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/28\">",
"      Crelin ES. Development of the upper respiratory system. Clin Symp 1976; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/29\">",
"      Pennings RJ, van den Hoogen FJ, Marres HA. Giant laryngoceles: a cause of upper airway obstruction. Eur Arch Otorhinolaryngol 2001; 258:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/30\">",
"      Sniezek JC, Johnson RE, Ramirez SG, Hayes DK. Laryngoceles and saccular cysts. South Med J 1996; 89:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/31\">",
"      Chu L, Gussack GS, Orr JB, Hood D. Neonatal laryngoceles. A cause for airway obstruction. Arch Otolaryngol Head Neck Surg 1994; 120:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/32\">",
"      Civantos FJ, Holinger LD. Laryngoceles and saccular cysts in infants and children. Arch Otolaryngol Head Neck Surg 1992; 118:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/33\">",
"      Hartnick CJ, Cotton RT. Congenital laryngeal anomalies. Laryngeal atresia, stenosis, webs, and clefts. Otolaryngol Clin North Am 2000; 33:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/34\">",
"      WALANDER A. The mechanism of origin of congenital malformations of the larynx. Acta Otolaryngol 1955; 45:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/35\">",
"      Zaw-Tun HI. Development of congenital laryngeal atresias and clefts. Ann Otol Rhinol Laryngol 1988; 97:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/36\">",
"      Okada T, Ohnuma N, Tanabe M, et al. Long-term survival in a patient with congenital laryngeal atresia and multiple malformations. Pediatr Surg Int 1998; 13:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/37\">",
"      Weintraub AS, Holzman IR. Neonatal care of infants with head and neck anomalies. Otolaryngol Clin North Am 2000; 33:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/38\">",
"      Santos D, Mitchell R. The history of pediatric airway reconstruction. Laryngoscope 2010; 120:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/39\">",
"      Lim TA, Spanier SS, Kohut RI. Laryngeal clefts: a histopathologic study and review. Ann Otol Rhinol Laryngol 1979; 88:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/40\">",
"      Moungthong G, Holinger LD. Laryngotracheoesophageal clefts. Ann Otol Rhinol Laryngol 1997; 106:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/41\">",
"      Roth B, Rose KG, Benz-Bohm G, G&uuml;nther H. Laryngo-tracheo-oesophageal cleft. Clinical features, diagnosis and therapy. Eur J Pediatr 1983; 140:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/42\">",
"      Phelan PD, Stocks JG, Williams HE, Danks DM. Familial occurrence of congenital laryngeal clefts. Arch Dis Child 1973; 48:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/43\">",
"      DuBois JJ, Pokorny WJ, Harberg FJ, Smith RJ. Current management of laryngeal and laryngotracheoesophageal clefts. J Pediatr Surg 1990; 25:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/44\">",
"      Parsons DS, Stivers FE, Giovanetto DR, Phillips SE. Type I posterior laryngeal clefts. Laryngoscope 1998; 108:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/45\">",
"      Rahbar R, Rouillon I, Roger G, et al. The presentation and management of laryngeal cleft: a 10-year experience. Arch Otolaryngol Head Neck Surg 2006; 132:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/46\">",
"      Kennedy CA, Heimbach M, Rimell FL. Diagnosis and determination of the clinical significance of type 1A laryngeal clefts by gelfoam injection. Ann Otol Rhinol Laryngol 2000; 109:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/47\">",
"      Benjamin B, Inglis A. Minor congenital laryngeal clefts: diagnosis and classification. Ann Otol Rhinol Laryngol 1989; 98:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/48\">",
"      Nakahara S, Tayama N, Tsuchida Y. A minor laryngeal cleft (type 1-a) diagnosed in infancy. Int J Pediatr Otorhinolaryngol 1995; 32:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/49\">",
"      Cohen MS, Zhuang L, Simons JP, et al. Injection laryngoplasty for type 1 laryngeal cleft in children. Otolaryngol Head Neck Surg 2011; 144:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/50\">",
"      Mangat HS, El-Hakim H. Injection augmentation of type I laryngeal clefts. Otolaryngol Head Neck Surg 2012; 146:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/51\">",
"      Ahmad SM, Soliman AM. Congenital anomalies of the larynx. Otolaryngol Clin North Am 2007; 40:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/52\">",
"      O TM, Alexander RE, Lando T, et al. Segmental hemangiomas of the upper airway. Laryngoscope 2009; 119:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/53\">",
"      Vermeer S, van Oostrom CG, Boetes C, et al. A unique case of PHACES syndrome confirming the assumption that PHACES syndrome and the sternal malformation-vascular dysplasia association are part of the same spectrum of malformations. Clin Dysmorphol 2005; 14:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/54\">",
"      Denoyelle F, Garab&eacute;dian EN. Propranolol may become first-line treatment in obstructive subglottic infantile hemangiomas. Otolaryngol Head Neck Surg 2010; 142:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37543/abstract/55\">",
"      O-Lee TJ, Messner A. Subglottic hemangioma. Otolaryngol Clin North Am 2008; 41:903.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6300 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37543=[""].join("\n");
var outline_f36_42_37543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LARYNGOMALACIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Vallecular cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Laryngoceles and saccular cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atresia and stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laryngeal clefts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subglottic hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6300\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6300|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/41/19090\" title=\"diagnostic image 1\">",
"      Sagittal airway 20 week fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6300|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/43/32437\" title=\"figure 1\">",
"      Laryngeal cleft class",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6300|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/16/30983\" title=\"picture 1\">",
"      Coronal section through 8 week embryo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/16/25871\" title=\"picture 2\">",
"      Normal newborn larynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/21/27999\" title=\"picture 3\">",
"      Laryngomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/20/2368\" title=\"picture 4\">",
"      Laryngomalacia surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/57/912\" title=\"picture 5\">",
"      Vallecular cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/39/2672\" title=\"picture 6\">",
"      Aryepiglottic fold cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/51/38719\" title=\"picture 7\">",
"      Anterior laryngeal web",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/24/5505\" title=\"picture 8\">",
"      Laryngeal cleft type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/61/23504\" title=\"picture 9\">",
"      Laryngeal cleft type 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/36/15937\" title=\"picture 10\">",
"      Subglottic hemangioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6300|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?24/21/24915\" title=\"movie 1\">",
"      Laryngomalacia video",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6300|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/52/10059\" title=\"table 1\">",
"      PHACE syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=related_link\">",
"      Etiology and management of hoarseness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_42_37544="Transvaginal cervical cerclage";
var content_f36_42_37544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transvaginal cervical cerclage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37544/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37544/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37544/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37544/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/42/37544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cerclage refers to a variety of surgical procedures in which sutures, wires, or synthetic tape are used to reinforce the cervix. These procedures are intended to mechanically increase the tensile strength of the cervix, thereby reducing the occurrence of adverse perinatal events associated with cervical insufficiency (ie, relatively painless cervical changes that occur in the second trimester and result in recurrent pregnancy loss). Adverse perinatal events associated with cervical insufficiency include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolapse of the fetal membranes into the vagina",
"     </li>",
"     <li>",
"      Intraamniotic infection",
"     </li>",
"     <li>",
"      Preterm premature rupture of the fetal membranes (PPROM)",
"     </li>",
"     <li>",
"      Preterm labor and delivery (PTD)",
"     </li>",
"     <li>",
"      Fetal loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the efficacy of cerclage for prevention of these adverse events compared to no intervention or other interventions is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H24#H24\">",
"     \"Cervical insufficiency\", section on 'Other interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Cochrane review of studies of cerclage versus no cerclage in singleton pregnancies concluded placement of a cerclage significantly reduced preterm birth (RR 0.80, 95% CI 0.69-0.95; nine trials, 2898 women) in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/1\">",
"     1",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor obstetrical history &mdash; A history-indicated cerclage is typically placed at the end of the first trimester (12 to 14 weeks of gestation) in women at high risk of pregnancy loss based on their past obstetrical history. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H25211294#H25211294\">",
"       \"Cervical insufficiency\", section on 'Women with prior pregnancy losses or preterm births'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cervical changes on ultrasound &mdash; An ultrasound-indicated cerclage may be performed when cervical shortening is visualized on ultrasound evaluation of the cervix. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H25211294#H25211294\">",
"       \"Cervical insufficiency\", section on 'Women with prior pregnancy losses or preterm births'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H18#H18\">",
"       \"Cervical insufficiency\", section on 'Short cervix at &lt;24 weeks, no prior preterm birth, no risk factors for preterm birth'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An emergent (rescue, physical examination indicated) cerclage may be placed when advanced cervical changes are noted on digital and visual examination. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H89361408#H89361408\">",
"       \"Cervical insufficiency\", section on 'Physical examination reveals a dilated cervix and visible membranes before 24 weeks'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Replacement of prolapsed membranes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all women are good candidates for cervical cerclage; the major contraindications are fetal anomaly incompatible with life, intrauterine infection, active bleeding, active preterm labor, premature rupture of membranes, and fetal demise. The presence of fetal membranes prolapsing through the external cervical os is a relative contraindication to the procedure because the risk of iatrogenic rupture of the membranes in this setting may exceed 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Several techniques (eg, Trendelenburg position, back-filling the maternal bladder, decompression amniocentesis) have been used to make the fetal membranes retract prior to cerclage placement, with variable results (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Replacement of prolapsed membranes'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The lower and upper limits of gestational age for performing the procedure are not well defined. In general, a cerclage should not be placed while the patient is at significant risk of miscarriage due to aneuploidy (ie, early to mid first trimester), or when delivery is likely to have a reasonably good outcome (ie, third trimester) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/3\">",
"     3",
"    </a>",
"    ]. Waiting at least until the end of the first trimester also permits evaluation for some fetal anomalies, first trimester aneuploidy screening, or chorionic villus sampling prior to the procedure, if indicated.",
"   </p>",
"   <p>",
"    Cerclage placement at 24 to 28 weeks of gestation, a period characterized by high neonatal morbidity and mortality, is controversial. Many practitioners avoid placing a cerclage after the fetal viability has been reached (generally regarded as 24 weeks of gestation) since the procedure may cause accidental rupture of the fetal membranes leading to early preterm delivery, with its attendant high neonatal morbidity and mortality. Each case must be individualized, weighing the risks of the procedure against the likely outcome with expectant management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H14#H14\">",
"     \"Cervical insufficiency\", section on 'Approach to management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cerclages are placed via a vaginal approach. The transabdominal approach is more invasive, but allows higher placement since the transabdominal cerclage can be placed at the cervicoisthmic portion of the uterus, while transvaginal cerclages often end up distal to the internal os. In either case, the object is to reinforce the cervix at the level of the internal os. Lengthening of the cervix is a secondary effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. The length of cervix distal to the cerclage (ie, cerclage to external os) may not be an important factor in determining subsequent pregnancy outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/9\">",
"     9",
"    </a>",
"    ], but the length of closed cervix proximal to the cerclage appears to be predictive: a length &ge;10 mm is desirable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32532?source=see_link\">",
"     \"Transabdominal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common techniques for cerclage were first described by McDonald [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/11\">",
"     11",
"    </a>",
"    ] and Shirodkar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/12\">",
"     12",
"    </a>",
"    ]. The Shirodkar cerclage is placed at the level of the internal os after surgically reflecting the bladder anteriorly and the rectum posteriorly, whereas the McDonald cerclage is a purse string suture that does not involve any dissection (thus, theoretically, it cannot be placed as close to the internal cervical os as the Shirodkar). In contrast to the McDonald cerclage, the Shirodkar suture does not pass through the cervical stroma.",
"   </p>",
"   <p>",
"    Usually only one cerclage is placed, although some surgeons routinely place a second stitch. In these cases, the initial stitch is used for traction, and then an attempt is made to place the second cerclage even closer to the internal os. Two retrospective cohort studies of patients who underwent cerclage because of a history of cervical insufficiency or sonographic cervical shortening found no improvement in outcome with placement of two stitches instead of one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preoperative issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30982046\">",
"    <span class=\"h3\">",
"     Fetal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ultrasound examination should be performed proximate to the procedure to determine if there are identifiable fetal structural anomalies (such as anencephaly) that might affect the patient's decision to continue the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/15\">",
"     15",
"    </a>",
"    ]. First trimester Down syndrome screening should be offered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confirmation of fetal viability, either by Doppler auscultation of the fetal heart rate or by ultrasound, is mandatory immediately before (and after) the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30982053\">",
"    <span class=\"h3\">",
"     Antibiotics and evaluation for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We test for gonorrhea and chlamydia if the patient is at high risk of acquiring a sexually transmitted infection and there is no documentation of recent negative test results. If antibiotic therapy is indicated, treatment is completed prior to cerclage placement, if possible.",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is not administered for elective cerclage because there appears to be minimal risk that the procedure will promote infection in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. When the cervix is dilated, however, microbial invasion of the amniotic fluid from bacteria ascending from the vagina appears to be more common. The incidence of intraamniotic infection is 1 to 2 percent when the cervical abnormality is primarily an ultrasound finding, but 10 to 50 percent when the cervix is dilated at least 2 cm on physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Visualization of opaque membranes can be an early sign of intraamniotic infection. Significant prolongation of pregnancy is unlikely if intraamniotic infection has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts suggest amniocentesis to exclude subclinical infection prior to nonelective cerclage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/15\">",
"     15",
"    </a>",
"    ]; however, others discourage it because biochemical tests on amniotic fluid (such as glucose, LDH, and white cell count) do not have a high sensitivity and predictive value for intraamniotic infection, and few providers would be willing to wait 48 hours in this setting for the microbiologic culture results to return. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .) Other experts administer prophylactic broad-spectrum antibiotics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    2 grams or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 gram intravenously 30 minutes prior to surgery; some clinicians also administer one or more doses postoperatively). The goal of antibiotic therapy is to reduce the frequency of maternal and fetal infection and delay the onset of preterm labor. Although the use of prophylactic antibiotics has been shown to prolong the interval to delivery (latency period) in pregnancies complicated by PPROM, there is no proven benefit of this approach in the setting of intact membranes. Moreover, there are insufficient data upon which to base recommendations about management of obstetric procedures in women colonized with group B streptococcus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30982060\">",
"    <span class=\"h3\">",
"     Assessment for PPROM and preterm labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPROM and preterm labor are contraindications to the procedure, and should be excluded. Watery, mucous-like fluid may collect in the posterior vaginal fornix when the cervix is widely dilated and likely represents transudation across intact membranes; it is important to distinguish this fluid from amniotic fluid. Mild, irregular contractions noted on a uterine contraction monitor can be a normal finding, but regular contractions, especially those of increasing frequency and intensity, may indicate idiopathic preterm labor, subclinical intrauterine infection, or abruptio placentae. We observe candidates for nonelective cerclage for up to 24 hours before proceeding with surgery in order to help exclude the presence of PPROM, abruptio placentae, infection, and preterm labor.",
"   </p>",
"   <p>",
"    Tocolysis may be used to inhibit transient uterine contractions following placement of a nonelective cerclage in the mid-second trimester, but there is no high quality evidence that this practice is associated with improved perinatal outcome.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    (100 mg rectally 30 minutes before the procedure) diminishes procedure-induced elevations in prostaglandin levels, which theoretically may cause preterm contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Some clinicians continue it at a lower dose (25 mg orally every six hours) for 24 to 48 hours postoperatively. However, a retrospective cohort study found no evidence that use of indomethacin at cerclage placement reduced the number of subsequent preterm births compared to nonuse of tocolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/22\">",
"     22",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Tocolysis is not generally used for elective first trimester cerclage placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30982068\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either regional or general anesthesia is acceptable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/23\">",
"     23",
"    </a>",
"    ]. We prefer regional rather than general anesthesia for its overall safety and reduced risk of aspiration pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Replacement of prolapsed membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, prolapsed fetal membranes are a relative contraindication to emergent cerclage placement because of the high risk of iatrogenic PPROM. If the decision is made to attempt cerclage placement in this setting, the prolapsed membranes must be replaced in the uterine cavity before the procedure. This is accomplished least traumatically by placing the patient in steep Trendelenburg position and allowing gravity to retract the membranes. Membranes that are not reduced with maternal position change alone may retract when a uterine relaxant is given (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    50 to 200 mcg intravenously). Retrofilling the maternal bladder in 250 mL increments through a urinary catheter can also help to reposition the membranes in the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/24\">",
"     24",
"    </a>",
"    ], although a full bladder tends to reduce exposure of the operative field and push the cervix higher up into the pelvis. Another option is to place ring forceps or stay sutures of 00 silk around the circumference of the external os and then gently pull and shake the cervix to help ease the membranes back into the uterus (",
"    <a class=\"graphic graphic_figure graphicRef65600 \" href=\"mobipreview.htm?13/33/13845\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Invasive methods for reducing the fetal membranes include pushing them back with a smooth surfaced device, such as a gloved finger, sponge filled condom, or Foley catheter balloon. A 30 mL Foley catheter can be used to hold the membranes in the uterus while the cerclage is placed; it is deflated and removed just before the knot is secured. However, such techniques may be associated with an increased risk of PROM. Alternatively, transabdominal amniocentesis and amnioreduction under ultrasound guidance can be performed to reduce the amniotic fluid volume and pressure in the prolapsed sac, and thereby allow it to retract back into the uterine cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     McDonald cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is begun by grasping the anterior and posterior lips of the cervix with one or two ring forceps. A curved needle loaded with nonabsorbable suture material (at least number 1 or 2 polypropylene, polyester, or braided nylon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/26\">",
"     26",
"    </a>",
"    ]) is inserted at 12 o'clock, as high as possible at the junction of the rugated vaginal epithelium and the smooth cervix, at least 2cm above the external os, as feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/27\">",
"     27",
"    </a>",
"    ]. Intraoperative ultrasound can be helpful for judging the site of the suture relative to the internal os, maternal bladder and rectum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four to six bites are taken circumferentially around the entire cervix in a purse-string fashion, each bite should be deep enough to extend at least midway into the cervical stroma, but not into the endocervical canal (",
"    <a class=\"graphic graphic_figure graphicRef55446 \" href=\"mobipreview.htm?33/26/34209\">",
"     figure 2",
"    </a>",
"    ). The two ends of the suture are then tied securely and cut, leaving the ends long enough to grasp with a clamp when it is time to remove it.",
"   </p>",
"   <p>",
"    At the discretion of the surgeon, a second McDonald cerclage can be placed if the first stitch did not result in optimal closure of the cervix. This often occurs when placing an emergent cerclage in a woman with cervical effacement and prolapsed membranes. In this setting, both stitches are typically left in the cervix until removal later in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Shirodkar cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is more complicated than the McDonald cerclage because it requires incisions and dissection of the paracervical area. The bladder is emptied to facilitate visualization of the cervix. The cervix is pulled toward the surgeon with one or two ring forceps while an assistant retracts the vaginal sidewalls. A scalpel with a number 10 blade or an electrocautery needle is used to make a 1 to 3 cm vertical or transverse incision on the posterior cervix at the junction of the rugated vaginal epithelium and the smooth cervix (",
"    <a class=\"graphic graphic_figure graphicRef67778 \" href=\"mobipreview.htm?3/12/3264\">",
"     figure 3",
"    </a>",
"    ). We prefer a 2 to 3 cm transverse incision and suggest injecting 1 to 2 mL of sterile saline into the submucosa to raise a wheal before the incision is made. This facilitates dissecting tissue planes. Making the first incision posteriorly prevents the operative field from becoming obscured by bleeding from the anterior incision. After the posterior incision is made, a similar transverse incision is made anteriorly.",
"   </p>",
"   <p>",
"    The rectum is then bluntly dissected off the posterior cervix and the bladder is bluntly dissected off of the anterior cervix using a finger, sponge on a stick, or peanut sponge on a long clamp. The dissection should be carried back far enough to allow the surgeon to palpate the insertion of the uterosacral and cardinal ligaments onto the cervix at the level of the internal os. Electrocautery may be used to control small bleeders.",
"   </p>",
"   <p>",
"    Long curved Allis or Tiel clamps are used to grasp and approximate the lateral edges of the anterior and posterior aspects of the transverse incisions and some paracervical tissue. Two atraumatic (blunted) needles premounted with a single 5 mm Mersilene band are used for the cerclage. The tip of one needle is introduced anteriorly at the lateral edge of the incision at the level of the internal os (or as close as possible) and threaded submucosally adjacent to the cervical stroma (and medial to the cervical branches of the uterine vessels) to emerge at the lateral edge of the posterior incision at the level of the internal os. If not at the internal os, the cerclage should be at least 2cm cephalad to the external os, as feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bending the needle to reduce the curvature is sometimes helpful for guiding the needle to the desired position. The procedure is then repeated on the opposite side and the two ends are tied tightly using four to six square knots. The tails of the suture or Mersilene band should be left long. At the discretion of the surgeon, a second Shirodkar cerclage may be placed if the first stitch did not result in optimal closure. As discussed above, intraoperative ultrasound can be helpful for judging the site of the suture relative to the internal os, maternal bladder and rectum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is the surgeon's preference as to whether the stitch is placed so that the knot is tied anteriorly or posteriorly. The authors usually find it easier to perform the cerclage with anterior placement of the knot, although there are rare instances of an anterior knot causing bladder discomfort, and even eroding into the bladder. It is also easier to remove the cerclage in the office if the knot is anterior to the cervix.",
"   </p>",
"   <p>",
"    Following Shirodkar cerclage placement, the vaginal epithelium may be reapproximated with a fine chromic catgut suture, although this is not necessary if there is good hemostasis. It is not necessary to bury the ends of the knot below the epithelium or anchor the tape to the cervix. Avoiding burying and anchoring the cerclage facilitates removal prior to delivery. Alternatively, if cesarean delivery is planned, the Shirodkar cerclage can be left in-situ indefinitely postpartum for use in a future pregnancy. It is advantageous to completely bury the knot under the vaginal epithelium in these cases to minimize vaginal discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective cerclage is typically an ambulatory surgery procedure. The patient may be discharged after recovery from the anesthetic and when she is able to ambulate and void. Fetal viability should be documented prior to discharge.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    alone provides adequate analgesia for most women.",
"   </p>",
"   <p>",
"    Patients are told to report any leakage of fluid from the vagina so that they can be evaluated for preterm PROM. They should also be told to expect some spotting, cramps, and dysuria (due to minor muscle injury from the vaginal wall retractors) which will abate within a few days. Those who have undergone a Shirodkar procedure may note passage of the fine chromic catgut in two to three weeks as the stitches dissolve; they should be forewarned that this does not represent loss of the cerclage itself.",
"   </p>",
"   <p>",
"    Although there is no evidence that coitus adversely affects perinatal outcome, we ask patients to maintain pelvic rest for at least one week after an elective procedure, and to use condoms thereafter. Women who have had a nonelective cerclage are managed more conservatively; we typically limit physical activity and coitus until a favorable gestational age is reached, usually 32 to 34 weeks of gestation, although there is no high quality evidence that decreasing physical activity improves outcome.",
"   </p>",
"   <p>",
"    Women followed as outpatients are seen on a regular basis with frequent (weekly or biweekly) visits for cervical checks. Ultrasound assessment of the cervix may be useful for identifying those patients at highest risk for preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. The value of fetal fibronectin assay (at least four weeks postoperatively) is unclear; a positive result may be less reliable in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, a stitch may pull through the cervix as the uterus enlarges and the cervix dilates and effaces. This may be an indication for a second cerclage procedure, depending upon the gestational age achieved. Alternatively, hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antenatal glucocorticoids may be considered if the cervix is changing and preterm delivery appears likely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerclage removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerclage is removed electively at 37 weeks of gestation or immediately with the onset of premature labor to avoid cervical laceration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uterine rupture. Whether to remove the cerclage in the setting of PPROM is controversial. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Management after PPROM'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A McDonald cerclage usually can be cut and removed in the office without analgesia. A Shirodkar cerclage often requires a return to the operating room for removal, either because the knot is buried under the vaginal epithelium or the Mersilene has become infiltrated by cervical granulation tissue. Patients are generally sent home after cerclage removal to await the onset of labor, which generally occurs within two weeks; only about 10 percent of women deliver spontaneously within 48 hours of elective cerclage removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, a Shirodkar cerclage does not have to be removed if cesarean delivery is anticipated and future pregnancies are planned. There is a theoretical risk of reduced fertility from",
"    <span class=\"nowrap\">",
"     inflammation/infection",
"    </span>",
"    of the cervix due to the foreign body and a risk of erosion into adjacent tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative complications at elective cerclage are uncommon, typically involving less than 6 percent of procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/36\">",
"     36",
"    </a>",
"    ]. The frequency of complications is higher with increasing gestational age and cervical dilatation (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Outcome'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The median frequency of PROM after elective cerclage is approximately 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/2\">",
"     2",
"    </a>",
"    ]. Rupture of membranes intraoperatively or in the immediate postoperative period is a major concern of nonelective cerclage, especially with advanced cervical dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolapsed fetal membranes. This complication has been reported in up to 65 percent of nonelective procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/2,37-39\">",
"     2,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median frequencies of chorioamnionitis after elective and non-elective cerclage are 2 and 25 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suture migration has been reported in 3 to 13 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/40\">",
"     40",
"    </a>",
"    ]. This often occurs late in gestation and thus is of little clinical consequence. When it occurs early in pregnancy (less than 24 weeks), the clinician must decide whether to repeat the procedure. It is likely that the same factors that led to failure of the first cerclage will affect a second procedure. In fact, placement of a second (reinforcing) cerclage may worsen the outcome when cervix shortening has occurred in the presence of an elective cerclage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/41\">",
"     41",
"    </a>",
"    ], and is not generally recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have undergone cerclage placement have an increased frequency of uterine contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/36\">",
"     36",
"    </a>",
"    ], but the presence of uterine irritability is not highly predictive of an increased risk of preterm birth. Cervical dystocia or cervical trauma in labor have been reported in fewer than 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/18\">",
"     18",
"    </a>",
"    ]. Excessive bleeding, maternal sepsis, and fistula formation are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cerclage is the conventional treatment for cervical insufficiency, despite the paucity of data from randomized trials proving its efficacy (",
"    <a class=\"graphic graphic_table graphicRef60929 \" href=\"mobipreview.htm?19/42/20140\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/36,42,43\">",
"     36,42,43",
"    </a>",
"    ]. Most case series quote a viable birth rate of 70 to 90 percent after elective cerclage, as compared with 10 to 30 percent prior to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/44\">",
"     44",
"    </a>",
"    ]. However, using patients as their own controls (ie, pregnancy success rate is compared before and after cerclage) is subject to bias since changes in the patient and her management other than cerclage may have accounted for the higher rate of success in the subsequent pregnancy. In fact, trials in which women were randomly assigned to undergo cerclage or no cerclage report much higher live birth rates in the untreated group than observed in historic controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H24#H24\">",
"     \"Cervical insufficiency\", section on 'Other interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing of cerclage also affects outcome. There is universal agreement that emergency cerclage performed in the presence of advanced cervical changes and prolapsed membranes has the worst outcome. It should be appreciated that there is significant risk that an emergency procedure may convert a previable birth to a very low birthweight premature birth (24 to 27 weeks) with the potential for serious long-term neurodevelopmental disability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link&amp;anchor=H89361408#H89361408\">",
"     \"Cervical insufficiency\", section on 'Physical examination reveals a dilated cervix and visible membranes before 24 weeks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SOME AREAS OF CONTROVERSY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14706495\">",
"    <span class=\"h2\">",
"     Progesterone supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with a history of prior preterm birth, continuing progesterone supplementation after placement of a cerclage is controversial. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5657?source=see_link&amp;anchor=H31324600#H31324600\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Cerclage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management after PPROM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether to remove the cerclage if PPROM occurs is a matter of debate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/45-53\">",
"     45-53",
"    </a>",
"    ]. One concern is that removal of the cerclage will lead to earlier delivery; however, retention of the foreign body may increase the risk of infectious morbidity. Several observational studies have addressed the management of such patients, with inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. The gestational age at PPROM was the most important determinant of neonatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/50\">",
"     50",
"    </a>",
"    ]. Based on the available, limited data and our own clinical experience, we remove the cerclage in women with PPROM if (1) there is any evidence of chorioamnionitis or (2) the pregnancy is at least 32 weeks of gestation. In the absence of clinically apparent infection, we feel the possible increased risk of premature delivery with cerclage removal before 32 weeks outweighs the possible increased risk of ascending infection if the cerclage is left in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management of placenta previa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cerclage has been proposed for management of pregnancies complicated by placenta previa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/54\">",
"     54",
"    </a>",
"    ]. A meta-analysis of two, small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] evaluating the efficacy of this approach found cervical cerclage may reduce the risk of delivery before 34 weeks (RR 0.45, 95% CI 0.23-0.87) or the birth of a baby weighing less than 2000 g (RR 0.34, 95% CI 0.14-0.83), but concluded there was insufficient evidence to recommend cerclage to prolong pregnancy in women with placenta previa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/56\">",
"     56",
"    </a>",
"    ]. However, the presence of a stable placenta previa is not a contraindication to elective cerclage placement in women with a history of cervical insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     McDonald versus Shirodkar procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;One randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/57\">",
"     57",
"    </a>",
"    ] and multiple controlled but nonrandomized studies have shown no significant differences in outcome between the two procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/36,48,58-61\">",
"     36,48,58-61",
"    </a>",
"    ]. These data suggest that the two techniques are equally effective, but could also be interpreted to reflect the lack of efficacy of cervical cerclage in general. In patients who have undergone a previous cerclage procedure, one study noted higher birth weight when Shirodkar rather than McDonald cerclage was performed for the second procedure (3020 and 2470 grams, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/18\">",
"     18",
"    </a>",
"    ]. Some experts recommend a McDonald procedure, given it is easier to perform than the Shirodkar since dissection is not required and it appears to be equally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/62\">",
"     62",
"    </a>",
"    ]. Our preference is to perform the Shirodkar procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management of future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of cervical insufficiency recurring in a subsequent pregnancy is 10 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/44\">",
"     44",
"    </a>",
"    ]. Women with a history of recurrent pregnancy loss consistent with cervical insufficiency who have been managed with cerclage are typically offered repeat cervical cerclage in subsequent pregnancies. However, if the diagnosis of cervical insufficiency was uncertain and the patient delivers at term after receiving a cerclage, then a decision not to repeat a cervical cerclage is reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37544/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cerclage refers to a variety of surgical procedures in which sutures, wires, or synthetic tape are used to reinforce the cervix and thereby prevent early preterm delivery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Placement of a cerclage should be avoided while the patient is at significant risk of miscarriage due to aneuploidy (early to mid first trimester) or when delivery is likely to have a reasonably good outcome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An ultrasound examination should be performed proximate to the procedure to determine if there are identifiable fetal structural anomalies (such as anencephaly) that might affect the patient's decision to continue the pregnancy and to confirm viability.",
"     </li>",
"     <li>",
"      We observe candidates for nonelective cerclage for up to 24 hours before proceeding with surgery to help exclude the presence of premature rupture of membranes, abruptio placentae, infection, and preterm labor. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Preoperative issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most controlled studies do not show significant differences in outcome between McDonald and Shirodkar procedures. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'McDonald versus Shirodkar procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest removing the cerclage in women with ruptured membranes if (1) there is any evidence of amnionitis or (2) the pregnancy is at least 32 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In the absence of clinically apparent infection, we feel the possible increased risk of premature delivery with cerclage removal outweighs the possible increased risk of ascending infection if the cerclage is left in place. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management after PPROM'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/1\">",
"      Alfirevic Z, Stampalija T, Roberts D, Jorgensen AL. Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database Syst Rev 2012; 4:CD008991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/2\">",
"      Harger JH. Cerclage and cervical insufficiency: an evidence-based analysis. Obstet Gynecol 2002; 100:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/3\">",
"      American College of Obstericians and Gynecologists. ACOG Practice Bulletin. Cervical insufficiency. Obstet Gynecol 2003; 102:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/4\">",
"      Althuisius SM, Dekker GA, van Geijn HP, Hummel P. The effect of therapeutic McDonald cerclage on cervical length as assessed by transvaginal ultrasonography. Am J Obstet Gynecol 1999; 180:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/5\">",
"      Funai EF, Paidas MJ, Rebarber A, et al. Change in cervical length after prophylactic cerclage. Obstet Gynecol 1999; 94:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/6\">",
"      Dijkstra K, Funai EF, O'Neill L, et al. Change in cervical length after cerclage as a predictor of preterm delivery. Obstet Gynecol 2000; 96:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/7\">",
"      O'Connell MP, Lindow SW. Reversal of asymptomatic cervical length shortening with cervical cerclage: a preliminary study. Hum Reprod 2001; 16:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/8\">",
"      Hershkovitz R, Burstein E, Pinku A. Tightening McDonald cerclage suture under sonographic guidance. Ultrasound Obstet Gynecol 2008; 31:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/9\">",
"      Rust OA, Atlas RO, Meyn J, et al. Does cerclage location influence perinatal outcome? Am J Obstet Gynecol 2003; 189:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/10\">",
"      Groom KM, Shennan AH, Bennett PR. Ultrasound-indicated cervical cerclage: outcome depends on preoperative cervical length and presence of visible membranes at time of cerclage. Am J Obstet Gynecol 2002; 187:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/11\">",
"      MCDONALD IA. Suture of the cervix for inevitable miscarriage. J Obstet Gynaecol Br Emp 1957; 64:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/12\">",
"      Shirodkar, VN. A new method of operative treatment for habitual abortion in the second trimester of pregnancy. Antiseptic 1955; 52:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/13\">",
"      Woensdregt K, Norwitz ER, Cackovic M, et al. Effect of 2 stitches vs 1 stitch on the prevention of preterm birth in women with singleton pregnancies who undergo cervical cerclage. Am J Obstet Gynecol 2008; 198:396.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/14\">",
"      Giraldo-Isaza MA, Fried GP, Hegarty SE, et al. Comparison of 2 stitches vs 1 stitch for transvaginal cervical cerclage for preterm birth prevention. Am J Obstet Gynecol 2013; 208:209.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/15\">",
"      Berghella V, Seibel-Seamon J. Contemporary use of cervical cerclage. Clin Obstet Gynecol 2007; 50:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/16\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin number 47, October 2003: Prophylactic Antibiotics in Labor and Delivery. Obstet Gynecol 2003; 102:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/17\">",
"      Rust OA, Atlas RO, Reed J, et al. Revisiting the short cervix detected by transvaginal ultrasound in the second trimester: why cerclage therapy may not help. Am J Obstet Gynecol 2001; 185:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/18\">",
"      Treadwell MC, Bronsteen RA, Bottoms SF. Prognostic factors and complication rates for cervical cerclage: a review of 482 cases. Am J Obstet Gynecol 1991; 165:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/19\">",
"      Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. Am J Obstet Gynecol 1992; 167:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/20\">",
"      Novy MJ, Ducsay CA, Stanczyk FZ. Plasma concentrations of prostaglandin F2 alpha and prostaglandin E2 metabolites after transabdominal and transvaginal cervical cerclage. Am J Obstet Gynecol 1987; 156:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/21\">",
"      Novy MJ, Haymond J, Nichols M. Shirodkar cerclage in a multifactorial approach to the patient with advanced cervical changes. Am J Obstet Gynecol 1990; 162:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/22\">",
"      Visintine J, Airoldi J, Berghella V. Indomethacin administration at the time of ultrasound-indicated cerclage: is there an association with a reduction in spontaneous preterm birth? Am J Obstet Gynecol 2008; 198:643.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/23\">",
"      Yoon HJ, Hong JY, Kim SM. The effect of anesthetic method for prophylactic cervical cerclage on plasma oxytocin: a randomized trial. Int J Obstet Anesth 2008; 17:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/24\">",
"      Scheerer LJ, Lam F, Bartolucci L, Katz M. A new technique for reduction of prolapsed fetal membranes for emergency cervical cerclage. Obstet Gynecol 1989; 74:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/25\">",
"      Goodlin RC. Cervical incompetence, hourglass membranes, and amniocentesis. Obstet Gynecol 1979; 54:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/26\">",
"      Pereira, L, Levy, C, Lewis, D, et al. Effect of suture material on the outcome of emergent cerclage. Am J Obstet Gynecol 2005; 193:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/27\">",
"      Scheib S, Visintine JF, Miroshnichenko G, et al. Is cerclage height associated with the incidence of preterm birth in women with an ultrasound-indicated cerclage? Am J Obstet Gynecol 2009; 200:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/28\">",
"      Ludmir J, Jackson GM, Samuels P. Transvaginal cerclage under ultrasound guidance in cases of severe cervical hypoplasia. Obstet Gynecol 1991; 78:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/29\">",
"      Andersen HF, Karimi A, Sakala EP, Kalugdan R. Prediction of cervical cerclage outcome by endovaginal ultrasonography. Am J Obstet Gynecol 1994; 171:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/30\">",
"      Guzman ER, Houlihan C, Vintzileos A, et al. The significance of transvaginal ultrasonographic evaluation of the cervix in women treated with emergency cerclage. Am J Obstet Gynecol 1996; 175:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/31\">",
"      O'Brien JM, Hill AL, Barton JR. Funneling to the stitch: an informative ultrasonographic finding after cervical cerclage. Ultrasound Obstet Gynecol 2002; 20:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/32\">",
"      Hedriana HL, Lanouette JM, Haesslein HC, McLean LK. Is there value for serial ultrasonographic assessment of cervical lengths after a cerclage? Am J Obstet Gynecol 2008; 198:705.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/33\">",
"      Roman AS, Rebarber A, Sfakianaki AK, et al. Vaginal fetal fibronectin as a predictor of spontaneous preterm delivery in the patient with cervical cerclage. Am J Obstet Gynecol 2003; 189:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/34\">",
"      Duhig KE, Chandiramani M, Seed PT, et al. Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage. BJOG 2009; 116:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/35\">",
"      Bisulli M, Suhag A, Arvon R, et al. Interval to spontaneous delivery after elective removal of cerclage. Am J Obstet Gynecol 2009; 201:163.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/36\">",
"      Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicentre randomised trial of cervical cerclage. MRC/RCOG Working Party on Cervical Cerclage. Br J Obstet Gynaecol 1993; 100:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/37\">",
"      Aarts JM, Brons JT, Bruinse HW. Emergency cerclage: a review. Obstet Gynecol Surv 1995; 50:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/38\">",
"      Wong GP, Farquharson DF, Dansereau J. Emergency cervical cerclage: a retrospective review of 51 cases. Am J Perinatol 1993; 10:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/39\">",
"      Simcox R, Shennan A. Cervical cerclage in the prevention of preterm birth. Best Pract Res Clin Obstet Gynaecol 2007; 21:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/40\">",
"      Barth WH Jr. Cervical incompetence and cerclage: unresolved controversies. Clin Obstet Gynecol 1994; 37:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/41\">",
"      Baxter JK, Airoldi J, Berghella V. Short cervical length after history-indicated cerclage: is a reinforcing cerclage beneficial? Am J Obstet Gynecol 2005; 193:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/42\">",
"      Rush RW, Isaacs S, McPherson K, et al. A randomized controlled trial of cervical cerclage in women at high risk of spontaneous preterm delivery. Br J Obstet Gynaecol 1984; 91:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/43\">",
"      Lazar P, Gueguen S, Dreyfus J, et al. Multicentred controlled trial of cervical cerclage in women at moderate risk of preterm delivery. Br J Obstet Gynaecol 1984; 91:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/44\">",
"      Harger JH. Cervical cerclage: patient selection, morbidity, and success rates. Clin Perinatol 1983; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     Grant, AM. Cervical cerclage. In: Pregnancy and Childbirth Module (Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, eds.) Cochrane Database of Systematic Reviews, Review # 04135, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/46\">",
"      Yeast JD, Garite TR. The role of cervical cerclage in the management of preterm premature rupture of the membranes. Am J Obstet Gynecol 1988; 158:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/47\">",
"      Blickstein I, Katz Z, Lancet M, Molgilner BM. The outcome of pregnancies complicated by preterm rupture of the membranes with and without cerclage. Int J Gynaecol Obstet 1989; 28:237.",
"     </a>",
"    </li>",
"    <li>",
"     Kuhn, RPJ, Pepperell, RJ. Cervical ligation: a review of 242 pregnancies. Aust N Z J Obstet Gynecol 1977:79.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/49\">",
"      Ludmir J, Bader T, Chen L, et al. Poor perinatal outcome associated with retained cerclage in patients with premature rupture of membranes. Obstet Gynecol 1994; 84:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/50\">",
"      McElrath TF, Norwitz ER, Lieberman ES, Heffner LJ. Management of cervical cerclage and preterm premature rupture of the membranes: should the stitch be removed? Am J Obstet Gynecol 2000; 183:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/51\">",
"      McElrath TF, Norwitz ER, Lieberman ES, Heffner LJ. Perinatal outcome after preterm premature rupture of membranes with in situ cervical cerclage. Am J Obstet Gynecol 2002; 187:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/52\">",
"      Jenkins TM, Berghella V, Shlossman PA, et al. Timing of cerclage removal after preterm premature rupture of membranes: maternal and neonatal outcomes. Am J Obstet Gynecol 2000; 183:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/53\">",
"      Kominiarek MA, Kemp A. Perinatal outcome in preterm premature rupture of membranes at &lt; or = 32 weeks with retained cerclage. J Reprod Med 2006; 51:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/54\">",
"      Arias F. Cervical cerclage for the temporary treatment of patients with placenta previa. Obstet Gynecol 1988; 71:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/55\">",
"      Cobo E, Conde-Agudelo A, Delgado J, et al. Cervical cerclage: an alternative for the management of placenta previa? Am J Obstet Gynecol 1998; 179:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/56\">",
"      Neilson JP. Interventions for suspected placenta praevia. Cochrane Database Syst Rev 2003; :CD001998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/57\">",
"      Odibo AO, Berghella V, To MS, et al. Shirodkar versus McDonald cerclage for the prevention of preterm birth in women with short cervical length. Am J Perinatol 2007; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/58\">",
"      Harger JH. Comparison of success and morbidity in cervical cerclage procedures. Obstet Gynecol 1980; 56:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/59\">",
"      Peters WA 3rd, Thiagarajah S, Harbert GM Jr. Cervical cerclage: twenty years' experience. South Med J 1979; 72:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/60\">",
"      Robboy MS. The management of cervical incompetence. UCLA experience with cerclage procedures. Obstet Gynecol 1973; 41:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/61\">",
"      Perrotin F, Marret H, Ayeva-Derman M, et al. [Second trimester cerclage of short cervixes: which technique to use? A retrospective study of 25 cases]. J Gynecol Obstet Biol Reprod (Paris) 2002; 31:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/62\">",
"      Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/63\">",
"      Fejgin MD, Gabai B, Goldberger S, et al. Once a cerclage, not always a cerclage. J Reprod Med 1994; 39:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37544/abstract/64\">",
"      Pelham, J, Lewis, D, Farrell, C, et al. Prior cerclage: to repeat or not to repeat, that is the question. Am J Obstet Gynecol 2002; 187:S115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6737 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.137.129.113-C8D6F1E5A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37544=[""].join("\n");
var outline_f36_42_37544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30982046\">",
"      - Fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30982053\">",
"      - Antibiotics and evaluation for infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30982060\">",
"      - Assessment for PPROM and preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30982068\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Replacement of prolapsed membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      McDonald cerclage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Shirodkar cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerclage removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SOME AREAS OF CONTROVERSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14706495\">",
"      Progesterone supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management after PPROM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      McDonald versus Shirodkar procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management of future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6737|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/33/13845\" title=\"figure 1\">",
"      Cervical cerclage procedure with dilated cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/26/34209\" title=\"figure 2\">",
"      McDonald cerclage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/12/3264\" title=\"figure 3\">",
"      Shirodkar cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6737|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/42/20140\" title=\"table 1\">",
"      Trials cervical cerclage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32532?source=related_link\">",
"      Transabdominal cervical cerclage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_42_37545="Evaluation and management of aromatase inhibitor-induced bone loss";
var content_f36_42_37545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of aromatase inhibitor-induced bone loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Charles L Shapiro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Shubham Pant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/42/37545/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/42/37545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (AIs) are an important component of adjuvant endocrine therapy in postmenopausal women with estrogen receptor positive breast cancer. AIs inhibit the cytochrome P450 CYP-19 enzyme responsible for the peripheral conversion of androgens to estrogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Treatment with AIs, therefore, results in bone loss due to estrogen deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/3\">",
"     3",
"    </a>",
"    ]. As more women are exposed to AIs, it is important to understand their adverse effects on the skeleton. The evaluation and management of bone loss associated with the use of AIs are reviewed here. The role of AIs as adjuvant therapy for breast cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTROGEN DEFICIENCY AND BONE LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central role of estrogen deficiency in the pathogenesis of osteoporosis in postmenopausal women has been recognized for many years. Estrogen inhibits bone resorption and, after menopause, estrogen deficiency results in increased bone resorption and rapid bone loss. The mechanisms by which estrogen regulates bone remodeling are not fully established. However, estrogen is thought to affect osteoclastogenesis and osteoclast function through its effects on local cytokines and growth factors (eg, produced by either bone cells or adjacent marrow cells). This topic is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link&amp;anchor=H341630#H341630\">",
"     \"Pathogenesis of osteoporosis\", section on 'Sex steroid deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     AI-induced estrogen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the primary source of estrogen in premenopausal women is the ovaries, the primary source in postmenopausal women is the adrenal gland, where aromatase converts adrenal androgens to estrogens. Aromatase inhibitors prevent conversion of androgens to estrogens. In postmenopausal women, AIs cause relatively rapid decreases in circulating estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AIs are divided into steroidal inactivators (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    ) and nonsteroidal inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    ). Exemestane is a steroidal analogue of androstenedione and binds irreversibly to aromatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Nonsteroidal inhibitors, like letrozole or anastrozole, bind reversibly to the heme group of the enzyme by way of a basic nitrogen atom. At clinical doses, these third-generation AIs are successful in inhibiting greater than 97 percent of aromatase activity in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. The half-life of these compounds varies from 27 hours for exemestane to 48 hours for letrozole and anastrozole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo animal studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    may be more bone sparing than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    , owing to its androgenic structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, there are no human trials showing a differential effect of the individual AIs on bone. The MA-27 trial is a comparative trial of exemestane versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    as adjuvant therapy in postmenopausal women. It includes end points such as bone mineral density (BMD) and fractures. The results are likely to provide more conclusive information about the skeletal effects of the steroidal versus nonsteroidal AIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SKELETAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer treatments, such as surgical oophorectomy, gonadotropin-releasing hormone (GnRH) agonists, chemotherapy that induces ovarian failure, and aromatase inhibitors (AIs), all decrease endogenous estrogens and cause bone loss and increase the risk of fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. The more sudden and severe the estrogen deprivation occurs, the greater the magnitude of bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/15,16,21,22\">",
"     15,16,21,22",
"    </a>",
"    ]. Bone loss is most rapid in premenopausal women receiving both ovarian suppression therapy (GnRH agonist) and an AI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several of the AI trials, BMD and bone turnover markers were evaluated in a subset of women. BMD of the LS and total hip (TH) were significantly reduced in postmenopausal women receiving AIs versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/13,21,23-25\">",
"     13,21,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a substudy of the five-year Arimidex,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      , Alone or in Combination (ATAC) trial (n = 108 evaluable women), postmenopausal women with breast cancer randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      had greater bone loss at the LS and TH (6 and 7.2 percent, respectively) compared with those assigned to tamoxifen (increase of 2.8 and 0.74 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a substudy (206 evaluable patients) of the Intergroup",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       Exemestane",
"      </a>",
"      Study (IES), in which postmenopausal women who had taken",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for two to three years were randomly assigned to switch to exemestane or continue tamoxifen, subjects who switched to exemestane experienced a greater decline in BMD at the LS (2.7 percent) and TH (1.4 percent) after six months compared with those who remained on tamoxifen (no change at either site) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/23\">",
"       23",
"      </a>",
"      ]. Bone loss slowed in the remaining 18 months of the study, declining an additional 1.0 and 0.8 percent at the LS and TH, respectively, in subjects assigned to exemestane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In premenopausal women, in whom the primary source of estrogen is the ovaries, AIs are not effective. However, in combination with the gonadotropin releasing hormone (GnRH) agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    , AIs cause more bone loss than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . In the Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12 trial, premenopausal women were randomly assigned to tamoxifen plus goserelin versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    plus goserelin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/14\">",
"     14",
"    </a>",
"    ]. Half of each group received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (ZA). Significant bone loss occurred in the subset of patients who did not receive ZA (17.3 and 11.6 percent reductions in patients receiving",
"    <span class=\"nowrap\">",
"     anastrozole/goserelin",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     tamoxifen/goserelin,",
"    </span>",
"    respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biochemical markers of bone turnover",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several of the trials described above, markers of bone resorption (urine n-telopeptide and serum C-telopeptide [CTX]) and formation (serum bone specific alkaline phosphatase [BALP], N-terminal propeptide of type 1 procollagen [P1NP]) were significantly increased with AI treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/23,24,26\">",
"     23,24,26",
"    </a>",
"    ]. In contrast, bone turnover markers remained constant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/23\">",
"     23",
"    </a>",
"    ] or decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/26\">",
"     26",
"    </a>",
"    ] with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several of the AI trials, fracture data were reported (",
"    <a class=\"graphic graphic_table graphicRef70977 \" href=\"mobipreview.htm?41/42/42667\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/23,27-32\">",
"     23,27-32",
"    </a>",
"    ]. In a meta-analysis of seven trials comparing AIs to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in postmenopausal women with early stage breast cancer, use of AIs significantly increased the risk of bone fractures (OR 1.47, 95% CI 1.34-1.61) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/33\">",
"     33",
"    </a>",
"    ]. The majority of the trials were not designed to explore fracture outcomes as primary events; therefore, fracture and other skeletal events were collected as adverse events as part of a long-term safety and tolerability assessment. With exception of the MA-17 trial, all adjuvant AI trials demonstrated a significant increase in the rate of overall fractures compared with tamoxifen.",
"   </p>",
"   <p>",
"    The MA-17 trial examined the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    versus placebo in postmenopausal women who had completed five years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy. Of 5149 women, 256 had a clinical fracture (5.3 percent of patients assigned to letrozole compared with 4.6 percent assigned to placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/31\">",
"     31",
"    </a>",
"    ]. The MA-17 trial is a \"switch\" trial, in which trial participants previously received five years of tamoxifen therapy. As tamoxifen mitigates bone loss in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/34\">",
"     34",
"    </a>",
"    ], it may have contributed to decreasing the fracture rates in the AI treatment arm. The IES and combined",
"    <span class=\"nowrap\">",
"     ABCSG8/ARNO",
"    </span>",
"    trials are also \"switch\" trials, but the duration of tamoxifen treatment (two to three years) was shorter than in the MA-17 trial, which could account for the difference in the findings.",
"   </p>",
"   <p>",
"    In the ATAC trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    described above, the annual incidence of fractures was higher in women receiving anastrozole (11 versus 7.7 percent) throughout the five years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/35\">",
"     35",
"    </a>",
"    ]. However, beginning in the sixth year, the fracture rate decreased in the women previously assigned to anastrozole treatment such that in years seven to nine the fracture rates with both treatments were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/30\">",
"     30",
"    </a>",
"    ]. This suggests that AI-related fracture rates will decrease upon cessation of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment of fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because AIs are associated with bone loss and fracture, women who will be initiating AIs require fracture risk assessment. Some studies demonstrate that low BMD is associated with an increased risk of fracture, whereas others demonstrate that a large proportion of individuals that experience non-traumatic fractures actually have T-scores in the non-osteoporotic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, there are several clinical risk factors for fracture that are independent of BMD, such as advancing age, prior history of fragility fracture, chronic glucocorticoid use, low BMI, parental history of hip fracture, cigarette smoking, and excess alcohol. Thus, fracture risk assessment should include evaluation of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical risk factors for osteoporosis",
"     </li>",
"     <li>",
"      Bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Osteoporosis risk factor assessment is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H7#H7\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Dual-energy x-ray absorptiometry (DXA)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H16#H16\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Skeletal site to measure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically perform a history and physical examination to elicit clinical risk factors for fracture and lifestyle factors that contribute to bone loss, including smoking, excessive alcohol, physical inactivity, and poor nutrition (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ). We obtain a bone mineral density study (DXA LS and hip) in women who will be starting AIs.",
"   </p>",
"   <p>",
"    Several groups have published recommendations for the evaluation of fracture risk in women initiating AIs. These guidelines for evaluating bone density were developed largely from guidelines for screening, monitoring, prevention, and treatment of osteoporosis in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Society of Clinical Oncology (ASCO) recommends BMD testing (DXA) for postmenopausal women taking AIs and for premenopausal women who develop treatment-related premature menopause following treatment (",
"      <a class=\"graphic graphic_table graphicRef66433 \" href=\"mobipreview.htm?8/59/9147\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Belgian Bone Club recommends measuring BMD (DXA) and assessing risk factors for fracture in all women starting AIs or medical castration therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A consensus statement from a UK Expert Group recommends measuring BMD (DXA) within three to six months of commencing AIs in all women except for those &ge;75 years of age, in whom the decision to treat can be based upon age and clinical risk factor assessment, independent of BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8597124\">",
"       'Candidates for pharmacologic therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A survey of clinicians in the United Kingdom regarding practice patterns in treatment-induced bone loss in women with breast cancer revealed that a majority of them were not monitoring BMD in women receiving AIs, nor had confidence in their interpretation of DXA scans and knowing when to recommend treatment with bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/45\">",
"     45",
"    </a>",
"    ]. This survey suggests that more work is needed to educate clinicians about these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women initiating or already taking AIs may have risk factors for low bone mass other than estrogen deficiency. In a retrospective study of women (64 with breast cancer) referred to a bone health clinic during a six-year interval, 78 percent of the women with breast cancer had at least one secondary cause of bone loss, other than cancer or cancer-related therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/46\">",
"     46",
"    </a>",
"    ]. The most common finding was vitamin D insufficiency (38 percent with vitamin D &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [74.9",
"    <span class=\"nowrap\">",
"     nmol/L]).",
"    </span>",
"    Other causes of bone loss included idiopathic hypercalciuria and normocalcemic hyperparathyroidism.",
"   </p>",
"   <p>",
"    In women who have low bone mass, laboratory evaluation may help identify other causes of osteoporosis such as renal or liver disease, hyperthyroidism, and hyperparathyroidism (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"mobipreview.htm?35/45/36573\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women with low bone mass (T-score below -2.5) who are initiating or already taking AIs should have the following basic tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biochemistry profile (especially calcium, phosphorous, albumin, total protein, creatinine, liver enzymes including alkaline phosphatase, electrolytes)",
"     </li>",
"     <li>",
"      25-hydroxyvitamin D",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measuring urinary calcium excretion (24-hour collection) may identify women with idiopathic hypercalciuria. However, patients often find it inconvenient to collect a 24-hour urine specimen.",
"   </p>",
"   <p>",
"    Women who have abnormalities on the initial laboratory testing or who have suspicious findings on history and physical examination may also require additional laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef62821 \" href=\"mobipreview.htm?1/57/1948\">",
"     table 5",
"    </a>",
"    ). The evaluation of osteoporosis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT OF AI-INDUCED BONE LOSS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonpharmacologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;We encourage all women to adopt lifestyle changes that promote not only bone health but overall health as well. These include increasing physical activity (including weight bearing exercise), reducing or stopping smoking, and taking calcium and vitamin D supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adequate calcium and vitamin D intake can result in positive calcium balance and a reduction in the rate of loss of bone. However, the effect upon fracture risk is less clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H2#H2\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the uncertainty whether calcium and vitamin D supplementation prevents fractures, guidelines for cancer treatment-induced bone loss include supplementation with calcium and vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/38,42,50\">",
"     38,42,50",
"    </a>",
"    ]. We suggest 1200 mg of elemental calcium (total diet plus supplement) and 800 international units of vitamin D daily.",
"   </p>",
"   <p>",
"    In women with low vitamin D levels (25-hydroxyvitamin D level &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    vitamin D supplementation should be provided prior to therapy with bisphosphonates. Administration of bisphosphonates in the setting of vitamin D deficiency increases the risk of hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Vitamin D repletion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H44#H44\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8596913\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic agents available for the prevention of aromatase inhibitor (AI)-induced bone loss in postmenopausal women are bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    . Bisphosphonates are specific inhibitors of osteoclast-mediated bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/51\">",
"     51",
"    </a>",
"    ]. They are considered first-line pharmacologic therapy for postmenopausal women with osteoporosis. Denosumab is a humanized monoclonal antibody against RANKL that reduces osteoclastogenesis. It has been shown to improve bone mineral density in postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are currently few other treatment options for AI-induced bone loss.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    , a selective estrogen receptor modulator like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , should not be given to breast cancer patients. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=see_link\">",
"     recombinant human parathyroid hormone",
"    </a>",
"    (PTH) is available for the treatment of postmenopausal osteoporosis, it is generally not used in breast cancer patients with AI-induced bone loss. In animal studies, high doses of PTH caused osteogenic sarcoma. Because radiation is a risk factor for the development of osteogenic sarcoma, PTH is contraindicated in patients who have had radiation therapy, which may prohibit its use in many patients with breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials comparing bisphosphonates to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    for the prevention of bone loss and fracture in women taking aromatase inhibitors. We favor bisphosphonates over denosumab as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. For patients who are intolerant of or unresponsive to oral or intravenous bisphosphonates, denosumab is an alternative option. (See",
"    <a class=\"local\" href=\"#H8597124\">",
"     'Candidates for pharmacologic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several randomized trials, bisphosphonates prevented or reduced bone loss in women receiving AIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52-58\">",
"     52-58",
"    </a>",
"    ]. None of the trials were designed or powered to assess fractures as a primary outcome. Fracture data were collected as adverse events. In a meta-analysis of six trials evaluating bisphosphonates in women with breast cancer receiving AIs, bisphosphonates did not significantly decrease the number of fractures compared with placebo or no treatment (OR 0.79, 95% CI 0.53-1.17) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/59\">",
"     59",
"    </a>",
"    ]. The wide confidence interval suggests that the estimate of the treatment effect is imprecise, likely due to the low number of fractures in both groups. These trials were not designed to study fracture reduction specifically in women at highest risk for fracture.",
"   </p>",
"   <p>",
"    The two largest randomized trials were the Zometa-Femara Adjuvant Synergy Trials (Z-FAST and ZO-FAST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In both trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg every six months) was evaluated for prevention of AI-induced bone loss. Postmenopausal women with estrogen receptor-positive early-stage breast cancer who were receiving adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    were randomly assigned to immediate treatment with ZA for five years or to delayed administration (when spine or hip T-score decreased to &lt;-2.0 or the occurrence of fracture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52\">",
"     52",
"    </a>",
"    ]. All patients received 500 mg of calcium and 400 to 800 international units of vitamin D.",
"   </p>",
"   <p>",
"    Results, thus far, are as follows (",
"    <a class=\"graphic graphic_table graphicRef78409 \" href=\"mobipreview.htm?30/18/31020\">",
"     table 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By month 12, only 8 to 10 percent of the subjects who did not receive ZA at the outset had a fall in T-score to &lt;-2.0 and received ZA, and no subjects with normal BMD at baseline developed osteoporosis.",
"      <br/>",
"      <br/>",
"      LS and TH BMD were better in the immediate treatment group. The differences between the immediate and delayed treatment groups in LS and TH BMD were 5.7 and 3.6 percent, respectively, in ZO-FAST and 4.4 and 3.3 percent, respectively, in Z-FAST [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There was no difference in the incidence of fractures (1.0 to 2.0 percent) between groups in either study. Fractures were recorded as adverse events.",
"     </li>",
"     <li>",
"      After 36 months of follow-up in the Z-FAST trial, between group differences in LS and TH BMD were 6.7 and 5.2 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/60\">",
"       60",
"      </a>",
"      ]. At this time point, 15 percent of women in the delayed group required ZA for a T-score decrease to &lt;-2.0. There was no difference in the incidence of fractures between the two groups (5.7 versus 6.3 percent).",
"      <br/>",
"      <br/>",
"      After 36 months of follow-up in the ZO-FAST trial, between group differences in LS and TH BMD were 9.3 and 5.4 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/61\">",
"       61",
"      </a>",
"      ]. At this time point, 21 percent of women in the delayed group required ZA for a T-score decrease to &lt;-2.0. There was no difference in the incidence of fractures between the two groups (5.0 versus 6.0 percent).",
"     </li>",
"     <li>",
"      After 61 months of follow-up in the Z-FAST trial, between group differences in LS and TH BMD were 8.9 and 6.7 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/62\">",
"       62",
"      </a>",
"      ]. Approximately 25 percent of women in the delayed group required ZA for a T-score decrease to &lt;-2.0. There was no difference in the incidence of fractures (9.3 versus 11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SABRE trial was designed to evaluate the effect of weekly oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    on bone loss in postmenopausal women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/55\">",
"     55",
"    </a>",
"    ]. In the SABRE trial, postmenopausal women receiving anastrozole were stratified by their baseline T-scores into low risk (T-score of &ge;-1.0), moderate-risk (T-score between -1.0 and -2.0), and high risk (T-score &lt;-2). The women with moderate risk were randomized in a double-blind fashion to receive oral risedronate 35",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    or placebo, whereas women at low risk received anastrozole alone and women at high-risk received anastrozole and risedronate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/55\">",
"     55",
"    </a>",
"    ]. After 24 months, there was a significant difference in the change in LS and TH BMD from baseline in moderate risk women, favoring risedronate (2.2 versus -1.8 percent and 1.8 versus -1.1 percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef78409 \" href=\"mobipreview.htm?30/18/31020\">",
"     table 6",
"    </a>",
"    ). LS and TH BMD increased significantly (2 to 3 percent) in women in the high risk group and LS decreased significantly (-2.1 percent) in the low risk group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Choice of bisphosphonate and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently insufficient data to determine relative efficacy of the individual bisphosphonates. In the Z- and ZO-FAST trials, ZA (4 mg) was administered intravenously every six months for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, other bisphosphonates and other schedules may be equally effective. In small trials in postmenopausal women with breast cancer taking AIs, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    were effective in reducing bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In these trials, bisphosphonates were administered using the same dose and schedule as those used for postmenopausal osteoporosis (without breast cancer). In healthy postmenopausal women with osteoporosis, ZA (5 mg) administered intravenously once yearly has been shown to prevent fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H29#H29\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Zoledronic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, until additional data are available, choice of bisphosphonate depends upon patient preferences and potential cost issues. We favor weekly oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    as initial therapy. However, ZA is an option if the patient does not tolerate an oral bisphosphonate. Although there are currently no published randomized trials using an annual dose of ZA (5 mg) for women on AIs, this is also a reasonable dosing option. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H55#H55\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Choice of bisphosphonate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged therapy with bisphosphonates is generally well tolerated. However, patients should be periodically monitored for a number of complications, including renal insufficiency, hypocalcemia, and osteonecrosis of the jaw. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteonecrosis of the jaw is an emerging problem that seems dependent upon the dose and duration of bisphosphonate treatment. Osteonecrosis of the jaw is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H48#H48\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In Z-FAST, women who were randomized to receive immediate ZA experienced more bone pain (11 to 12 percent versus 4 to 7 percent) and fevers (15 percent versus &lt;1 percent), temporally associated with the ZA infusions, than women in the delayed ZA group. No moderate or severe renal dysfunction was observed. In the Z and ZO-FAST trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52,53,60\">",
"     52,53,60",
"    </a>",
"    ] and the Austrian Breast and Colorectal Cancer Study Group trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/14\">",
"     14",
"    </a>",
"    ], there are currently no confirmed cases of jaw osteonecrosis in women receiving ZA every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;RANKL, a member of the tumor necrosis factor (TNF) superfamily of ligands and receptors, is essential for the function of bone-resorbing osteoclasts; RANKL accelerates osteoclastogenesis when it binds to its receptor, RANK, but is blocked by osteoprotegerin, which is produced by osteoblasts.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a humanized monoclonal antibody against RANKL that reduces osteoclastogenesis. It has been shown to improve bone mineral density in postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a two-year randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (60 mg subcutaneously every six months) versus placebo in 250 postmenopausal osteopenic (mean T-scores -0.88 to -1.33) women receiving adjuvant AI therapy, subjects in the denosumab group had significant increases in lumbar spine, total hip, and femoral neck BMD compared with placebo (between group differences of 7.6, 4.7, and 3.6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/63\">",
"     63",
"    </a>",
"    ]. There were no vertebral fractures and nonvertebral fractures occurred in eight subjects in each group. The most common side effects included arthralgia, back pain, and fatigue.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    for the treatment of bone loss associated with prostate cancer and for skeletal metastases is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=see_link&amp;anchor=H5#H5\">",
"     \"Mechanisms of bone metastases\", section on 'Osteoclasts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8597124\">",
"    <span class=\"h2\">",
"     Candidates for pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from some, but not all, clinical trials suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (added to anti-estrogen treatment with GnRH agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or AI) improves disease-free survival. This subject is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\", section on 'Prevention of breast cancer recurrence'",
"    </a>",
"    .) This topic deals with administration of pharmacologic therapy when no decision to administer for breast cancer effect has been made.",
"   </p>",
"   <p>",
"    The trials described above evaluate two different approaches to osteoporosis prevention. In the Z- and ZO-FAST and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    trials, pharmacologic therapy was administered to all subjects in the immediate treatment arm, irrespective of the baseline T-score. The SABRE trial used risk stratification and treatment was based upon a low T-score. In the three-year report from the Z-FAST trial, only 15 percent of subjects in the delayed treatment arm met criteria for receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (ZA), suggesting that treatment of all women regardless of BMD results is unnecessary. Choosing candidates for bisphosphonate therapy based upon a combination of BMD and clinical risk factors to quantify fracture probability is a more clinically relevant approach and represents a model for subsequent trials.",
"   </p>",
"   <p>",
"    For the prevention of fracture in patients taking AIs, we suggest pharmacologic therapy in patients at high risk for fracture, including patients with osteoporosis (T-score &lt;-2.5 or history of fragility fracture) and patients with T-scores between -1.0 and -2.5 who have risks for fracture other than AI therapy (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'T-score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We favor weekly oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    as initial therapy. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is an option if the patient does not tolerate an oral bisphosphonate. For patients who are intolerant of or unresponsive to oral or intravenous bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is an alternative option.",
"   </p>",
"   <p>",
"    Guidelines from societies and expert groups are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Current ASCO guidelines suggest pharmacologic therapy in those with a BMD T-score &le;-2.5. In patients with BMD T-scores above -2.5, annual BMD testing is recommended with initiation of bisphosphonates when BMD T-score falls to &lt;-2.5 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/42\">",
"       42",
"      </a>",
"      ]. The guidelines are currently being updated and the recommendations for annual DXA scans and threshold for treatment based on T-scores may change.",
"     </li>",
"     <li>",
"      The UK Expert Group recommends bisphosphonate therapy for elderly women (&gt;75 years) who have one or more risk factors for osteoporotic fracture, regardless of BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/42/37545/abstract/44\">",
"       44",
"      </a>",
"      ]. In addition, they recommend bisphosphonates for postmenopausal women &lt;75 years of age with T-scores &lt;-2.0 or if bone loss in women with pre-existing osteopenia (T-score between -1.0 and -2.0) occurs at a rate &ge; to 4 percent per year.",
"      <br/>",
"      <br/>",
"      Due to the rapid bone loss that occurs in premenopausal women receiving ovarian suppression with a GnRH agonist and AI, they recommend bisphosphonates for such women if the T-score is &le;-1.0.",
"      <br/>",
"      <br/>",
"      In women who are not candidates for bisphosphonates initially, they recommend repeat DXA after 24 months and initiation of bisphosphonates when the above criteria are met.",
"     </li>",
"     <li>",
"      The Belgian Bone Club recommends bisphosphonates for patients with a T-score &lt;-2.5 or history of fragility fracture. In addition, they recommend treatment for patients with T-scores between -1.0 and -2.5 in the presence of risk factors (other than AIs). In patients not prescribed bisphosphonates, regular measurement of BMD is necessary. Bisphosphonates should be initiated if significant bone loss occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8597419\">",
"    <span class=\"h2\">",
"     Monitoring response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the response to therapy is important for identifying patients who are not responding. While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach is to measure BMD two years after initiation of therapy and every two years or less frequently thereafter. BMD that is stable or improving is evidence for a treatment response. The finding of a clinically significant BMD decrease in a treated patient should trigger additional evaluation for contributing factors that may include poor adherence to therapy, inadequate gastrointestinal absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients initiating AIs, we suggest DXA of the hip and lumbar spine. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients initiating AIs should also be assessed for other clinical risk factors for osteoporosis. The most robust non-BMD risk factors are age and prevalent fracture. Others are long-term glucocorticoid therapy, parental history of hip fracture, cigarette smoking, and excess alcohol intake (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Lifestyle",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We encourage all women to adopt lifestyle changes that promote not only bone health but overall health as well. These include increasing physical activity (including weight bearing exercise), reducing or stopping smoking, and taking calcium and vitamin D supplements (1200 mg of elemental calcium (total diet plus supplement) and 800 international units of vitamin D daily are suggested). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nonpharmacologic'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pharmacologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all women receiving AIs require treatment with pharmacologic therapy. Risk stratification based upon baseline BMD T-scores and clinical risk factors can identify who is more or less likely to benefit from bisphosphonates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women initiating AIs who have a BMD T-score &le;-2.5 or history of a fragility fracture, we recommend pharmacologic treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest treatment for women with a BMD T-score between -1.0 and -2.5 who have risks for fracture other than AI therapy (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8597124\">",
"       'Candidates for pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not meet the above criteria, we typically measure BMD (DXA) every two years and prescribe pharmacologic therapy as indicated above.",
"     </li>",
"     <li>",
"      For the prevention of bone loss and fracture, we suggest bisphosphonates as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      is an alternative option for women who do not tolerate or are unresponsive to oral and intravenous bisphosphonates. (See",
"      <a class=\"local\" href=\"#H8596913\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Denosumab'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The choice of bisphosphonate depends upon patient preference and cost. We favor weekly oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      as initial therapy. However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      is an option if the patient does not tolerate oral bisphosphonates. The optimal schedule and duration of ZA has not been defined for AI-induced bone loss. Four mg every six months or 5 mg annually are reasonable dosing options. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Choice of bisphosphonate and dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8597626\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the optimal strategy for monitoring patients on therapy. However, we typically measure BMD every two years after initiation of pharmacologic therapy. (See",
"    <a class=\"local\" href=\"#H8597419\">",
"     'Monitoring response to therapy'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/1\">",
"      Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Ther 2001; 8:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/2\">",
"      Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/3\">",
"      Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/4\">",
"      Geisler J, L&oslash;nning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/5\">",
"      Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 2002; 57:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/6\">",
"      Dixon JM. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. Expert Rev Anticancer Ther 2002; 2:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/7\">",
"      L&oslash;nning PE. Pharmacology and clinical experience with exemestane. Expert Opin Investig Drugs 2000; 9:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/8\">",
"      Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003; 86:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/9\">",
"      Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/10\">",
"      Lamb HM, Adkins JC. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 1998; 56:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/11\">",
"      Wiseman LR, Adkins JC. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998; 13:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/12\">",
"      Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/13\">",
"      L&oslash;nning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/14\">",
"      Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/15\">",
"      Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/16\">",
"      Saarto T, Blomqvist C, V&auml;lim&auml;ki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/17\">",
"      McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/18\">",
"      Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat 2007; 105 Suppl 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/19\">",
"      Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 2007; 106:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/20\">",
"      Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26:5465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/21\">",
"      Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/22\">",
"      Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/23\">",
"      Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/24\">",
"      Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/25\">",
"      Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009; 20:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/26\">",
"      Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/27\">",
"      Coates AS, Keshaviah A, Th&uuml;rlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/28\">",
"      Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/29\">",
"      Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/30\">",
"      Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/31\">",
"      Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/32\">",
"      Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/33\">",
"      Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/34\">",
"      Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/35\">",
"      Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/36\">",
"      Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 2007; 18:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/37\">",
"      Nguyen ND, Eisman JA, Center JR, Nguyen TV. Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab 2007; 92:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/38\">",
"      Khan AA, Brown JP, Kendler DL, et al. The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ 2002; 167:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/39\">",
"      Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/40\">",
"      Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/41\">",
"      NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/42\">",
"      Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/43\">",
"      Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/44\">",
"      Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/45\">",
"      Lester JE, Dodwell D, Horsman JM, et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006; 94:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/46\">",
"      Camacho PM, Dayal AS, Diaz JL, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 2008; 26:5380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/47\">",
"      Schwartz AL, Winters-Stone K, Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 2007; 34:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/48\">",
"      Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005; 23:5814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/49\">",
"      Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer survivors: potential for prevention and questions that remain. J Clin Oncol 2006; 24:5125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/50\">",
"      Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/51\">",
"      Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/52\">",
"      Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/53\">",
"      Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/54\">",
"      Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 2006; 15 Suppl 1:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/55\">",
"      Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/56\">",
"      Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14:6336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/57\">",
"      Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008; 26:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/58\">",
"      Safra T, Bernstein-Molho R, Greenberg J, et al. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology 2011; 81:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/59\">",
"      Valachis A, Polyzos NP, Georgoulias V, et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynecol Oncol 2010; 117:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/60\">",
"      Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/61\">",
"      Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/62\">",
"      Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/42/37545/abstract/63\">",
"      Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2062 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37545=[""].join("\n");
var outline_f36_42_37545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTROGEN DEFICIENCY AND BONE LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AI-induced estrogen deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SKELETAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment of fracture risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION AND TREATMENT OF AI-INDUCED BONE LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonpharmacologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8596913\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of bisphosphonate and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Denosumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8597124\">",
"      Candidates for pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8597419\">",
"      Monitoring response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Lifestyle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pharmacologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8597626\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/42/42667\" title=\"table 1\">",
"      AIs fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/21/2395\" title=\"table 2\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/59/9147\" title=\"table 3\">",
"      ASCO DXA in breast ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/45/36573\" title=\"table 4\">",
"      Secondary causes osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/57/1948\" title=\"table 5\">",
"      Laboratory evaluation postmenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/18/31020\" title=\"table 6\">",
"      Bisphos AI bone loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_42_37546="Acrochordon - close view";
var content_f36_42_37546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53025%7EPC%2F70871%7EOBGYN%2F78524%7EDERM%2F78625%7EPC%2F58450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53025%7EPC%2F70871%7EOBGYN%2F78524%7EDERM%2F78625%7EPC%2F58450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrochordon (also known as skin tag or soft fibroma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pedunculated, soft papule is present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical acrochordon (skin tag)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrochordon  (skin tag or soft fibroma) of the thigh",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrochordae (skin tags) in the axilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3QY+7tGfcUgjI/wBXwfQ0pYjB4NSs3zKQcDHaoPUKQkJuZMR/PEAPbnkn+VTSqJYct8znA5Hy9R2pkJzPdcn/AFgPP+6KnmwDEoAxuzkHpST0ArG3ia+myuHWNRlTg9TXP3MNympmRfLliZpEjD/Kw27QQD0PeujuSY5Sy8STLsjx/eBOP0JP4Vj6gUFu0UTjfbzBgwGSM4yT+ZqZdhoVJrlrjiGLao243ZJPf2pZdl6SjKYpY2yGHDI3r/nrUEBnVlEb20hJICl2UgflTbsXy3Czx20UjKCrIs+Cy+xIxkVncuwxpH8wwzogVhnplWHqP8KhurJvPia3YEIjEoeoBwMA/n1pi6gL3dFJZ3Mcygfu3Cqy+455/CorC9U6jPbSMyyjCqJBtLqBk4/OkO2hZXZLHg/e5DHofofesy7jX7JJDc7cqf3cgUEMe34+1a9zDG8aurEMueg/Q1m7/NliinX7zbyBx0/yKBRMqSCa4iNlby26sMpuWEgnHUna3Qeg6nuKpjSbs3TTyzKBNgDy5JEJcLg7gWYds8fjmt9fMgeFNoc7D947TIM5PP8AeFQ6jHciWLy1EMbTbzhgzHCnOOwzkc0i0zJEmqXKNHIkciRuqHJALkEcBlGM8Z5HWtSy1K2WGaO4jaB/NONwBXdgd+mc9qvQxolukDkRqqkFQO3vWdaMsdo0nlu53FXVv4yenHrgige5ob7hIWUeWwQgswUAqM0oOCuPlVmztYjr71QuLOeOErDcSyIRgwq5TafRO+B6Hr7dKLCF3hil8zcGHO4fNnpyKQWVrmgVd5CjhQfvcqMYpiIjhId3PzEMB0Hp9KeqSBPld2Q8bT1B9vQU2K5xcltvzhQpGRx1oEQM3kq4eLeGXaTjIA9RSxA+UyIQiknrggVajkUwSRmLdEwwzHqh6ZH+FVbi3e3kIRwWkbEeDgN9fQUB5DTZm2VrhZCI0XLOSAq8ZIzWVZ6rbR7pLpS0so3Equ5VHZQ3TAH9at3UL3EyJcoJmMigqfuJzk7B0BwOpya6KOGIAmMI57hk5H1NUrPRCk7LU4+9nvbu5SC1S3hjK75G25IU8Ag9OT069DVXTtLe03PPHJhn+V3G4FVHB5/P8am1SNdKmuJRI8bSs805ZW8sKDhQmAe3GP61B/bv2/AXS72YKPlTYIU9sF8H9KLMtPTTYdsh+0IZEX7M8m4fLwhPXA7An8jVq90yFJ0ktmMc7ElWQZI+vqPUVXtH10zJbmy01FnXdGHneRo1HUEhR+NQ3Gnap54ju7xo4Acb7WJV8o9vvZOOnU8Uiuomoxi5tG2QRw6gFxuc4VvUdt3GcA+1U7eJw72DX1xcWUa+ZJE6iBkHA4x8wBPcHtVl0vwsltdyLJxtYyIHz7grj+tYkwu/OtzqQCTRnyYyrjer5Hyv9cAgHhgapbD8jT/t25m22trd3Jtz+7e6uJNiwngBcYO/g9RjHGTRZzahZ6Tcoh069toNtqUw0bjacHAIIJGSP1qTTr5de00WclqbeW2Jind1C+W2T0XqSevNVLy0OhwmNC0ljJHgCQEkHI6n16nPvTb6EqKenUNPXTLJne3sns2lYhzcASQyZ7bicq30Kn2qlc6VdO7XlnayTbVIYB9657bcfN6846V019brcyG3s2UxXjFJi0e4KqqCXx37D3rmr2W+0UTm1WYwW5wkEzhRIDjHluR8uM4x0+lNBFtN2LWn+IxGsUUsiB/MHlGZCpIY4IPTGG7/AONS6ndy2iCW4dZVZSJpI8Z8wEbcg/iB7Vnrcpc2MslxA05dxHdQyYDxtuBCle2M5B79avaQh0yS5j1KJp7Wa4c7JFBDR5AViOh4GPXikDNCK6tbuYNAxDy7yp6hjjOMfSr2mXtzBclJDhCigAfcLDGfpmsM2Gn+XLZoBG0bYhkQ7Skf3h15OMFPpitO2XzniEsiTDJ8wqwOD65FGwmk9zpNHube+geWWIbnYthlHTJBqtrOhxeW5t1WOUY2MvYjvn1rItIZbNljt5fMt1XOCcN16/rW1bao0Tsl4pG3+JeQRnrRe5lyuLvE5zVr5BazWt2Io5zh4WdsBGHc+3881ZtJtPu7e2vbS/T7Q8Q37GUlm9Sp6ntSTaVpV/u1CaOOeacl23DmNQDtUenGCaij0lbWyiMKEBQwELrvCq3zd/qKHsWmjRvwJ7EwXUSvB5qZDjGRz0x0POQfajSbgWANvqTG7j3YhlxmVwf4SP4mHT3HPFRWRhtws7llhz8+ckIOPmBPoeo7CrqhBK1zODuOQmDgxoB0/HGTSJfYzdQ1U/2UUnjigifeVmlywZGJGWAwARkZBPauemv76LVNEjPkSxbHa4CodwUBUAOSf48H6V1NpFF9iSdcOTGqFWOBJx05789aoW+kWtxq8kkgZBLINgjJV0Reo46fMp9aEPbQ05LVYLVDaqDjgg9c9zn3NV7G1hMjoYo2DxhwMcDsRjv6/jVTULaUIls2q3cbYIQuysJVHf7udw7jNOsrE2+JLmQzOV2oxG3j2pAldHOaotx4andrGNpbeSYsbdjnqc71J5A7MO3UelSm1a+vY7vWDFcsYwUKHNvEM5GEP/oRz+FbF1pc97yNqu2QDvJ2j2H+c1R0gXaWyxyxwl4iYyVH3lyfX/Jpp2LsmiO/khh1CDyoRjcYzhASPlP9QKt3qQzRF1VXKp84YLjYT0P9BSyJsCxPDKHR0IZkOCm7j2yORVm2ltiCz3ULLt4ViABTT0FbqcjqVi9kVWxmDQrH50kCqcAZ6r1x3JHcUX2rRWbI16yRSff2q24SdgFPcc56Zq79oZoGSzUNO7HZz92MHCk+nH51ixaXHZbzeqZ5w/2ZppScxnqjj+6u0ge2Kq4mu59QKjNCARnuKaclTn5R2FSIdqjHHFMfaGIZ+B3rQwK4QhGlj5ZpGzk9R0x+lTsySMmOGBwQTgjio7VmEaKFxlcnPqafIm5VYhWZDlSR+lJ7DKpU6l5nO22Q7YiCQXYdSfQZ49+az7tIZbgQKmwyMCwT5SuOo/QVrWDqUYK/KsePxyKz54A+szXCuqsqCNTjhsHJz+dTLYa8xjjy3EV0BIG5WQqOfb61XvhJG+yMl1HzMn8XsB6+uKtz3a3MnkJEDKmC5P3RxwAe574qIBLYHfJu3dSx5Ge9Q1YLla6RbyBcNhxzG/of88EVmwCK+juknz9oSYOC33o22jp6dCK0p4ElberSKWI5ibAY/wCPvXNaor6TrbSrdXMsdwApjAD5Pr07HknIwCT2qS4I1J7xlijzGXm+6FXHJ9fpjmqsNtczTNcXDQhkIVQFITA5I3E9Saz7mK8tpUuL90bbGY2MMpjRcEYyBz7ZJxWZZalbSRNGLdPL3Mkkgi3tEBw3JJ3dc5IHBzQVy2Wh06SxXVlAY1MhCF1284wcfj6e9Nt5ZHvivluBAoDQv1Bbn8sAVgS2Gn29/D/Z6KFeMKFD9Cv06ZUn8q1dKjS6sxc27TQtK5bIlJIxxjJzxxUoTSRrX00ZSd02fLGSyE4ZeD2rJYyT20DCQwuZAXO3G0+nPZQQPrTXka5mV2u7SWGP/VqSEkZh/FuHHB6AjnqaoeH55PtTx3C71DPtLcEox5DDpwccg9OaCkrI0zMbB0W6c3EZ6OVCnjkg49P1qeCC5iu7oxtujciQLnocckfUY/Kql3aSSxMguVjjLYAaPceOg3Z5/Hp71qWSGWPLnDduSRx/SmK+hMNzbSWyXGck9R9BUEce26YujODtYZ4wB1qykYhYzB9ijJz3HrUMt15sUc+JHWNiJCcDCnjP54pASJIdsmAiR5w2SBjuKjhdojJK2dzgYiPTZ6D37/WoJpILm4/dfMqfM4xjc3b6j3qZEGB5sgIL5HPOPSi9gFfyBJaGAP5bSEiQ/wC42QabqGoQ2tuZMzknCqFjJV8ZPXGMd81IsTRzr5Tb0UlirjjGOc1XuoY7m7K2bAIm2Ly2Pyg43vj0/hHpzTQNdCjFLLOVnlWKS8Y7suxZIR2ESjP4k85z0qu8RaYbpJEbdgkKqgfnk/rWvPHAWEW5vNY/u4OrEdyCP50l1o1y0aF70QoDhY9olAHoWIz+VN3YJpGNdebptyLqS6iaNYhgSlV/i7N68dKtw6xaXqM0XmSKAchI2JB6EHjFMl0Ym4lT7RcPG0aqyfaSFYZOcdPfNR2OnATXFvazDfbsrKsp3F0K5UknqRyufQCgejGrLHbyRm2jnaLkFZLctsz79cfyrB1A2ct15d/EUTaRKHRoxJF6Fj0Izj6Yre1FZYCxkSTayE8E5JP8PHHORWUti9/GLqaQfbbaMNjkoGK5VVGe44LHnP0pIuKRj3pt7O+i1PR7q4urcMsNypDH5D93cRnBU4Ab3wc1tagI9R0qRbe4dbkjb9kuR5cq8+hx6delXp7W31TTZ4L2CNJ3t2Xd0PK565znPaqcULf2NBDq0oe3lgRo5JGGQMA4bjqOec1WjEY9lLMmttJHJJaxxRGHEjcbshn579q1ppINWjEMsoZI5Y1zntuANc/rVv8A2E0klwr3EkzPPbPC/wDpUYY5+7yJBjggjFZEWqa1p0LpcaC8sMowsxZYivcHaCdvXnJx6UW7F6S1Ow8TaFKiqdPAlv1VSr5x5saEEo3rnHHoSPerFs0+o6eLhC8UJ3I0oQeY+CQ2Q3CjOR0zkVzmjeN5kmeOWGBbgMFMcjupUZzt5Xjk9+vrWvp+roZry2uEukLMZSCoYLvYtwc8qcn8Qaqxm4yKI0mNtcglQmbEMkZa4+YjG0jHYZ56Cr01gZZo57XC+TncAcMV7gfpxXL6jG2l+J7RdMk1GG2nimEVtKBIFYbTwSeVPpkYxV3/AISN7Nyb9PIQoCzbGAGO/f8AEgmpZSuzda5l8oSSp5RQbWPTP+0fUHHPpWnpd9Dezul9EioRlM+o5BJ7ew7VgrfpqUYEbsLYIXyjDEzY+T5vT2745qrFC9yqy3khhnADG3jIUZI+vzH15o2C19GaOpamNI0Ga6ugW8iEo4BwWAIHXvkfzqWPxNayS5jmiMUg3K+8DI/zisO+1KaCHN1DC+nNJGl0ikN8oYfPsGM9MEc5xVqHR4pXnhsHgltiDJCMja8Z4wufTgflVW0FZdTpJ5IbzTDbAhlcM0oGQSuBx9ScD86t6ukojQRKXDEo64GemM/rXnun6oX1aO0tYHRpHCYMi43J83yr/dOPXseK7W38RW0jESx3CzL+7KrEWDnuVIpWIa5XoQ+GoS1oge6dZV2oSYwGXjgZOcDjtikisIpPEsDTLJLEy3EUxycLIWVlY88EitDfEUaSC2nR2AVmliKpgdc55P4UkV19hmuoUc7Zikxc4+dsqCfzxx2oFLXUq6zpUUeYDcSmFw3lh5CWRscFSefb8afayybETUGECKow5I5PbrxWpc6QDcyXRlLtuUDPRRnP86zb+SFbqN7wo8P+rTzUBG72HO5jx2osCldWJ5ZclEikjRXGGkDDge3qaZNb5vI1jRfmhI+XngEY5/E1Tuo9Kj4OjK7E4AYIpOfReufwqO42iF5LvTJFMMRECM2QFGTsDKcDJ+nNJpBFFa/kltry0S7UGRHbOO8ZGB/49j8qbIkl67W0bxwRr/rZWwSB/dX0PuaoLF9okgvmVltmYEReaXCIeFkBPOeSSOmDXQaYzIQrRgHOGYLikW9iGG1s7JF2CLIP3iOG9y3c1SuLXffed0SdPIwOQGGSrHHryv5CtuaLcGUgbW7Z/T6VTnsIjbuiHyUK4ZV6E9j7c88YprUzbR7GBwAMn3zUEy5TadwZyFz9T/8AWqYMFAPPWmTgPLEA3TLfkP8AE1uzIWVpAwO0NgdR1/KhJ0ddjZVvQjGaeRgbu9N4BDHpSsBVvII2HmGQwuvzCRe3/wBasVL69EJW4tdhZmVLqL5kYk9dp5UY55BFbN3aQ3K+XlgFw7bTj6D8f6VUjeVZZnC70jOIyOGOcbjjvzxxUMrQoWS+UuxU86I5IYy7ix7k4HJJpt3cQxZ2qvA/1SkNz9Gxj86uXQtJ+AINy8EnGVPoPU1mXNlb3TvFZWyQRR8GcDDFu4GO9SPQwb7U38wW9np95DKvzEJtGB2LjIwPY4+tZ1/rEz+VJJod7NciM7IzPCFbnD4UNyDgDv2rU1XTZrKEJYT3BuCf3as/8RPGR1OfTPQVnWYFncCGO+c6uifOHRSCwPKHgEJxnIOB35qbmyStdGDfa7D9mt7e/wDD1+1pdyokRBiMgAPKEBv90ZJ9jWVZ3Umm3DajZWt/BIZXJ06dfMRxuOEBHKNgHnleo4rs5f3GstDr1tF9nvoCoYIZIw7MCVDHAXOM57nvXN2GnzmGax1q7RPLmlS1upEDtHsYkbsEDdgg+4qkNNNEo8b2mpaSzLaXL3ELFdoQAQuucbnznoO3bpmtHw7qNtc6fmz+1yF1UgyR/Km4DJUegyfesxLRL66gsruWO11xFZ9wAMUzDDFJAABtKnI74GQSQai8KTSWjpayQMrRySPJbO+XiU4KYI5K7SCPbFJoejVj0FL22MYSAxuuwARhcMQPY1WvtOjlCrIm1XOQ8eVZT3UkdjViS3FxbJ9nRJYephc8H3Vv4W96BeskiW7ec0bch5MB1YfwsO/1qTK/Yr/Y9RtFS2klM9sw+TzsEMPTcMEfjmrWgzKqvaNG8F5BkmKXksmeoPQj39qvtdIkSqPmLc7ccD657Vz8tpcrczzwlBE0xUMMjyjgEEHrjgjHTnpQyk29zZmImMpRsnHK/wA6eiSLEGjAA3Z3A/yqhZTvd26yQeTHOG2Oi/NyOD9fX8auss3G2ZQcAtEY+ntS3AsoyOyDDPOegIwBxSvaiSEkttbHyjHX2P05qtBJKqMhUqw4DHHH04/Wnwq8lwPPkZVfquflZu/P5cUeRLIrc3MpZTIoVTjBzwKzR8mtGFZ1e7k8yRUyQDkIBn24Oa25rdoXIhZCx5KD7oHqa5rXoiuqW97alnljwl5JH9/y3zhUHbHX6HjmhFJm9p8iq8kd7JtuWAyQMdOAF74HYVoyqBHFC2TJISpdcgkHqT6Y/rXHxLp7vLGNOnd9u4Ga3Ybvfc/rWjpkt/CJJJJPPjZtqISSYUH8BPsecnn8hTTFKN9jUltfswljOxYDCIlkDcowJI69+TVOCKdoC+2Mahbtklhwxb+E99pGPoR7VsrbxXFvHJLtuCx+5n5F/D/Hmsu9sntAkxmn2qSFfGWRM5w3dgD37d6oheZA8sV3h1LKVlXzI2HMbA8gj8R9aqpDNY3l1IFUJHztxxsYksPwOSPqRVjVLcSRfaLWaEyBQHXIxOvcAjgkdj+FJp+oLIAyo91EFIDKuGx6MT8p6EdRUlJaaCXC28kf24JHuHzMRwcVmCRY9EtrOdNy+QBITzsUDv7np+dLPBqMqSIbdbaOJiiDeHeTH3c/wjgg456VC80tnoUtsbUyycRqcAsWYhd3PXkjrR6gkaV7ZwvdLdadvRcbsLjHHb6H0rnXimXVJLafTYTDHjZvbbEwYZ2nII4weDxyK0pop47horK7ZriMhhvi4bnBBIxx+dWLC/NzPfxXsbRSxqjsrHI2bMBgR2ODTQ1dI5W60uCztRKsMg8smU286K+I88lDnlQSMDOeeKzra6udJ8rWdOtrq40OJz9oG7IVW+Usit864YruQjHfiurJla7hlhiee+toJGWKPHlwDcvyljxuIyDjJ9BWZqEt7Z6Rqk81tbPZXYFyUWQh1JwDtyMHdxkHHNXcbk2hL/UYjqdpOLWZRHExIljDDDYPQZ9KbpTWuq3LwrPHLbSNzGpG1fXA6A9+eafpdsuteGNPu5QDthVTAOowApDHuflJ9OazpbS3sL1rqIohjZTuUbTIucEH1wDn8KXWwRehjanoEug3xms5WhtbyX7JKiPuEUuf9ZjkYIYfQg1dsLVwk7TJ9oaGR4mDZIcrjdz1J+tdPZSwXOmSwagFD3ZdnjbnAOQq/jkfl7Vl6PFqC6MJAovLWSVpkP3ZkAdvmI6SA8+hx60C5mtGVprfT762eFLaFGkjZCNgUo+OOfrjFZ0cOoRWMF9bXZGxPMlikT5Om2TGc7T7jr3q+80Bkcz/ALgSHejP90gHPyMeCPY8is+O8spYEsJ7iORDcSbpFbKiFH3Y467iQoHuapPSxTJbOBrmBb2Uv9pn5kOwDYQflX5emBj9asy3M9hIouJoJY5m+Uq3zFs4wcDg8da045o5ZHd12SSuHAYkEDgc49cfrVa+sbXVQPNiVpSp5zhgR7j3/lSY1pud5o14s2m5jYmM5XnB5HrVHVrRbjUNMRFP/LSQsMDCqARn2J21yVlHeQS276bcGOKULvEqbxuGMHAIwc5571uWmtSvcNeTwtcZX7OZbX95GAGyzBeG5IHQHpRuZuDTujZ1DV4dP0+WcuxaPaghUZZmOQAo7knpWbptiHX7fqzyfaXUZj8zCxLx8o/qe9Kos9ZvoJLWeKTbHlSMZUnqOec9sda1ri2EtpJbtgNgbCy5XP8AkCpFokTC3slUKggDZz8pHX+tVtYjR7CS3ZebgGIDuFP3iB7D9cUlrIGRhIiMiqAysBlSPr0NUdsiyiWGQ/ajxHbucoB29wO5P5UybEOn2r/ZGhmDGQExEHjAX5R+gFQRXQguFhuxhzxvPCv7/X2rRiuHt5EguFBYg5Gc7z1JH5mo52SXbDtyr58wYyAvoR3J/wDr0FLzLUhQHAXoe4qjMN6kqAmBnB4qObSvKi32Mkts4OdkTZB56YbIpALhotqeRKSOGyUP5c80CseuLyCA3IHIpEJaZzxhRtGe/c0MApJ6U2EKGnI5IbOPYgVsZkrKOCT+HrSSL8m0nrj8KFyeoHApW5Oe54pPYCO2JEe5hyxLEHv6f0rJlgaffDcCQsGZljjPl7c89QQT9c49q1YQGtwORgYyTUMwBjIwSAfxH0PaoYzn59KcqBabbYdeF+bPfc4xn6c0sct1aRNHc2mSgypicbT6cHnrWzFkIvnHI5bJ7n3+lQ3YNzC6gKiMDseTPX2FQ0Unc5+eTzZSkspSWLHCgoxkbryfbHSqNjZxf6ZcRohlM+A5HzbOOp6kNkmpbq/EkVwl89uJVmcMGO1iQvGN3XioDm3spLmyfHkxf6Sn3lXAzgDruHYDt+FSX0LTW8N5p8VvMCVlgKFiM8gggfoDXIHSXuxcB7iK2kWQrKkjHEjKflzjnjsRnIwD3rqJnMVnAJw1t9nIl8tCQSnQ89TwegqNrI21xFfWsIDgbZvUKT275BP86LhFtaHFajb6pd3Nnc3mlBJdNk+cWh+aZFByQCQdoB3AEc9O9Wb1dP1nWJLuGXF8tkuJ7c4IKuQGwecc/dPTpXb26K+pG7Yho54jGjA8FFPX8ck/TFcNr+kyrqkV/bossUcG5oQ2zIVdxCt/30OfT2FVfQpO71Oo8N3MyRAT7HLkgbD8r+4Hb/drb1CzW+sn3KrxyJllx1H+I9a5XwebeaxlVg2XYSeQ52yRg9CP5gjIro4bhkkNuXGfutKBzt67sepHH1FRfuE172hHpHmW/wC/ZzNZqoRWwN0ajjn1FXLmBYrlwZMQXOHVw33W9P0BB+oqS2QRSt5KYSRc4Pf6CmzRtHbywyBBaE7cAZ2gnkZ64757UyLu5hvqP2KR3CPNKylTFEPvyJ7ngEqeue1O0OdlMVtM7SGZTNC7HJViSzx9eQM5X2yO1SzpJBMIvlYxOjB8/eT7u7684P4GrFzpVrdROp3RMrCRJYjgxyDkMPcEfiM5pI006lyC6VoXF0fLGMmQ9Dj09KUh79AlvI9vHkESuvzAjkFR/U1kWq+fOsF8kYv1AkcKcgnp8voD1x2rdhJVxHIn7w429xjHrQQ1YiEbWc7ZJZWPU87j3OaqxtFJdalH0leQHa3IA2DB9+laqs32gpKyyBVzg9wf51jyRxx63NIomaOWBHxnuGZce3bmgadyVkF08cs6FZUyjvnOT6AdAO/0NIdPiVt8f7qdh95WPzD0OP51blQRIz5MsR4eNTlseq46kencU1ZLWWIyRXCPnLK6LvGD6ehzxTsJtiQpLFFiRHdA2S8R5HuQOtXVuA9vFsKSpIflcdvf61BZ3nloQUmkgI++FBz+R6U51trgGezk3uBgxgYDEd/Y0ydtyvFp7FTIiyQsSSzR8DPfK9Kqz6deRSSzWl/EIpeWVod2W+gIH1q/Ldztblre6CxMMlW6g5x07ehqtbXc1zcb5ljDfdVIxlQfU0aFWZg2V7qkclz5jwXMkUgCx+Q3HygEhg2Pzzin3V44t0mvrNrIRSoZFLgrnII+bjjHPr9K1rndfxiOx2Kittacg4Y9wigjdz1OQB71x+qeBNPkvGuNRM2oMyGSQEnLHGAVRcAHPfGeOtCDmTZoSeIE1KbbY27Xs65CsG2Rnt98/e/4CDWddWjSxefdme3kvCkDxw8LIN4O3eeT/wABC1EvhGG1mLWk9xaTyKBIu7zhIO3Dc8exBrQs447GKb+1rEeahLAr5jgL0Gzd0JOPoTimVZLYvaafIvJ42cHyEWFFVcIuMscD8RzXNzSNPp6JMzPanUg7PnA2KRJsHtx+orRvLnNvFbarPEoTJaTcqGY55Dv/AAjPXnBxj2rnbXW7nWrjzdJgt00yCTKyvlQ7BMAIp5Y85yQAcdaEI6y1t4LLSrSdJVtI5I1N1ltqZAx1PQ9qz11C4upnXSdN+2xOuGuLpTDbD6ZG5x/ujHvRZ6VbpKb+Zmv7zcZFkuWy0eeoEfRDnPQZ963rW+lupXBh2lh/rHOO2OlF9SZXsc/PoWm29s9xfzSTXezYXzsVOcYjTog568n1NO0+7ktrKKK0zLHGm1scquD1HrnFX9Z05JI1W5nmfzZ4VAY7R98ZAxzWZJZXEF80WhT3MMAZvLuXlLxsepCKfvHr/s8cZqgi1awzUFt7KZJlcPBeAriPk+YBkYHqwJB/3RnFZHh2G4VI7wfZkuroNOxMO/ywSSEUggbcH8c1JPp5jW4/s6KW9uGybyaRCHCsclQ/3QT6YAA/CrUV+bwRp/Z01lIAAqfKmRgcA5x0/lRe2xa7spXdhdx/L5kIZ23ITE3AIzjg+v1xWbbXt5FdFIrYHLbI7lZN6SyD+6CO+PzHetl5L67iWMQMkU2UUF+cEcuT1Awf1FUr+4a4gXTbW0VxblFmxLtaIrj5V/2uBg9s0RHcmtZ7mRYoV5iA2mTGC6g859Of14Faq2/lx2405limx8y5PGDwuM44rA02/kSSaBrMvdeYyMokAYgcrjOA3XqD15q/aXk9zM0Mim1nBBaN4svx3weCfcZpO6HfsatnBKJ/t8CRi8AwysPkuF7q49fRuxHpXTWc/wBstI59PnXyZOscmSMg4K56qQcjvWHaX0FvGkRlD5ztP8ZJ5PH1o04NZ61P8u2K9/fIM8LIMB1PuRtP1zQZSXMzfkdHmMN1b7Jtudkh5KjupH3hUUFrHDkQhUDckjo3PepEEd7AIZvmPVeeQfb0PoaotLNpyqLtzPa9PPI+eM/7YHUf7Xbv60EodcgFhbxxDMhyzk52L6j/AGv5U0wPaxlUDOCMhxyfxx1+tAZlcMu0MRgnAOB/X60sk5IK4BUDoO4p2AWK4MkO4OCuMMCcjP4dDVO7V1eS4tR2G8AZzjqR7/zqybaK7xLkpIfvMh2sT26dfxqvOk1u+PMMi4L44Djj06H8MGlYrRHrTqCvHOKjcGJkm4wBtbnt6/hUwkVvlH40nLMAuNrcEHpWxkADI7ccGmOchmHGOSKICMCMnc0Z2nPcdjS4B3jJIOcUmBBA+C6jIyd4x6Hr+tKXyxX1pChZQE4IPynHFCchhyGU4I9KlDKz7ZXKEfu1GSOxPYf1qu8j7tsYVpWOFLD7vqas2h3wiQkDdzg/WoYiGu5ZPmyvycdPeodwRz+s6ZbrqNveIim5BYM8vImOBjcPbt6YrM1pX0vybm3SVJBNGbiJBndHnLsT3A6g9s/hXT6lKkp8osA6gMBnHzEkDH6/nWWbNJkWO7V5X8uRJQ7ZyeAf/rUmi4tvco6s0t8o8i3RoCS295Dkn1wB07nkZqa3a98h0lf94fkUR4HJ4BwfrUeiM8emRpIkhRR5YmCltwHA3DqDgfQ1M13Y2V1CJrhNruSDyWBCnjGM96gtrogCLZ3UEE6n7EW2RleNpI+4R6cAj8RVi40+1l0u8tJAmYUaWIHnC8kEeo6g1BNqaX6S2x0y7YOQI5mZEDY5GMnOQQOMZ9M1Wjv7q9Xy5LeK2KZVssxfOPmAIGAOnrkdqL2Fy3HSWcE9pbiaMcRgpj70LYGQPY1AtlOLm5QSh/LKF43br15R+vAI4OcfrTdUutUktFaG2guXRQXETsrug9Vx+AxyfSlspbldO8xzZJLITIxMoJV/TBXPHAx7U7Jj1Rae/aB1wjG5hJZYm4Zh39jkdxWzZXsV3CZkLCJ03YIzxiuOttWs/tdxa6rEIHGJGXDCJx/z0ib+Y4Ix6c1eUx2habTb1L3TZjiTMn7yA5yWz3U9x260DaLeqaUEs5H4l+USR7yT5LDsAex6Vft4rW6hiulAhBUFHU+vZvWtAXUBRpHkjWLjO7lTnpiubFybS5ltIkO5XxEGGSUbJG4A8AZI+gpE6vQh1Ei21fzy5DDbHIAQNij7shJ4ABYg+qt7CtxBPuU3dydvBCQIAPxY5P8AKsyS1nslkfz2ltpDmZ9illbkBsY+ZQOMdh64p9tHf6cY5dPmjvrcD/UuAHRccbGBAdfTPPoT0oKexqGVA6kSSHGMA/Nz09M1lzoRrFxMqqP3QjjbfjexbO054XBaoYtaFxIfsK4ut2GOCUH8sn2NaVusLxPAy72PLs4+Xnrn1PtQg1WpVnW+tgrXKpI2/Agjk+Un6dWqhd21/taWBLePJ3tac+WrE/eTnAf3PB9utbqWUigtHI0qgbctyf8AgPpx2pkp8hEeUqgDZy3A/I0xJlPTfJuYS0LJb3cT+W7YwQ4wSrD6dj0zV+V5LS4jkkRW8x9mVyS3BOD9MZqpdWMEztcWV0tvecA4IZZcdAw/keo/So9H1Q3l8YLxVikt1I8tzkO/RnQ/xKOmR6nOKAab1L9wlvIiXNt8kpYKmD1J68fnz7U29ieXy4rdmUyAl8nqi4z+J4H4mn3MaXN3KI3wYk2hR8vLf/WH61lrNeWmoSxRKJWECkvIx2ou45+p9qPMVjUnLwsAIVjVV3/KfuqOigfhUGnXG95ZJdySu+5wD93sq/QUycG7tHaS+YqwAwoVM5xjA69/Ws+4tYVuY4rPV5beccz7pFcMfTac8/ligXKtmdHdQx3cK+Yqll/iUdePX1rl9b1a1cGC4mKRwSBUXJ3TS9ti9TtPB/8ArVY1DVZLA/ZfNR76UAQmNcCQHq4zwNozkE8EelZrXVusLvGizSwxll2fP5bYxnPQtz1J+gzVCjGxzUtrDdWuqXviB4jHG+2LTvL8pZZidqh92C5UkAAfKME89akjtYdFhXTpmV4JOXmDfNE5bJOB1QZ4PbvTJ9OudXkkncgmyKvGkTboreQYyoB+8/J8xvwHer8K297dW1xOi20Hm5eVxjYBuBUnsN3GKH2RrFbmtbaXFDceZKztK2GMjtkYIwcfkKtT288cQ/iVc/NnBX/61V4p9PvYZrCG8ieZFeKIQuJGk6FMAHnHQ+w5q3Fb3N7bh75UyRj7Nu+QHoQx/iIOfalYz5jNvbyfUPsdtDAk0ETtJLcSNtThdoUHGSSTyRnAq3LaPcxKs11jbgJHAPLRcfjuP5irK3W9GhZQssRwFyDx7UybTFmhfy3uIQxGFEmMe/t9KdyW7GHb6nZ20r2WYYLlGKyWwIwffHcEHr1pL/TTd2kyxohjK58onlhn7o/lmk1jQQ8xu23TsiBSjIu9lHXa2Oo5Iz9KbpyzQWJuob8Jp6r5hwvKqOpDHJHfgD6UbmiaSuZ+nXb2qO4fdJcsY4pS3zRICQN/pjk89Tj61FLp9l9mlmJC3c8gELSqGdogMBdvcHBz/vVeGnWeo6bFHe2oijIDOHP7x++XY8heenOe+OlU9Lltrky2LqiEZLOONyA4Bzjrxg+lVsPdXM3To7iJZBPDAZWbzJLbGNpP3dvJGMAVcgisLyVjcWzIc5ZHc/J75zkfUVrTwxi+tmPCuDHkZG4dR+XNWrzS/M3ZUGRTlXVsFc+9Jsd1Yy7NBp8zW0iiVXH7mZfvSr6H/aA/Ok1i7lhRWhjkna2mUnaueOjAnscGormC4W0MIYBt/RSd6AdHC9+eMD1qzaiDUNNEcW0JNGV4OecY4+h/lQIvQ3UshLwRMWTqpYBx+FaEOsRyWym5DJg4YuAQR7kVjaa3nQxF3aK7T92ec5I4Ix3qwXkilaC6t2S4bjfGNyt+XI/KgTVzRdYYYtkIAhX5ox6AnovqMn8KRleQqyNyecjpXKNewfbPsoaSOHLxtggbT0xjqo6/jitPRNSYR/YLqQCeMB1kA+/Geh/off60xctjVIaHAQgKcEL2HtStKHjDsoUqp3c/dGOv6dalkZGK46HJBI4x7VmaqjOPs0Jy8ykOQc7I8/MT6Dtj3ppE819z2UBWGQecZ5pACCSv0pykhcMMDb09aSByVO4EL2zV3IHDiXJA+Yc/h/8AroJB4BI5pzruQnoB0Oa5XVPFVtBKYbPE84OCxO2Mfj3/AApSkluOMXJ6G+rNuO3lc8VHfN5dtJcL1iViR6isXRtSuL64AlAi2MNwU5Dcdvatq7DGSCNseWzb3z6Dt+dZxne45Rcdyuqm3SIHGzby30FMt1xFlwcyEufTnn/CoprmKSCO381Cf4/mHC5xj6mp5LmOTKRJIyj5XdVLDPpkUCIZoVuo3TC7MYGRkFvWse+kFqkrk/dcgKx+ZWI+VD3IZhgfWtsXNvFD80vRcBAjE/TGKwtct/tsyLcKkccoKxRyckSAgh2PbHPA596l6FQIdPv4rWKCBV3v5QBUuqkEAdeeOv6Uq3kF1cAPKzyBZNyhT8vTgf496Zprw3NsHjAgiVcyLGMEN6E9eP1qGe3MGoWkhT5JVkAXJJUgAgHPqPypFqxqWxjktTE0G1BwcpjBHf2PvWXqckvnSW0Q8yfaC8v3UK44JPXdjjA9fSuihU/LIp5OCc/Sqmp6bHdzebho5ABiSL5XBz27EZ4waTBStqZ+kiRJBb3Upa52mRwFAUgkhQB1455J7VdNqqMLqyt1hkGBJjjzF98d/esvSpZItZvIL2PbJHgLKg+SVcZG30Pqp/DIrWNy0lykMYw+N7nOcZOBx69aSYpp3KGu6dBe3Vm944RmV1jfPzROvzKwB/iGG+vToapC5+yxQQ6xbQS3iyhV8ngSnnBRuozgfLnPXqBW5rapb2glhCbopRN1yWxwfzyaqawhu7i2tVhSVo5PncjAWVk5kPf5AQFx3aqsguzBt7a40+a4nkuQ8UJXYiMMQBhnZHkfMRzyMHHtV6KeyuT9ot7iWSVkKkwncqjPQtjGfXGagg02TTprl4g94ZZZDJOf9eka4UAf7xGPl5xnr1qa1nt1gE9owOODFGcAt7L2PtUt2NNy7p9xdMqKtzZmQDhYxuJHqckc/hSy6RLEVm8xpbSQlmiVcJHn0XoR6+lWhpi3qJLe7JBtLARfKFz0PHOfepbBCsrRJLJGVG9JlP316EMvQkH0xkEGmiXLsE1rFcqN1vtfaBHNbkbh6HB/keKjtnuLTy4bqBcg7I7ktw7E/wAQ7Me+evbNTOXtrxokXDfeXptfPXafT2PI+lOvNUthbyRSqsmAFlB5UHsG9yeg5NMSuPmt8xyTG58tB97acLnPf1qskKFyEtoyAf8AWSjGG+nX88VkfYtWjmF1cSSS2gbMdrDgvAPUE53n8c44Ga27WSO8IdJGkXOMknIIHT2/Gi9xuNircxTCN7eSZVB43Jbr8i9yM5/A+pqpc6Ak1vH9nlCxwDdAAmHRueQw/XsR1rYlVi8g+Z9oVSHPtn8uf0qC5nZFcLGqgkbe2T9KBJmLa3V3Z3btcMjSB1d1B6jaACF69QRUuqXEl3bMunzRRyM7PmR9rByBlFI7HuG6dscVfEDIJZy++TaWV0UDH+we7CsgQS3FyDZQW0dxOCqM0ZYBFOGkI+ufrxQtGU7PVmb5kVzKlvFbRBQguLhGceYhDFRGT1HzZ6c8e9XrGO2ezc2vlwyb/mWEjAxwRjqT/nmmXvhVYVe5sbh4dQZ2WS4flpSANpfGMngjjGOMVk276pDLIZI7eEnKlrqN2QMOMKVGG7Hk5HrTYKzW5pFngvCzwMIYojMMdDlguB7tnP4VeidoNSitrpUDMDLIQuU/2UHoOCf+A1l3N5cQQxpDBFeykkyLFN0whxgFPlUZztJ96u6TcSyLFPfeXI10ufNQfu0JAGBnk8DAPT6ZpaEtOxr28VquY7dVQPkuF4HPWs27kttLtp5ZU3Q5UyKACWb7qMM/3uAfetBrVbK4imUB4Nu127r/ALRHcfqKo+KLdDJpgXbv8/fGrfN+8CNtU8cgnr+famiFozNTTUtbq6u54vtO9xFlQAYAq8hG9Mk9OuKr/wBszQaotjJL5iSBTDMeG5/hf1Poe/1qe1nl0m2js7hXEfIJ+8Ek5LKP9nqQfQY9Kynso7+581pmMTBiZI8cYI5A9s/pTNorqzp7a0S6g3zjc2SdhPT6GpEeS2lW3c7o5B+7Zjkgj+E/zH0rI0e+nYAXMWLqJvLkwch8HBKnvwQfxFb17Et3Yt9ncE7Q8RcdGHIP50GMr31Ib1LiBPOCmeNfldEwWHuM4/KvPdevn0XUp4AkgsLlBKVZcbGYkOQo7YB+hOeld7bXolKgkRnGRz1Hf8u9UNeSKbUtPlBCyRP5YbOeHVlA+mcZFA07Oxy+p6ol4DcWW/7VbxKrnaVBQckFT14zityazE1vDJaMpMP7yBmI+cnklj33d6oDSmtZpIBGrtyyIWG6Jm/uMeChP8B49MVR0jUGh0y1hiKiaUCMW7fI8ZBIYLu7YB/xp9DR+RqXN2LpYJrKHdDJJ/y0OFQ4IIHfg+lTeddW0sPETxyE4DMy4PpnB61Wtbi1vbm4sbYtDIsgnWNlwyEr0/76B/Oljunu1McUIkt0JUy9DkHoF74PfPWgmxHqF00VxJI9pPHJDGuGQbwQWO7kfQflWQkjQz3csCNCu7cqyBkVycZGduFPU5zzVibUp472OG7gcrtIeRVOGVSDkZ5Oc4I7c9a2LYrKZZI2DRscAqeMAYP9aY07I563vY5ruaXFwkr8SW8hKsccb1xwT64NbFtvuQBHdzjuDuDMD77skYrA1O0SK6luolb7C7bZYFYgBhwGBH3ckUsNgYvKlvJ1uYzkBZOgAGSM9c45yevpQMseK7uJIyjyQXlwcJ5XkBmIPDEsp44BOevFZnn3GTcWzSbYpNqbOWdTjKkngZHI65IHetOC400zRptgtxyvlKMlVPUkKM7jjGMcD61auHt4SwkSYW7JsAeF1H0Bxx2/KmIngntpLX7RJO4jzuKvKTn09genQUgm+x8GOSNXJ+Z02hvqfx71lS2TXEtvJpt+HhIJZXUbWIH94ZwefSrcxuIIGgu47oK42syssqA46EHkj8KLXFofQbMGYEN8vApyAMGQ9M1ASF4B4FTKQCOcEjpVmA9kVoXRsFWypHqCK5ZfCuk28iSLbvLs+WOOSQuoP0rqvMCKd3HHWsm/3zFxC+wDHmEfwgjIUejEck9h9amSTHFtbFWOGKLC2pEW3h5UUfPjsBjnmmwxrNuuHWVWLffmkJYegA6CrduvLRRgKgALEclqehDTn7oVDtHHfvUJdCnqZmZo7JTbI8y7iNshAbIJycn+tQmOykVpI47qCYHb5sOVfd3DY4J+oNWppljupzaJ5sG7bKc4VG7sPXtkVHJLNYXP2iVVkjl2oXh5CKRw2PQdz6UBexXE91bOjzXVvNGP7w2sn1AOM+4FYeran52oQK9ujouTGI5gzSlv4kXGSABjPTk812N6kdxayMSQgUkuuM4AzwfesZNKhtOAg2OBJMW6juEz1wPSk0VF23Obt9QuJdQdodPkshHLvUS7QsmedpAODgg45B/lU9/eyve2ov3EEu5mWF48bhgjcrBsMP19QKt601yus2kttEZNPkQw3Mewcn+FiSe3THvS6rYSXmj3MF3C8aRIXtmEg8yNwDsYHsQeMdx1qC7o04Lv7NHAt35aGVcLtJYP9B1z7VL/AGg0TRr9lnJKbuqgAfietYnhe6M8DxahA0N7ayG2ZGGVTb12n0JGc+1aeo3rQg+RsyeDIedgPPTufT/9VOxPWxha5q9rbXs1vEzrcSIkjGQbfKIyNxzxnpgfnxUHh+e51CWSVh5FuIlYYbLOckHca5nx3OseqWliUBtYo2lliDEMm4ZBZ/4mYgE+v0rmn1jU0WPTIZXbUWPzQIMRqhIO9+eRycLnr2p8mhas1bqewanFpMzx2LwrPMyE7IyfkBGAzP8Aw46+p9Ki0SC+siv2vzrmQcPLt3HfyWJ5zgn6445p/hLSrYaJFHDK02Tvfzogcv3yMZ/WrIsZRK1zpjrb3UZ2ywMSY5R7+nscdsUmQ1bRC2N1BHb3ju8se25eNt0bcKDkZ44zuzVWeLR7q+Ei3kMN03zCVH8sjGB36/jVWbXriyvLuS50i7hYENNGCjIR18xXBxgAN1wPXFZt54zhmeGWGH7DE2eLuRY3Ydc7SCPoOc0rXKimdYhuLPEyvHcxy5J8rg59QBwQfQU+5uLe4jt7qFlhaBykhI2lFbj5s9MEL1rj49U0W8t8/bWjuJPmzbvI/TuQNqY/DNZuoyR3FzGdQi1G1ZiRHNcuFgP+3yCT9CvHr3oKUbs6678S2wiiWZpVgd9scsURLTsOgiHXP+1+XrVXT5EcxS6hm2CnbDG/yRxE+rdGfnkg/TuTDbwTyo9zcJDq2SRFc8REYP8Aq1U5C5P8QIz+lbelXFtta13PDIiY+z3CYY+vB+9+GaA0WxpRyuoK74toweFOMevWoZrPz5DcQvFFc7cedDwTgcBgeG/zyKjTR7dfkjjWLAyDFIVIyenBoRLuzYmKR7pVGdsnDKemAf4uKL2J9CoL28s7oC8iO5jhtoyMg8Eema1JJop4NocEggkEcjn9KeGS7UrIvBG07/6g1XdGttySo08G3AOP3qL7f3h+v1oQPUNUe3stNnlBYMUwu08s/QDHqTwKq2Fo1sk0glYyMV3Feg2jhfoB+Zyahe5sb54pI7i3kghlChdwLbhksWHUYxjn3q5arHHCJN64IDIN2QAe9MnoZ099cJPdK6gZxIiHggNwWOfcU++vE/slotMLNl0jMwPyIGYKxU/xHB6jp61GLNdZu7h5gz2zxbDnrJtYY/DP5/Steayj+y3TxsqMiBtjJhQVGRx+FC3D3VuZY0nS4oYXLyySRsC7TuSZAeDgdv8A61Q2WlxrYRwRkKGjO1Xydq5IOPYEdPpW19kt5bQmaJW/dZB/DtWb50em29q9yCjRr86Yzww+Yf1/Ci9ha9GWJjJZARzxme2ceWJUOMcd89MjPNYVrJNcajb3UsNwsNu6wxqCGJDKwEjD34x6A+9bWvMw0aYxS55QFvRWYDP5GmXMRXWZo2AImgABjHJ2nAI9D8w/Kn6ExZyfjafZdWJQ7obmdI/MVsjcGyDz04BB/ChrSSxuFu7cnyQmJI25yDznHr/Q0mpzLqN/JOwVnsn2Op4Ekx4EmPQfdz6lh2Fb0bxG2a2lUrM2d2SMnI5NBunaKRh2LLLrFxBGVMksQnjIP3ipxgfgQPwq/FdvZ36C5cra3OAkmSdsnYHPTI49MiskQxwyaFqSAn99JbzFDkEFG+Ye4KdK3tS02O6hmtdoIdfMjAP3gT29waCXuRtbRmW7tom2sGFxCwH3d2c5/wCBA8ehqGzjFzNPc3ELKsimMoSflCnBP13d/YVkjVLmK50m8lRvJkVopjGMsMDJOO+Cv61v6QYp3QiTzIp4/PAB4G7G4fmAfxprVEtcpUMI1CASSSN9ojcrvBwQV6/gRz+NYNmyy2tpFfxL5EzxzwttDKz7irLz93Pyn8TiupvLaURXhtDGpDfMrHA4QY+lcrpTsfCNpOFybYx+YhG4jBG4Y9MHP5GmgWqK3inQjJr9s9hdyWl1PF5SspJCgMc+/APTNVnudQ0i4ih1BDbSMpjE0aiSG4A4A9mx2PPvXTXW2PXrIMWe3EcseSckM+MDP/ADz9K0r23S4tXt7uEXELrtfauVb3I6g/Sgd7HJ6nbpqENtf2d0st+uY7fC7U2n7yEc/XPbAqpo14bVzbSXItUGWEMqZcEfeUknBOTuyOPmqFbOO0upr2CWUWR4WZRvZRjq68Eg4B3DnAGeuasRPc/b41u7tl+1ANDNDt2Slem1u5KnleDx3p7lXsUdQaaQyabaztMJ8Ey+UNqjOcAYyx4PtWGi395P/ZMmp3ETK2PmRFwQMocY4HY816ObK0myWzn+DYCpiPc5OTu98+1clrtt9g8WWDy/cuFMayAYVyAc/Q4wfwoSQrok8OSXkFpJbYtzc2zDzLfaI8k55DDqTg8HuOtdTaX0V7BiMtHIPvxOMOh+lYdwwh1a3uMA+bbskuP7qlcN+Ga1bq3WVBLDIYrmMbopVwSvsf7y+38qdhMz9QtSsnm24CXa8kL0I/un8+tWI7r+0NOVWOAVJGe/oD6EYrMTVFa78i6/4+oTucR8Bh2YZ6jPUdR+tRaQ6vJeyo+0/aHQAjIwO9NITPo9UD8leemfWo2miSTbLLErA9GcDFVo4X0+PcQ11BnIbbmVB/7OP1+tSPBbXLq8KwN5/wAxlVVJ29+cfh7Uaoz3IbrUoSryRuJUQfKE6O3Qc9MZqtZSRtC6y3ESuJHLndgFjySSepqfVPLWSC2c/N/rEQc4xwBtHU+g9qhjtCJjJ5IVGXDq+JJGA6N6Aj05pXYbDjOhylmwlKcZQgise/1pba4a1WSFJfMAY+YCQGxkn+6Bk89z0p2p6Zp04aeW2FyDyHLED8NuPyArk4bG9SO7urUFYZISUt2AUNGp+X5uuRjPPXjms27HRTppq7O4066RN2GQAltrbiOASOOOlDFWaRVCyQOMmONwT7kDr+FO06aD+ybW7ceUdgMhkB+Rupz6UXGo6bLDLM1xatHGNq/MBliemfrx+dUYyQkVyTpzxogkZ496DPBXufoMGpYFH2uR1/eHdw+e3t6cVz0l7Ha+WumzRTz3EG9ofNBX73VSMkAZPbmotL1Zmme3aWWOZBs+6E+Xt1ydwz+I6UNiUWdJd28aPyoEMmQQBwD/APqrNk3/ANoWysoIwYmfceDuBU/jgjPvTZrW+u2bydTu47fu3yMGI/ugr0/2v0qKTT9QtdVjmmvJL+x8rY0ciosgJJ5yoAIHGBjPPtUDS7k/2VobqY2gRbtnYLuPDknOD7YauO1rxZaWuI9JnVXy6KAnmurBsM+3v8wIG4gEjjpWp8Q9XlstK1OOyn8u9t7CSeeXftaNNpVXA4O987R7hj2rxrQtZ1RlmeKKGzmYbBNHBuEbt9wEkf3SNp7DnJ5rSML6scX0Og1y/udHVLiWyuZ5JZMBbgoNjEcOShP4jt0riNBgudR8TXs7TymBHE85D7FlZDkL7AAnA9q6LxrqcsGhtZSKqCdDHvEhcsBySS3OTjOe9avwo06XTfDtrfTQRtBezmMmdcIwb5QD1OCcEHA6Yom+htBcquz1jw9pafY22QW8fmfOsZB3D0OQetOaA6ZdLOJdjbdskUkm4MPVTyePQj1p9hp7W6/Z5ppZFjAaIM21fL/u5XOQpyPmz25qW41iFYBDFYXEgLFWaOHERx/t9D19az0ZnrcytfuzeSwWiZ3SMjyiONjuiU5ZcnHBO38PrWlbX+yfyZ4ZxEJGAHltgEKMnv8ArXL6fqQTUNT86O8u5oh5UCwoG3Dk+vZiAT7Ctq11C3uJ1tZpWjdBtMHPmvxkkjGcZJ6ce9IbVuhPFcW1/eMY5I5beNscEHn39PbP1rSltYY41UQJJG/BHUAf5NRfYbdnU2lpcRSgY80RgE/UZ5HsRUtnfxq32e5/0ebAysild4/2c9f6UWE23sY82hm1uh/Z1xPp8VyCXjhYGMOO+xgR8w9COlVpLXU4nMd9b2Gpwkg7f9TJ9VByAffcK6i7WR4njjZQ+4Oqn+8Pu/hnr9aZNMXSCWMjaxBKMOV9fyo2Hc5y1u5rOYxSy3UCEjYuoQ4x7GQZVvqTn6109s/mRK07HOOCDkfgfSpWiikR0MaPvOPTdWe2jS2ZL6X+7hHJt2OI2+n9w/Tj2oaYtG9SzOi+SzlkEaktvPU8Hms2WOS4t2MwVpZAFih3cR56bvVu/PAq6kqXVv5UwYGaMqQy8gEY/Oqt75Kxw3sgMRjk8uZeSRJtI2gdSTnIA65FIdytqunxpHpUMW61AleFJ4SqyKRE5GDjg57HiuV1O7uNNvbWy1mQrbzACXUYRtVoweFkUcRsxwN3QgnpXUXd28sZENncxNA3mxGZABIyqSAOeDxjnFVobz+0Wup1ht5baZVRUkcfOmD1GCOcniqQJs27KNCytbSDYqhRs+vTH5VJfvKthcOyN8kbjd/eO3pXJ6St/oMoijtElsJWwsZdibfntgcqOmOwwR3Fa97cTXlq0SNjz5VhEaDax4y3zE8cA9BQJrUtWkjSRJbmXO1F84H+DAzt+pI6elbCQQuc3IWVOuMZ7VmxQXDbEZvLVeWWLlT/AI/XqauwSCIMnl/vQcHaTk+/vTREjI11kGm3tnbJ5jGJjED0xjgfgw/lXn/iLxsBJaOlneWc0iMkU0wGxi4HCkHgg9M45Fej+KYUgszPEHZ0HQc8NwQPfpXl8+g3N/Y3w1BVliyY/LA4VQFIH58/WhLUqNrHNjxMbu3hsIG8spgCQkDADAMvqx7j6Zr1PVY0EUV0n/HxD+8V16sMjIPsRXz74hR9H1y0mCvGElBYOOTjqM9+D+te+z3EcenqyyvIsqo25+Mg/M3Hb5Qapo0n0sUblpLfT9FkwFL6kg2geruP6mtZLtIDswx+zMQMcjacfpz/AOO1DcwrJoFhb7xE4ntmDZwVYMCcfQk0yzIm0lLhYmL/ALxJ0HDZ3EnaD3HOPUGkZ77mZNas9u1koVfJuZmRQcnbyyn/AMeNRWs5tZH+yqQIpiUVieUk6qfowPPYU7RLySXVbOW8AXBmjJB5JQhQT74JJFaVvDHJe3dqSrBIirAjG7dIxH6GgrbQuaZci4uZN7GMl/JlicfMj/w5HoQevfiubksWjtlubc/LcxJHIjNhZSpAC49SOAfUD1qzh13xhydRtSsGcY8yPJKl/UYB57FfQ01L21vfDWyVnAeRo4277vMO3HoQQKfQm1tiC3eCQxSSbjA6R4fGCNu5WGPpnP0rUurp1t3sif3+5Yh7o3O4+20H8aynieGxMrxsSqj7SoGQzKfn4/hfk+xz24pLi+SRLC6jlWZSXiZ0P8aocA+mQTwaEPcspum1DzQoSIIDhQCBg4H5dvYVX1vQD9imm052LhvOa1+9FcY6jafusexGOcGt2yEaWkTzL+9kATYo+ZiP4B9Oar6gjqDDIsssW9dkER2jrnDHq38vamDldnInVpbOZjdyyyxDG4rKDJB3AkXHIHZ+/Q+tY3jDW4rq3jNwJlHmKkMktsybSDknPQkkEZHauuNnKs8trbBIJYAXg2jajRt95DxyM5HtwRXG3UKLOLURskSpj7M5BMEp5G31Qnoe2cd+GkHqa2m6jBezWbo4eIwS8E+6hlP0/kaux3i2kIs3cG43BInf7rJngk+3pnPFck1vZC5S5aNQCrNLuXG8EjGP9rIf8iK6+wksWt8YRIH4w8ZVc/iMfjTaFpYbcWIWwzKjyhnwJCNrPJnqG/vZx09qxdKKWWo3Fp/pPmAiWVbpQjszcsNo9DkfhXf3FhZ6hpelxw6ha2D2CMojnDBVYsSZEwMZII59q5zxx5GqXlvdWMkks9nEsa3Mg2m6IX5t2R/EeQfUU0rGakz6FIbYuByBx9az47YPc3NxaSIl5lQ6k7Vk4zhx26n5uv1rRlBCqB3x+VULsQNNtkdEZ1xL0Y7R+oPamySppE6X017fH5ZGcwor43xqn8Ptk8/jSXOoRySuls7S+WdrFFLAH0461Fqe22uPtGnWp2lQtyoi2goOjA9cjkH2+lWbNWlOzzvKBGRGmAMe3Bz9ajyGUb2CdrCd4Ygs5XavmPg5PH3VBA69eTWZJFdR2zW9zA4V8JHkbkTj7oZc8cdwK3Gsrh70It/MFhHmN8ink/dHI7DP6VBrVtP9hIa8UGWREDOgH8Q549MVLRrCXKrFZGs5EV7+5iivFXDlJAjwn+6PRR9OaztXvB5MqTyzbFQ+WYYlYIMdZMj5GPqTgD3NaV/4cTVFRNQlLwoAVRo1R8DgMWAyM9lz7mo/7At7VCtg8o2ocQFSwPGMlhgg+5J+lHKw5omPpOlXUoleB7SElVQP5SvwOnIC/wCTTrzRdWiSS4S4s76a1iYpHLbmMOMZKbgx449DzVOG5uNKhkuYHZLSa9WKSymt9zwl2Ch4nB+YHJyD65GMYro7W/ZrgralpJPveWG3ZHf5H2t+WaTXcV3c5TTNYmsrv7Jcpe2dsyB0USLLgHn5Mg+YvPUcjuK6cSPKvmnVfMs4xghIgjnJGAMc9ePeuY8QXTWujx2l7aBpBI8cTRSjfEvJViSDsYDA984rifGev6tZ+F5LSSz2CQqtnqCuWEbf8+6HA55GeoHPPQCUi2rq5c8Z6U/iy4tktomX77yBPvPEThVIOSTwjbieSeOtcrqnhPXPDmhy3WmytNYqyi4Qn543Q/Mq9mww4PbGO9d58NphaRPDK8n29Rl5n+YtNjJU98jp0AHaovFF4Ni2EjyTC5QmVQ3CKEBMpHoe/vit9lYSpy5rHhdxcvrOsWhkEk7hgH2tuBBPRQTxx+tfQemRXt7pEVrolhIlljaWuJQ6bemNoz8ykZ6jBrxf4VwS3ni24ktDE8ipvSK4bHmqXVSAcfewa+gNB1mDR7+7SdDZs0hkntpmAaLPR+cAj1I4PXg8Vi11NL2VupPpz3MMUY1aSO7ng3bM5RJk4/hx16EqTkEemK377UX+ytJE9u5UZVI2Mm30J9B/nBqvrN5YSWxu3v7a3IbGFfcrNjhTjliecbRkisbRLu8vJFT7IdNWM8Wu0ecAR97HRc/3myQOAAcmkjJ66ketFrSCBLaT7I6EyOxAMz93G05AZuoXBxgZ9KfFD9otPNthd3aMQ4E1oDvB77vlb8a6Gz8P2drNHLbR+VPjh487s9cknJb8c81Dby/2devawL5lucskpPyD1UdyR6Dt3oaG3pdFO3u9St/L+yRw3tscgwyTGOWMjsNy8/Q/nVv7VcaqjeWltA8XG1yzyJnqCpAH51ckt5Gfe0xGQGG0AdPzNQT6Wbk5hvZoLuLOyRkVyPboMj1GaQJiNo8ptwVu58r/AMs/MMan/dxyv06fzqnbQpEXiFxeRFiSrGQsVfupDZHPWrkepz2kpt9VhKTLyjwkskg/veqj68D1qxPbQX6sJlVllH+rQ/L+JH3j9KBq/UxrjVLyIrCqrLIhBMlqobcP90nAbOOM9OnpVu31u6kZYJI40fG4CTcrOO5Ckdvx+tWLe1gtJQhUKuMCTpyfboD/ADp+ptFNG1kpWe5XDxxhfnRh0bPQD3NGoXXYnhDMASYFU8lcMCPxrHuTJJrj3zKqx2eI1XzMGSTGWfHTcowv0LVNNd3jwRQLBbrMRv3SuXES9yxA7elZ2mpOAI4reMw5ZzO0o86ZixyRuGFB/wA4piNxxDLDFeQyb4mkUhSRtAzg/WsSxCadFatIimylUbXBxsP90/Qkn6fSnTLZWzSqqtp1wzKxa5jyrKSO5yuTyOCKLLTPs0U1pLOi2pkKtHEnXuMAk4BGDTFYu6xNHBGJISzSIfMiiBz8wHr2GMjPvUVlLZzagLkSmaJQViPZmPLv+fA9hWRdpdaTutrFPtcFw3lL55Jkt3bpgn74ChiFOMY68il0OC3utOto7K4kMcUYUsWKlACVVQvGGO09emPcUJXCyS0O0t3gbaEVsD+L39xUF3J5MKzOFUD5WYHlh7e/9M1lNptxbypPY6hdowI3xXL+ZE/4HlT7g/gaLGQ3ZK3MeS+4uyn7sfOFHpnufY0yLeZQ8TauklqkdtMrvM2Mrwqgck56Ht07muctb0RwSsJd3mysQc4DAcZ/8drR8Y6SkFmslq0qFVJjVV3BXZh8gA529DxyAPSuF8U6Nf21mrWyWd1cQxhQzvkKzYVSEHGSTwPfJprQtJNWRwvxJ1QXmoSW67WIuSVGOVwq/wA816xoiSS6BpVtcS7lWFQQw5y+FI/IvXnGlfD7UrqG61a6uke5t7lQ8Spv3kDLEjjO3PQYyM45r0bQtUHmWrSQSbXmZthGWURIQDnuhZiQT2ot1Le3KuhsajMbrXNHtUjLK1x9pbYMDaiknjtyVFWYVFvLGp2h7gtCQD/GpPb/AHf5VJahpHu7p5YLPMCRxuQW2qctnHGcnB/EVRsb2MXpjna4lkSQTJLKmwMrKQ2B6cMaDN6rQjubWKx1S2ndkkd7t2EuO0mQQw787fxq3bqYdcvbiUCMkQp5q8LgqeCP4eufT3qLXbeS48IRTRIxuIil6gxyTu37R7kcfWjSbyG7iu75G8xL0AocEfcG3B9+nH1poN43FtRu1NzjZOkatFnkMzh+CfQgH+faqlnaWaaw94YUTM7IyH70MmAwOOgznr+XWn+S0eq6m9qvMMMDrCzYUlSxO044PB9uauXlurahctCQrSRq20jax2k/K3uOMGktgZV1aOWxuGu1ZjYuNtyDyQvQSAe3Q+2D2rmPENg1zK82nmWC+k/1cnAWSaPojjo2VwQepFd1pl2l2u9MkKNjjvnvmuf1XTnhnkj0+J5oMK88KDMkJU5R4s8ZH909QOPSmOMtTN0zXbhLiOW+s8DyCxMcu5SeAxGeQQRgg1tQ3p1FYxEk0auQ29xt3Y5wOoJ7cVzd5qdsAswlSGdpNxDxlY5egkCkjgnrtJyG9cVLaajpV/CDYaklq23DvEysXB6DZ/EfXjIPSgHbc6C/jW5AFs5juojuWc8rFnqGHfP93+VeeeJGvoLuK4+zi7uIN9tIF/1ZUgkgng9OQOcevrvNd6tZxCGaHy9LlOBeeW4CcjqCSyg+rcCodYnWwSKHEchE6hooyXJ6gkjHueSfftVJC1MLwxaTG5a6JS7uzKxYsRiSPGFx/dPPfqa6Sx1K1gtpYLhmhWNthSZCWwCRjGOew4zXJ6Jqd5p91ceXapOZZfKdVkH7qcHaSTjGGx69frXU6TcuL6GVLXfHaffiuj/y0IONwXvjJznvVE3OyFzrC6TpY0GSz06xa3YOszRJKJNx5Ic8KRjGeRjoK5rxBFqpun+13kd3e7BzlGQjHAymBWrc69C8bltB0lpY03JlWIcYz6/UVgx6hHdzv5NtBZRxgBI7cFRtK5HXv2PNDIimj6F2L5bLKztHgFtzHkVWjuLaOXEH7xm6iJN35kU42SSKjXDPP0x5h4/LpVuKNUXYoCgccDilqxlRHm8yV3tnwZM/MwHYY4qgGhtHEd5CyWRyYnP/ACybum4HjJ6fiPStV7dvLTY4VkGM+oz0IrO1GTzEWzuYGaKZiH2gsNgwT059B0o21Ba6EcUk1qpR3Es1yDJDI3IP+9/ujH1pbhYbWe235kl3lyzcs5Ufwjtye3Sue1nWbXTLya2a4haZofNRHOOAck4OMOPlJXv14q99rjgmGsS3rrbrbIkkjYb5XOVIGPZRgetQ3rYuztc3TPDDbPNPKvzNjrncx6KBWU+rC3knDMsSuPMjLo7liBgjgYyOuM9DSnTJprldQvHzcjIjWEAfZ1z93ry2MZJ/Dii8juLqNlnljeHtkbHU+oK8Z+gptsmyKKxwXURtvtyq0inbImFZgfQN1wexHoagu7K5uYoYL66txeqcpIxaJHOcbuOFPT3z6jitq4spTBhrYXCdWAAYSfVex9x+VYoDJLMumS3pikCj7NLP8qjJBwTlgd3G09e2OtQ0WnoYOoJPLO1rqkgtLpeT5e2KMxjnzc5wQTjj1A4xXF+NbuK+0rT7HTWu7uF7pBJcPJujKr83lovRV3Bck4r0c6DpN2FW2t4JLyRy8VzMPMXzAQACp4U4G3bgY/CsLUDBP5aR2gjtQFPlhfkU8o2WHckHg4PSpW5pG2zObm1aGNptUiuEs5I1HmeXh2PYK46E9vUetcJc64baLUtQnu4oru4hZUg8k5hXOVRcnjJOTjOOlb3i/RBeapJDpYQWungB8NtMrA/xdmYcjd19a4DxXfzMHsJlH7ttrBDux06nueK1k7bnZyrk5lubPwsgiuLh2OqQWFzCytblomkdnOCflXkjAxzxzXt9sutXKPCsul3Cy4BeeSTc47ny3DqePcCuX+CXhwzaOt3eRLN9oYTb5BkuOxyemCDXtSW2+HZJho+myUbwPp3H1FZps5JtKVkcBomkXuiXHy+HlJVsia2kgBA9VHygfgAa1JNUePOzw3qSyLk+WTCjH6EvnPvzXRuWsZo0nd2iZsRsfmZD/vfxL+o75q7PGkyMJlWSI9mXIP4GlYzctTmI7vVruJVexeGE8NCZ4/N/FwQMew/Orb3Czx/ZrixuoJ0w0bBE3RnsVGecencE1cm09ERPs8kseMcBtw/AHp+dOuYborh5rd1xn95ETkfgaB6WKNtqCANDcERzpwyFSm09iN3UHqD+HapLN7zymjeWOZuonCjIHofU/wCTVTU7G/uNqWs9uJyp2B1cgD0znoeBg/pWdpLskjWssUen3cOBIiMyjJ6HkFWB9cc/WkPl6nQC3i3b9+6Q9XJ+Zu3PtjtUltp0luUNmqsnXyM4Gf8AYPY/p9KZ5t1Cm67ijeE9JY8cfUf4Ul7qC+XIisyxIhaQ5xkf3R7n/PWiyTFvsV7vVYpma3tY47guCJJZfljQDg7vcemOtUIUuICVSIJaH5jMzl5H9eSBgcdTkjtViysJ3b7XdQLHK4VjACCqkdMnuQO3Sl1OQXMclkIvMjlYJLhjz3Kj146/l3pgmtkQ6YBd2y7YMW7cqh6vzkE/7I/U+1Pv7EyYlgJZCQ0wZdx54JB/X8K1xBvhGzBZcDKjH0HtUUuqwQJGkUglmDYaNP4fq3AH50BfsZ9nCILKeObfcrJByzgHcFbjjp0qB7FbTUYpbI7LeXCtE+cIR0C+gxnjtjioZby7DSGC1jETRrEyNP8AcdnIyCFIxgZxniqOu6vLa3qWcn+j3EuGXJB2r/C2RwQSD2zxwDQKzLtxcRT3MF7cSRNb2qyTxoTgyTNlQfcBQcd+c1n6RFa2MOWvjHf+Y3JBcNtwMMBwRn8ec0nhzdfae6A+WsExeSFh+9eQgNlvQc8D0xn0rWiv0spGR4mM/mltiDLMrgf170a3DbQltdbtL5PJcSi5RcmFEZiRjqDgAr78Y71QtjcCN5ZJZYYWZY44kbLZCgbmPck5wBwO+an8Ra2sFi4+zXHnqA6OQIxBn5VZ2JwoOenOfeobK9C2ltNGvnApv8yVdkYB6BR945+gz61WxPL1I5/7VlgRJzG16pJRyuUaPPJYDocenGQMcVgXU8d5e2/2mwkWXLSmeZcKQgIVwyn5gWZmAHpW5Elzdyul5NcebK/zFD5caKOQoC8+vJPU1MdNjtpri5s7aSRolUmNJiDyCSE5A6EcetA72ZkaBbxW9xLZ2EjtFKofz5c8jPz8n+LOPpurA1Wwe4vkELgSNAptzvK/PLKSUbGCVKqcZ6V0V/rUMUllPBewyhJjCVkAWZAykkMDjJyF646Vi6frtk1pb3dpLul2yyH5cE4VUzzwQOTT6FJPc2vDYsr9BJaEJBNKTjcQ4K/L5WTzxt5qDxe6xzWaQgllMkUu3LHymH7w/wDAF5+rYqGSZNGsnsdiyzzRpcWiKctIzZDkAdCG+bPA+bmtLwukrCW5uzvvcCLg5VACScHuSSSx7n2AqnqT5l/xBIbbwrqM6FSkFs0yKOQQq5UA/gOlc/YadLpVggmhM0dyonnjXpHIfmIHoQTx649RTPGytpXhy6tVCfYL10toxux9mMjgN152EbsY+706Yx1sIW6tTghomRTjGQRjP+TSJTaRzEKtdX85gmnkiuGiBcOrDaJJD1I9AB+NWtet3eSO5mkuWWDKytvXJVh94HHGDg1m2qnTdU1a2tRIViKSq5HABZiCfxyCeh74rore+t72IzIEZJBnaR91u6kf5zQNuzuczi40rU0PmvLHdBvNi4R9wA7gfNkdx3FdDbiJoibfqDu2kEPn3z1J96yvEUcVlpPzqkltCwkjwGLwkHn3K4Jwe3fIpNO1YhFku3DWw+7dhegIGN3oPfpTBptXQ3WNOFzDNIGljuG+8ysFVz23L0bn1/OuQvvB9zZ3ZuLWW2uHIUbhbhGJHJzzgke+MjvkV3t9dQwqEuJ4SwKkqXHIyOTU8yC5twjEEHlSvJI68GgFJnnlhFDKGtNUeKC4ZduxQ0STfhu5zn8apPp1tpJudkMclvbgyw+YCS2MZTn0GR+Ird1wQrbtb6m0bLFKYj8uSqnBBUDnPPGO9ct4ssdRsdGEtpdMunrMix2s53yDJ5AkHOO5H607lmrNp0GkKI5NrQTxbp4x8vPG7HfIyDn0Hrg1Da3jWuqGCd2lkZthlGAJo9vyP+GCD9auWmpRyPDazvLaairZWKdURZOMHa+MMCMjrnpWPqOm38SWVvDFBLPDIbhGPWPOcKT0IIIHboatENanUrBNciHyIJZJHOxVRS24+mO9UJDZRXE8MNrd21xDiKYXDAjeF5wuAR1966Ow8QwN4bgltBcjU4bRrIW6xsy2js37yV2HAwD35PbrWJ4gmimvUaKSac29vHbtNMux5nUYZ2B5BPvQZpu59EKucZ+7jj3qRASRjqR6U0sr4xIoGPX8qWMOCRkMeooESYA6fe7Vz3iHUWsbe6vIQDcbhZ2wbpuzy30z/wCg1rXdy1tbytIU3A4TnGT2/HNUJ4ree3tLV4PtWxtxYjCbsHksfc54zUy1RUdDzK/0e28Qq2nyEykMTd3Djd5eTknP98kDAFdFpmmtHewrKjQIfmhReFOFCjcvTcecr2xx1NdXYaRbWGwxworK5fagwik9SB6+55qnGYf7Mia6AeEptlPQrzlW9sEdayUO5vKpfRCvemwSO0lVrh3X9yYl+fH91uwxzyTz9aWCWfZtkgjEZ/iaUZB7A4FQxrJbR7b3MpmIMkuPvN159GHQduOMVZjJlcAPvZhhJO0g9D6MB+dU2ZtEyXV6jK72IkQHAe3mDDHqQwB/LNYEs8MOtW2oXiSWhug7s4wweQABAMZB+UkY9a6eGUr8q5Dd9wxgDqfwrB1HSkvEWchGhd9yxSj/AFa55k9s9xjGD2okJGbqWnan9vlvbK5htWukBktJYS6TYPBY5zG+DyRketYllYXFv9pjgS1jS5UM7G6Yhsgb1wFIVyFUknryetdKzXFpqNutw0/2b5swsPljU4KjcMkj1BNXNQsLXULjzrN0S7VQ2Y5Nnmj+62D6Zwe1Z2NL2PH9Y8MeKIb+6njmtbezRCsBCsSwY4Gfc9eTXOQfDDUY9ZZ9VylsrgyPuGXy33h2I9fTNfQk1tM2lNcW1/M0a7JCLgKzAIwJBO3sAetc9PY6vOhSK6jFrbsWgdodzyg/eA54QqSoOMkfhRO73ZtHES2NHw9BBot7JY2ibrZkV444+fKJzlfYHk8+9dGVnkIDOIyBwEXJ/WsLSbG5toEMc6GJ8hQibBtHQDGeOvFakjXMTKwLMvrjf+HYijdXMOpaNus0LJPJKxPXLY59aiffA0Qjl3A92AIP1pVuDsVvlHYkHj/61Pe3DJ949dwNMNhC5bO9fLlboOoP0pwaNoiGfZjpgdPanFVMewgMpPGT0PYj0rIuWkkglLbsbdqsvGATt3fqfwoYbkiNPIZJowqQOco4HzlR069M8n8apahpsV6sTfM1yuSryEsMHqD2xWwzoEEfYAYCjGBTlkV8ZAdPY4pDvYzreys/sLyi0gV14aNQB83TH1zis2+0e3VbaKNCJJJSzlWKNwMk8cHn1HpWxeW5SSOW0VduN0iZ+/jgH8M5/Cklihup4SshXZEzAZ5zkZx+FU1oTfUjM91a2ygSpNvbZG7Ltw3beOmO+elQCESaipRXRbVPTO92OST6HH86nhlUSzibDRIpi5IOePmyPfIFJbbbZfKnk3GQtJjPXHVc9yowPcCpsUVtVl85ooIpXiEkqLMVOGVT0A9zx9BV+2kijt1txANmeAq9aoCwil0wyA4eR/P6nO4kED8BgfhU9zNeWsYigaBrl+EBHI/2j2AHWkJtGdcRQw3N3dw2iS7XJMSgr91Qu8kde4x1JPFULGy06G6ugtvunlVZDOyNJKcZBAJ5wCeB2FbttCqabHbpIQu9V+b7z5OSSevJzVXXpbhPLgSAbc4knEjDysjO0Y5yR37D8KondmZbXFvbma0jCAhmklkL4MY/uhuuRx83QfyhM1zDcrFo21ILlSBez5PKkZdQeXADcseOmM1Z0rR45VN1dKZvNIdN3KIOwC85wOefWoPFd+um3qyO7S+VZT53tjBbG38MIf0oQ2tbIjm09ruSWOF7p1i3B7l7gkyytxwMYBGeoA9O1b1rpCW5REDStGoUF33beO2ap6YQljpsYaXlRNJ7lVySfqxq5balG7siO5kz8wU+vr6GnbUUm1oibUI1srEySbERdu3HzE+gx3JzWda215eXtwbsbLeRFYQr1YcqdxH06VNK/nayjShjFbgKvOfnIyTj2BA/E1ZuWW3CXSmRhFkyIOSUPX8uv507EpmP4gtbdLH7U0Co8E6tv+63HuK8v0bS55dSijgkleZH+zyqJNg8sZOc44Y/u8+ua9N8VSkaRdnzIxGVWVXJ+Xg85PoQa5vwpLG+vX04wIbmZnhbjDRrhF+oO3P5UGsZNItPai01yJ7S3EcZSS2R5ZMsCArtg5Jbn6eldJYQmJJAzSEls/dxk+v9aq7lm1Qwu6+Us3lkL0O9Sx57cItXbQrJ5wlZmKkqSD6UzJu6Of8AE0n22/06JCz+U32hsjn5flUfmSfwp2iPPZWAaxH2i3CljaO2AD38on7v+6eD2xT2QS6nqkaKxaM26IMkEhju59u1VJIjpthdzPeyIHDhFQA4fONgyDySFxn3oZppy2I7C8jvLy41iwnj3rMbdlkymVGdyEHoQx4z3zRcWFpqF19q0y6udN1If6wwIuHx0EiEEH9PrVB9D1PSNKhFvHaXc0JVTMuYpJMtk715D8k88H09Ks2d0upTfa4bG5iuoj5TvA8bujdSrqSMr7Ec+1AO1iSSbXLLH2+2ttRgOVE1puifBHUxncfyJrE0i+8yC2ht7e4NrIjG52AS7ADtJwDnBPBGOPzrrbHWYGfybtZbW8jBYiVCEK8DcrdMVj2lnbz6rHMCoUSyxu0L8P8AMWUkjp6560Ci+44Mum2u2wtrqXTWHzwxW7F4Qf4k4+Zc/wAPUdvSommuhafbNKhSJGXfJkhhIOpdUU43DrjOD3Ga154LzS1L28zz2h+baeHi9dp/iHt1rO3G2ka+0sbkkzJc2i8bjjmRPRx3X+LHr1BGZf20S6hbX5kE2bVnZpST5mCoGMA4OGyAOKp29lJrMMlze/JCY2jt7cn/AFRP8b/7XA+grQs5Us9Rs1gmU2F27G3fsNy5KHvwRkD0JHarr+XGJJG3B+fmxgFcdD7VVi+hj2N0k2kR2VxGJpFBikgZQ2WHBz+QOaz/AOyItPnR1iEscy5kj3tlSOyc9AOin/61T2Vql40960r2ty771KMCQmMhGHf/ABqaWG+kDRiS337tyuA3B7Ej/wCvTTJe50liIm8PltM1GxtLNrBoZYJphCouPNDCVs4zkcE9RgVg+KLv7dfI1vi6aO3jjuLo/IkkqphmBPLfUDmte6tb3/hHtNl0jRLHVpZV23Ty2aSs7lsFDj7pA7nrUniZYX0vVC1rZWjWX2cI0K7cSsoMkJPRiOvtVXMVoz2fCO4UqhwO4zniiSGMuMQRc9TtFOz+9UgZJ6j8P0qRzg4U5yc/SgZSkhiaWFfKQFSXJCgH2/z7VJL843Md3zhOfTp/WnwcTzuRkb9oIGeg5/Umi6UPDJs4JBx9e36ila4DQm3ecsVxuxWJeKILeVCgEMyMVz0zzla2y4mjWRSNhXd9fWqihZIvKdAycqykZyKhoaK8qm3xG7FoXOIpT/6C3v6Hv9aqWqPB5kZG6ItllXhgf7y+uKZHcmxLaez+csSjaQNw2ZwM+mOAfTjjmiSO9jiJRhKg5CxuN4HpuI5H5H3oduhaLk8m5gZZEBk4kbPGxRk/nkfnT3uIXtbuWSeJRJC2FLj5VAP/AOuuW1i5Flcwzi2nZ5CY5YAuTMSfkGRn5iR1z0xWlZ3A1BGguobgRA4eFAsYB/u5zkn1JP0FTcbiaW4XAkePlyi7SD90dv5D86dEltLIz3SRbQq5LgEAc/rWRp9rbvNKxtlikLnc5kdmx0B+X1A9aVFksb8jzWugyZie44aI+g46c9Tz70gsh09qsV8HUS2+nXDfNCr8NJnh2U5AU4+73xk1oR211bkJGy3MHTDYSRfYHowH4GkuZ4ri3lit0NzLjbiMZVcdix4H86dpxvLmICSRIAOR5Y3Fh2yW9vajqLzKOm6gIrCKGSG5inViuGhYj5T6gYq2upr9oIMdy4PRhbsAfzp8dmEuJ0aW4bf++XMpA569OOo/Wla1aPBW4nAxnBbeB+eaFdDuirdXhK7lsbvfIcNiNRux7bu3rUP9sy20RN7peoIFO3dhGyOx4f8ApWjFuSV3mWMooCiRBwO+SO2c0kwzceYBlYkAII4w2f8ADH40rMaZUN+J7eQsZLNiCFWeMqSf977tXYYldCjtJtZcAgjp69Kpw3sFpcT6f5iAcBR2w3QH6HNWre2WIh7f5FJIMWfkVvb0+nSpWrB6ELM1qsKXeXVPk89FwQD/AH1HTtyOPpVXUZ/sVxFHFNtkmOQ/VcevvWreFvIcsQp28cc59qxhPFc3wtFIV5IhKABjaMEPj8SPxqnuJSIre4v1u3bzlu4FcxtJt2428fQgFiPT61Nf+WoWR1k8iHKzKCVBB68j3Az9aksojY2RVVw2wBBnjLcgY+rZqS4WRNMisZNpe4Pkr1+bu5PtwfzoSdhtq5naVZxCOH7M7YQeY6kbh5h5xz6En9Kbr4me1bdDcEs6hGiH3CWAz1961fLOnyRxysHjztSQcB/XP+1/Opr6KNrb5Gx+8RgD7MKVhc2pktcXz/u3jW2JYAsV3ErnqB0U8DqTVlVMMZc7XUk7nchmJ+oqztK3AMqlozkZAzUdzbRyNhIASc5DdM00S3cq39y0VrC0QRJZJkCZb7vqxHoB/Sqd5Iz262kSO6P+7+6eQfvfN6kg81BqkqpDM4QeZCVjULxjBVjgfX+VUI9aUXLz/I8UZ5/vZwM4z1x6Umy1HqdCLo2cIjMUnmj5Y0XDAn3xzgdzWFriW02k3tw8xkuS8bOXUr8oYZ4PbG7ArTsblb29ku7YpOEUwQAP95urn8DgZ9qqeJIG1CE2gnk8wLhtqgqXyAEC4+7zk+1UTsx22SaR7aynaJpAFlmx/qYs/KAv99uvsOfQVf0+xS0thgIkQG/IyTt+vc9ye5NYOlarI2kNcz2TedLvkkeM7l8zuD3HTj1A4rTOpQ3dglvbSIVYKr7CMqO/HrxgDvmhasckyOzg23spcAsZGlcO/wDE2Dj6AYFa4aRYjyq45z2FYqSTyXE0qIpiY4Z93yoegXPfjjPrUlxcpeymyjJCJj7Q7Ajg8hPqe/oPrQiWjn/HFqt54K1Z0aSG1ltH8qLOBnqDjsM9veotNaN/DVnPHDKpW1V1UJll4G4Y68f0q742uWuZLDSrQYa5lLSuv3VSNd+D9cAYqXSCIpLlL2cBIz9pV2kKqqlQX6ehJP0NMpPQhmuDFqGn3j7VSaQLIG6cIcMPwYfhW5p0qzI5ABDPuGF7GuJ0W3mv7y4MMjpZ25MVrHMpJ8o/MrcnIPUKPQDPWuo07VIllgcE5mXaB12MMk49jz9KLhJaDJXlS6uLvy2IZ18xQcF1UsRge2PxrGurq31O6gsZZlSFdQ851HyEFV8xQfTBwfY4rU0q6OoQsbTcEbK+c2MY6HaO/Qc9OvWsm8s4rbxLplqiKfNhldWcbgrgKp7decj3NHUStsyzea9ZxutjcXAluI5gXZJFAdNpIYknrxggcg/UVm6lq2nweTqUE0ME6BUlSTpcxf3S3T5TyOcjnsa2bjSLaNle2tUV7KIspVBli3LAn3Ufmc1Ti0y11i3keYvJbS5REByFHI+X09z1JPoKdylZkh1zS7+0STTtTtRdx7pYgkilkbHIYZ6EcEf/AFq56JhIBdGIWk7xr5kkTfKsgOVdgPvLklTnp6irejR29xp8VtNbxSvITBLlOY5E4Lg4yCyjt3q//Y9qszQzLiXOYpo/kcbhzkj15/LnNAXS0NPSNQa/tj5y+VcpxJH/AHeSPl9qivrAofMtgiSgglccMewP+Pb9K5K5tNT8OzJPb3UM9uHwqzfKVyBkZ6AEfgODjitqLxXaTGJLqKazkdiqrMAFLf3Q3TP40EuFnoc9r8j2VzbGMlIJbuN5NwGYpgeeO28HBxxnnvW9qWGsJw3CoDIw39hzz+VU/E0Q1UvaSRSQlo9qy/8APJfvbjj3CgZ96XSJHvLaBp2Mki8OrHCFwep4/nQX0IdMEatdZIJZxKOOgZQRVgviQtKyIMEEgdvrVC9T+zb9Gncm0mIi8z/nm2cgH0XkjP4Vc8oq5JUFt2cYqkiX3OktLPTY7aENZ3c9y1k955kdy0IfBI8sBfQAn2rjfHdqkWtWpsrcQWLwxsoZi+3cMg8985B+orrLZrTT7fTvtV5qnmlTcKbZlCREkgqN2ck4+b6iua8UNBqV3cSpJcMkkYAa4IL5xjtxx2FNaGcN7n0RGwY4Tqce9K5CqSAcDmohEglHlhl2rklRgf571E8zLFtlBJIxuxw3P86p7CJbUFIv9oncM+/WpHBIyhyQc4psMiGJWJA4HB4pUIIPIwentRYCpG6wM8LDgEsigfeB7Aex/nVWdHZj5rGJG/5Zoe/u39BUzAF0vFHzFDtH/TPjgfUc/gKLoh0VY2PzAHcOw7fj6VLQyvPGkkYjRdrx/Mrx4HlnGMjtz39azo7maFxBdPHaKTtMgGEkb/YY9MjqDyO1a1nJEkDPIVWGMnJJ4/H1qrfKjaPdPdKqWqRtI/mDiQ9ckeme3ely3QRMySON7BLtZJgbuQtEu7kA/dOB16A+tDTJALa/ucxPjY8kwVWB7jj37YNJoGlAqk85uIR92KBZmURpjgYzwT1OOmcVqLYW1jcPNCgAuGw0j5dlf6nJwf51DVzTQr29+zwJJbQmIoPLkNwCDjpwnU+vOBg1LqmjrqsCJfTPJ/EgY4RWHIOwcEdsHsafZwwTvKiSfvo2wrq3Kj0/DkYrQgBXKP8Aez1JzkURV9yXZFDRrhEt1WRPs7DKmM8AEdQKtWoVQ6IMBGIGB1U8j+dZmq3y2cjXVsouIjhLjnEY7Bg3cjuADx9KiZ0e7EyxoFkT70VuwXI6ZPXpnnA6UttB2NS834idB86Hknj5T1FWVxLHgjIPJGKyo7IzR+ZBqVwoxnETqR+IIIot49QhYRy3kb7vuO8I2ufQ7cEH86LhY0bQbJJwMAbv/ZRUF4kdpbSSvIEiQEkv93b3H+e9RJcT29zIZ7V2iZQ3mQ/OAemcdf51YvUtdRsXSVFmgYg8cjIP9PSgNmeQ65r4fUzOVAgkDRmSQ4LAAEHHbpXovhKe6m0aK4fcWb+F+rL/AAn8qpXHhTSHlMsVlB5qqzFnXdljwBz2xmtuwt2tYY0QtsA+47ZHA9eoP6VKVmazknGyNAGKWMqck+p7H1rjFtZDrlxqETxhI0KRrj5xnPfsGILfjXT3d5AIJGthvnYBQgP3XPAyeg5NZF/CNMhe43K8aY5x97twPxxTkjOJLb3pkSxDr8zKJNgI7IAM+2TS2s11da28yTQm2iURbMH5W4Lc9fT8q4m61gW0DJv8togfPlz8pPTjHYY49ad4c8U2080cK3MVu1w+FhZ9kh9N2fugjHvSTaL5HZtHpd6iyxiKeNdjjA3H5SfY+tZOoXEsFpPFcgsuBiRvvKQR8rfl1/Onm1gMkAZkuXkcllPzIEA+bg9ewyeap3lqBNNHbSMLIYEsbOXUL1OM9D2xVN31MlbqbXLrlHAiHzA9qjnmTymTLM2clV5OPWs+OZo47cZkMhQOYwoJPPU+nFT2T3TwLMttGA67id+WyeemP0zUh5nJarFcvHexpazF0lJMhwQdwBBIya861O++yW0juWAZ/vKeh9D39K9yu7ZiRPtLErtnh6GROxHuPTuCR6V4h4qhtLfxBdWzytNCpAjkz/CQDj6gnGDzxVJXdjaE76Ij+H3ja20/RYrcyKL1GZP3o4ZSxIYHuBkk+uK9J8NapHqCpLCJXSeTasnGAi/M2TnqTmvmzXLE2czG2Mxtsk8nHl56rnsD/wDrrsPhV4iZtmi3MvkuAUiGWG4Mfm74LHp24zRboXOF9bHthns1kitSIo7l8yRO5x+6JOAP9r2PbmrsdjHBthijiQFcu+MnHoD7+tZ+hWkc2lqLq2id5WYSq2M5BIwfQjoMdqkXTLnT55fsd3J9nEpLQTDcFACn5WPbrweKZzO21zRmZbe1IWOIsxEccYHynPqPQdTWTcqNItVNuDMd2QZDh3cnqc/e5x7ipLe31ISJd3rWrSMuBEFKiJSc4ByeT1JxRdSltSszcwOrFmC8hlPyk8Ed+/ODihoIuzMHV7u0j1zTZZElVLO3kkkdkIPznDNjH+z+RFVRaXWqSTRSTQQGGQTwQ9QG9HP8WBgN2z06ZrYAjvdQ1MXBPlBvs+eg2BBu4+rGm2ML2+nsRJFCVY7iybgjj0bg4PHHpQ9y76Eek3TNr08F35cN2+F8rqrbFX5kPdfmaqd6EvrW4trZxELieX95GPm2+YzYU+uO/wDtCo9SWbXtEMRBK28hnllX5CWyd4Q8nGCRu4yBx60aH4bRJJJdKuikCARQpOnngrj5iNx3AEnjnpQGm7NWzuG0+02FAqMF2Pt2hOOA2OmB36fSm60iwz6Vckk/v/LmY8/LKpXP/fQTmo7WKWxKxzyLCz5jDhy0LkcYYHJQ49OPepJrdbixnt8Tf2cQY5kX78DDHK+3Qg9uCOKBWLSxu0EpEkpBkfO49QMDr1HSsi0S4KvCsphgSRtyooOQOcjPTirOl6hLNYQresWnKb1ZsASr2Yds8jI9ar6zMS8sMbOr3JSHcBzlgckduFWgcb7MztL0oxIwwvnSQJcDcxchtxPX34FTXpbz0ubInY0ILR9eBk8ehGK1HVU1C3kRmw6GMBstgjkfoDzWTcTBdTa0j8wfvCY+OdpBOcenJ/GmU2a09vBdxkkgo64Lnnj29qwmsIVV7a5Uvayj7vPKjg59cfmARW0G8u6eJsYf5lVO3qPb1puqW5ktlEbESA+YpB6H09s5xQSrrQ5GS3Ohah+4EkunTfOys7SSx7Rz8x5K4HAPTBxUmk3CLcSpB88UqrOgB45HP6g1NryedBDHZsFE/wA0YPUMuWx9Tgr+NYcOoW8UsFzAxS2dSz7Q21QSOTx6nBHQdfWgrodK0TTxvDcRq6uNpGcAg9qyWM9o0drHIrQMf3chGXA7pnOCR6mtRX89MuMAcAdcj/CnYQSxl7aGfYd4hdjtOB3IximjPY6yzkuYdD09NM1LTbKNIz5sM0ibjJk/Ocg9ePyrj/Eslw+oY1C7triX5T50ZDIQB/sgdK0Tr9lKVB8P6ex4ByznB9+awNWmjvrp5obeC1QgfuYySgwOvP4VoZxVmfSbFgEyMcdKjliDRMpAK8jB5omZvIOwZccA+lLFuKoCcH+tF9QILVyHeKcZ2/Mu4ffHr9addwR/ZpioKkoxBUkc4pJkfyQ8QDPESR7juKl+W5hwCdkkZA/EUkgZW+zLH5aLI6+WpPUEcADvWZPcXCL5dnCsoYlvNOVVT6Y6tj0HHvV5LgXUu1j8kcKM4HcnOFP5En6Ut+MqijIIPB9PpUyVlccTPfyvJZml86XKhtw2hcn+70Wlvozd25ebd5D5KpjjGCSx9/So9Rh+2QlGDLBBIhaaMZJIIyCO6jv2qxFKxkS2mILmNgGU/K2eMj/Cp33GXHUclTn95uOOecCnyECLBCsGG0qe5NUZrhYLUXZO23wPPPaMjgnP4YNPilub9N0SC2g2/I7jLn/aC9B+P5Ubh5mZcf8AEnu7WTLzrKmzbGN0jNnOdvfqfm/Ord5cQzwxR3ATzAci3EvBJ7P6/TpVedIVjkjWfyyVCyXUj4ZmHUFj0x7d+BWfDq2gt5qS3Nizo3lt/GQe5yAev1qdtC2rm9EIp1/eyxOcYH8IA9h2FTIu2IopO4EFDjuOlZEGoaQxQWV/GxYECKKcknGOi85qKZ2uzK0Ml3HaoSuU2o8jDg8nkAdPeqTJcTTljjMiMnyM5wrrwynrz6j2pHdmjaCRQJF5yPu+zD2z+VcxLpz72EkTtE+HUsy7hzzniny2Gs2ciNYz/uudiyybgG7joPlI4x1rO7LUEdfZSi5tYZ92HI79mHUfmDTblEiWWcvHC4GXkbhcD+92P161gaFqFywuYLu0KTRzSFRHIGJPBIA79TWrcT297ZmJusuI/mXkZ9sdeOtVoRZplLT717m1FzsMQmdiEb7zRA/KQO3HIz61b+Z3EUxLluF38qRjOcD/AOvUoRN7GIFdgxjpimeYS6xRk7oAdz46A9APfGaQ7lJma21CASokkSsZPk+UZC4wV6dWHT0pNfWGLS7iWQK5WFpHZxuBJ+VR7ck/lUesXPkTWyITHEoZCcfMzcNjP0U1534j8RrfRahppuSnmSJGwLbmPAwgxjg5JJ7fnRdDUG9jnYoJ76O7EThLBJGYy9QSD255A9PWqFxfxQ63Fp8EX2m4uT8yJbhm2+hBHPHvWus8dvpd5aRowcXG0kYUICobbjGOmT+WapfB+zj1nxJq2ry2/niH9wiSKGA9SCeh9h61clskaxlZNs6zwhuhnmhtrySW3YeWElJPknPzLjqDnHUdMeld55Jt7URpiQ4ChRwoJOOlc/qWgW32wXVkstlLIPmgdeHOOCCM9uCB/Or1tqXlxWdusiyTS/Mm70UEksR6EYz61FrbmcpKeqNU4gmACqW4AI+85xkmrljJJFANiebDkkRhgGX/ABFZ2lBo41nmLSTSkkv3A9AOw6cVqIu8nyyBg9fWhGbCeaR4wtvbmNmYDdIAMfRQTk15f8YtBtBDpc8SETtI0c06ZWRxjK5I99xr0CXUUM2HJKxuyswBIBA5GapeIdOh1rTriOSVICyh1cjIRgflz7DnP1p+ZVPSWp4heaY32Yv9oklAG1kLAFieANwGT/SvPNdhOj6ujWUriRMSBwfutnt+lezXmha1FCxXS7gzx/6rDAxqDgE/iOnevMb3wrrmo648MtjcLcSyFQXXAA9c+lKT2O1JNNpnsHgnXpJrWC9iuA9rdgPKmwZWbA3Y+uM/Wu8v7pZp7a3XYqviZzjOU+nbnFeeaX4Zm0GC1tUEQvfJUlkOBMQTyD0DDP149KyNf8T3mlalbzoo8to5Le4jYj92Tgk4HT14q2c0oKTuj19SlwyvvPk5ypP8fv8ASq2vPH9iiCuWuI3E0SZAJK8sfpjI/HFee/27rMul5ttQtoRtAQ7c56YC5/nUD+IdWsbWY3ljbNJOVSSaG4LOQT/tAcD0/Ggy9k7nYaMYZNOWZ8s9wDPsj+9liTj0GMgc1Q/syUajGSWlt5oXmezJ3K5QgD5j3+bp04Fc1pHirS7bUcXV1NaTXB2zQzkoHJ+6y8Y46cHpXatfRNdQ3MLAw26+UvlnO4t95dvsAvPrRa5bvEbHqCXkTSQxk2/lEzKV2tvUdGHp/gO1VtGmnsj5VzG0UE7mZSOdpPJT1yO3t9KZq4jOiXTI8S+akZWX3eQIc/UNXSwQR3tltdU2tyccFSD19iCKQuayILo2ctodhRkmBLEcArgcjvn/AArMm1Y2tqk/L3QzBKMYBCnAkPsMg/8AAqmuZV025DXoVYt4XzcYWTPGcdmzjI78Ed6WxhaPUNQE+WM2wuG7Arjbj0AH86BWVjD+xrZK1i8bmxSTiXo0J7MD2U7vwPt0qS3e/W/IuZDvsSUDqmFO7GXyOcgEAjsSfWuiiRttqrHeCphYkZLFCQBj3XOfpXGhXWWUIP3UL7oGzhpSsjiSMHvxkE9xj0zT2NItHX37ieLyrIefexkOCTiOIjnLn09uvNY1xIhvrG7D7vtCtE7/AHdjLkhQOw+9x7Vq2UK2oWB12RAnYgyAB647/Wquqwv5Mw2pH50nmxsVz5ci9D+K/wAjQ29xRWpXuHCp9olkJZGBO44AXuP51orbQyouxupwFB/I1W0uc6rpzTxjypFYxyfN91x1GP8AORXBx+IpdB1uWyu3CWEzb0Y/wN3APofTtST7lSXNdLdHS6hFGuotZSEpCqM4bpjdhgo79QSa5y2ulW/MG0l4N0scYUKoR+oGeCuQ3TNaep3PmPY3SxtvdmB3dGblse4PK/lUEim6ukvPLLhy0PmE/Mq43AjHQ5B6VbRPQgsbwWEgtxHKICQ0TAAiME8p9Aen1xWvbvFLdJNdQ+fbK27yhIUDjnHI6Vky28jN5cz+blXVmPG5DgqT6H+oqS1aSBhBKMunLMf+Wqj+I9sjvRa5LR3NrpMd5Cl1a+GS0D5Ic6iUzzgkZ7Z71y/iW2FjqMtv9jFpsQHyRP52045y3r7V0MN7HNDYJcRXQilt5NMkcJuU5OVZPVgSMisLxV5b6oiRJMrQwpbs06FXkKrhmZeoziqSMY3vqfQYbci8cE8dqe4O3CngVUKyK4COAueSQcH/AAqdpkhhYzsI8HLk9AB1OaYDgD2+vFQyobdg4GYWO4qvJQ5649Km3Z24xjOM0rIcZJOB6UDMiAxR3uox74yhZZVOPuqy8c+zbvzqjc3U13GHWK5jiHRgAGcDrjnIHv1NWdb8q31XTpQgBumNuXA6kAtt+rDcB74p1xBau4fyo2tpR12/dbHHPXmod2NE9o7LCgS1fy1Xbt3L0+maoagXTbIltc+aDtUhPmAP0yD6/hU0ayWk0aQTFI23DZLl14HGD1FZmr6sqXQtmR9q/LIYg0o56qNozk9MY6Z+tLQZFDexySiWFZJrctugtzHh2cdZduckHtxx170y31W8uppooyloiBnZICJGX/efovH8IGferULW2oxFbwukbDBUKd2P9pxyP91cAe9EVjbPYSRJHHhY2CGP5WGBgqSvUj9Qeal+RSa2M+z8O2crJPObm7Mq7RLNK33+pwD15yfSrX9nTWUcFwjJcoq5eIgJhSe2MBsdeRmtq3hHkx4JKqAAGPPQZp8ALQRqwyqAocHpyaXKHMxqWtrfWqfaLeOWI4O0rgL/AIVz2nWkuk2dyLGZjGkrkRyjKFSxI57dSMj0710luBAGic7kHSqF5cmG7u7e3VDJKiSDd91F5BLfj0Heqa0EmyK11G2vLWRWKx3EQG+J2wy57/T3rQEsMhMOVeNhxggnd3/xrnl0O1luIlvAbi5V98dyx/eRgf3T0UZ7Dj1zUk8k1jKIr6GOeBsul0iheRztdf4TjuOD7UvMNy5ZxqHukmUzQyXUjKcfMrKQueOc8dR6Us0MkU9sInF1almf5h86YH/1+vWqNiZ7fSbWaNmkST966MTujZiW6915IweRVm9K3s9mFDfOsjsVOxgABxn69vagN2LYX32h5DC+EYkoT1Pbr/k1fjtVjkwRh5Fy24nnHTH4Vky2s/2dZ41zIGG4jhzg9cdD+lWbC7kceVOjOFbIZCcg9jg8g/nSE2cB4/up9Msp7afznlactauMk7+e/oucn/ZIryW2uIoTI93KsF2C9ykjDcEZMtwe5yBx3Br3DVmi1a61r7RGJlLCC2VPvExAeaQp5BLHH/ABXnPiz4evPbXcmmzlbRI1lTzoSC7ZB2nBx0YHOOhpxSRspXRm2d6dS0q53KkKvtmaMcsWdBvOe44wPxrV+Ad3bwQaxp1zKEkWUS4fgFSMbs1VfRILXzoVWa2huoVZEhlISKYdMegwSOO+PWuX+FMcreOYVmwkkaFZWcbycd+euacnZplJKUZI+mTcG60+aKzMU0RGRNKMxgjHK/3jx249651NNOnardgySSRK4kDSYJIfqfYbl6fl3rchsXtlaf7QzoSBuY8cn36dazdU8QWT6gi2Ekd5NJG8TCElwpB3LkgH0fih6rU546bGlb38a2kXmsob7q7DzwemKtwubgBpFbys8Kvf6mszSNLETrcPEQx5dpip6j+Bedv1JzWluitFRYmXLEDYByee1TsF02VEEcWjOLkkOnzvgkKvzAnAHHc1at4IWkmYySOY3AXLcDHfHrzVHRX82xltZYyEO+I7uOMkVJG5MCvLGqv5eHHQ7x1/lRoDRLqq7LaVw7lsqV4GSQw4prWMbbpZiHnZeQvTHZRTvLUiVXYKJFKhhgkLjoPxpml3SkKJfmlQlWz0DDqP8+tCFr0K89rFK8mQrIUQ7H5wPm7/AI15t480JYLrzWb9xcLtRj853Dt0B6HjJ55r0/UXW2IkLlo0yvKkZUnoCM8iue1iNNdsWtEjDRMQWkd+T7KBz07nFDLhJ38jzfQ9Ni0hvNuGmurMnET53+XxyQnp157YrodfC3Fpp8dvAgS5fcHLjkbT0xweuevaobvTrjQI3m3eZaKpy8rKjpg9CD6e35Vx9prU7ai11FMIrK0lKC08vOEYfNIuenOOBx6U2zpWrujq9QtLS8t5IZYUZCNpWTAIx6A9fwrzvxFBqnhO6M2kz3ENkwxsDEhM9OvY/pXfXl19uszcxOk7wLlVaMK0iY+YZBwfp1BFc9esdZ0G6JdY41G4RMCZGGD+AFHKVvoR+GfH6XTC11qNHt5ztKheFkLA7hgdCcn2JzXruj6za+VIEmiYoA+4ODwSfmx+Az6GvkeNznAJBHpXsnw81K1vrCJp3SO+tyIzMQAxU+o7jp+VNXehhJKWqPWdcvIb/Q7yKVGwyZ3Mp2nByDnoORWelxNFN9pISeNwgPmPtII6ZPOep5x9fWoTrtpFA9rcalZwsPld3lXDJ1Jx39KytJ1SyaH7NHcF7KcsfMSJmCAk/u1wOQex7dPSlZkWNi/vZo7S2txbTJLNJ5nmRurFUJJYjByOGx+NYmpmMzSxWbLC1ztWFMFSkig/MAexXIOO+PWr896q3gWCKaZA6wws6mNUwpZgSwz6fgKt3ECC0YFoWnchWmYcRcgrtHYBgPr3przGlYsfa4ZLdSrYDLvXJ5INQatLPPpE0cSBUCCQkqc/LzgfXn86x7C7Z7FTMFGB5chzlonBwQf9nPQ//rrWjuMx7ZvMjQjHTOeKSXcNndHOeVNpEpu7MPIkzIrxoPv84XI9R6jt1rjfHltJqNys1lb3LTE5IERADDuPSvRbCX7TFYAHOBvZmAIyBgAfietTOkKF9+51IJG3jBqrIrns+YxZYJV8P+Y8Y86BRNheeVGTj3xmpog9rpSxzOXdVEsSg5/eKdxXHvzj6mrOuSTJYuiqVeVcfN/CpIBPv7Csp50gM9jKT5iMEZw21kUKPnB9fu/jVXIeojGOTVLi5jRhZGOMIc8scsfw/wD1U+9zcW6FFEcyElB3wfX6iodAI+xzQzPtdZGC5XP7vHyH8v5U2G9ltLiN7WYxzD7rrnIOeTS6ivY3xLY65o+lA6o1j9mi8rypI3ZW5J3oVB+bnBz6VQ8TalFcay5ikaRIoI4RLKMPMFXBcg+prfgvBpmk6cJ/EepWYuIzLHbwW4ZUXcR1z0JyfzrP8VaOkj3Wpf2rNfzwpE0rTRbGMTj5GUg8jPHrVmSaue6qVwM8gqO3WnRkCbBIOc8GoEkEWPNfK4G3j+lEhkOeNiE8N/Ef8BTGPuFVyRGPm2g/K2Nv1piRs0a7pN7Y6uMgfQcVKrKi8DA9B2qETRrOY1/hXc7dlz0BNIDP1ayF5atG0asUYOvlMY3z/s+jDqD6isma7u9JB/tOZH06TkXE6iNQf9plyoJ9wBn64GveXjxuptIxJK3QuPlJ9h1P6D1NY02lzancpPPcyXEbEuLfcFj9C4GO/QfnnvUjRSfWZr+MpGr2kCvsjZhveU4OCg6DHXJJ4HSr2g286WsTNcP5jKB8vHUZBHseue9ZN7o2mJcSTMXS1tj5aRzZco+PmKknJxwMBs9etYNpZXdnK8eni1n06BsRtNP5c8IJyAqkjcvPAYgjB9qzNEkz0WWAbys5ZpB0bgMffOKzruwEN7FdafqDxyBWacHEi4xgFsDpnr/9asa1bT9QXMDNdzKdjm5yEVgehH8J9sfnXQWmnQQq3mqjSNy7FRg+gA9KRL90ztN8RbPMtb1lW4gcoQ6HDEdMFT3GD0zUh8U2cM2zMRcjLKsoGw9Pm3Yx+p9qrzWq2uqtFbqRYTbVmfA/cEjheB1Pb0/Kr8EMcEIg2ZtA2UJUEn/eJ5J9z170ajvEtxXS38JMNxGMc4jXLD8+v1rMilkN7eSNcF3aZoCroCdqKuBxj6/iauzaDpl0/mGyjSXg+bCTE/5qRzWRottd2mr38W4TJkOgnGC52hXIYdei9fU0w0exq2EhluJGkIVumRzge1O1W1+2KtoGyHO6RumEBzjI7np9M1GbhbaTd5bRzscLE4+8x6c9CK0LSJlg3HJdjmUnjJprbUixGoKqxdAUP3geD9eKwtRaSzvEuBMkVuJghXd8yhlIJGeoJIzxXQTTsp8q2ZfObrk58sZ5P58AdzWZLpokgu18o7nOGViNxOAQVY9DnBx0+lDHFJO7J9PhE8P7yWYoDxtkIqV7aW0DXEBklKDmJzy/0Pb8ao6JL5YkiYurIdsiMMGNx1GPTuD71q31z5OlXUmSSsZZW69uKQmjD04R3Wi2ySW3mXEUzSOHQbg7MWZTnnncaydR05YfB92ID5Ft5E08bCdhs2szDI9McYro7+Iw3u6CQF3VWAPG4jjA/wDHfzrJnaRLB7ZlMiRrw7ABFYt8wz3Bzkde9K4ynf8Ahy21Z932qaOGWFXVgi/Mu3PcdAMHJrmvDnw6tvDk76gmp30crJkXIVCVJ7BSDntxya6N9Wis/DVguoM0Mi/6O2WBMgXggepIx+dXrG8l1OaOU2xaTJMYdtkMY9v4mPq2PyFGnU0TklpsQ2ekT6naj+0mMkHX98hV5eeCyliFPsv41oz6c0FjJarvitzgqEYIUOchh7itPyJpRia8CA9UtxsGP945P5YqD+zLBZQ32WN5QOXkJkbn3Ykim1ci5VguJoBi/gdh2ngBdW9yByp9sEe9MGoNcySpp8Uk5X5EzGUjVu7MxA4HTAyePerNzEttBI8Sn5ckAk4z0A/Om6fCUijCv8gHG7nPqf50E9LliHbaxpE25iRydvU96p3M8aXQLcQT4RmH8DnhT7A4x9cVckZvtMQMnYseOewGPzqG4UFZVkUPHIPLaMtwR3z+tC1AZASAsROHhfncOuOP5VDfW0gljnt32FyFkRuFkB6HPZuMA/nWfPM9rJ/pLnHHlyk4DdlDH+8RxnuRWgpW+tyqsd2Np3DlT/8ArpFWaJY78keWbUmYDGC4X9O/4VBeWa3I8yQNFKepjYoD7E9SPyptvIkkMaXI3B/u7wCCe4Hv16VYFpLFzBcbVIyscqlh+fX+dMS02MyTSreN0laGP93neuPMbBH3uc5x+eM1laj4O0u8t/Ns4LRboqf3ixkeYMHhiDyOePQ1t3N9KkhR7cTSrkg2r5I/AgY/Oqt1qV7E4MenXYz1dIwF/EBiPypLQq0t0eTXHhTX9LiE+mW4uo2f7kT/ADbhweDgq3GK5fxBLqunQzCbS7m1klG394h784B6Y+le2TeJYoNVjS5gmglnOXR1xll/iH1Ax+FGpXJ1R4ktoXkUMXCrwMkEZZzwAMn7oJ57VdkbOtPqj5ahtZ5JVEUEjFvu4U9a9Y8E6dFZrZLdKt6z7kktlHmKARlGI74PHP8Ae7V1sHhiBddY3cUMrBmdVSJVUEqu7A7Y4A9q6CexhiiMVtAkIU8vnqR2A7mlazI5laxzE2n6bZ3t3O+nW0EojAUxYBXqTkrxk5HAq3Z6f5ZjgivLxUMex1c5UnA59f1q9cWkbvDAzYVm3OM84B7+uT/KtiGAR4CMFBIGMcmkrsL2OZltJ3iEMksMkiXIdXLNGWByAT19MfhWrBdo0atJbbI24wFBVT0IJ/xovbRDZ20zFmaJ/lJGAwL9D65pob7PJlmkhR+AJAcL+PTpTDcqS20n75bQmB0JAOd+UzkKy/xrjgdx2NV4NSkj8qO9iSNeBFOhzE3+yWPKn2YCtYWylhLAcPggqDhXHv6H3FVNanhtraac5tZFjZnLpuWQAZww6H+dNaivrYydMw0bTszBNzKjx/cOGPXjB5z2q+81xNkx+TMCcB2BQ/8A6q5vShHZWNvE4mbYiMI4mMqIWGWUAcjrnkcZxVs3l5KzJZxPbY48y4XGPdVBJz6ZxQx2uOujczJM7h3DvsUpKOcDAxkdzn86zDFM12rXcQImYLhTkbhg4Y+mOnuuK3rSzfKElmCchm+UD/dX/JqnqNq8Ej+c5WGU7kkI+WCT+63op/nx3oAkuHktr+2O1Y47hWhJ/vMpyn4HLD8qrToCGYKwAZs8defWobllEQiuPkkwzJk8oQOn4HH6VOzGWziKj5mX51PZv4h+eatENHU2Dwtolg2vf2TsUE2YuoneQLkjPyEYTOcA1l+JdSv4Jr2wvPspa58uQywLw8YUeWq+iAcgfnVQ63pb2VrbazY3M81qvlxyW8vllkySFYEHOMnkYqHxHdzz36Nc28dvG9tE1tEj7vLh2/ICfXHWmZWdz6KZADnGTgDrims3OA319qaZDtySfpjrUTuAwZQx7E7aSYy027jYKrrbxGTfCu4hixZySqk9eO5pzET7iQ4UHG0kKKcJNiHzH2ovGRwMfX/CgCtfQxhJIolaS6u28tixycdWJPYYzxVdi8byJav5h3YknZQEXA6D1wOgHHvUsMcl5KzMpitEUpGmcM5/iJPYHgevBp18myM24ADSrsQAYxnjP4DNK1gMzS7bybdXZmedwXZm5J3En8Bz2q6unrFtuoUVZ8cgKBvXPQ+p7jNW5YkRFUY3bQOfQdqUq3lko6ktgFTyPw9KFHqF7mXqGnwXyLceUWdRjzYRtYfh1BHpzVAXj2UeHfc+4RIHQ4LHoenA9foa3sHO7EkU/OWUbt317GsydJbvUZGETeXABHlR/H1JAPcAgfialrqgT11IpQWs5rcwSAOxR23Almx9725/GnxxMFZEXfwA0Y4wfUen0NL9sgEgtWLKyfKSVIwO3OOtXIri3UlYpoifQOM/XrSAWJzKu0qVYDlOjfj/APWqO5WJ5oJCmP3rBfps/wDsamuAJkjmT5SHUHHU54xVOdRCIpFLKPtK7h2OcjPt1oZSQXUObuKKUBvkZyG6Ek4/l/OpSEiDea5WPbyGOce1TXKLchNhAlTOCeRj0P44NU7grGwa/ngV4zlYweh7NjqT6VI0WILUK7PIqiZyHcoMYUfdX8KkBHnThlDZVX59cEf0FVLS+jkH7qK5lBzk+UV5/HFQ3t3PFOkqQHCZjkaTA2gjI6Hnp+FMdrvUdqlgLiIXMLMt3GuI2U/eH9w+ozz9ao3FzK1ksDqF82SON3PQfNub9FJ9qupdXsqL5HkJnoWQkn9Rj/PSuW1R9Sk1Zd3k/Y7Vj5shYorTMANuf4sDrnaMnGetLzGlfRnQbReatbNJKREI5CBIeW+719vaofE1xANFvVWETLbATyEfdQR/PjPqcdPc5xWVot8Lm+nSC5WURII3bGHLdWA5+7yo3DPt61tahNaWui3LT+WlukMsjZOBtVTwfqSOO9MTXQ5zSrGTUNQudUvY/NmaVhbLIylIo2w2YwBxu4/LvXQwM0ly8Uaxbh8pYAkJ/ia57SXudQ0JHaG4sUVEjLBDul2ooPAyUGQff6Vt6JtDfJJE+0AELkY/Pn86m2upUkaS2bRlNsj8dS5zuq1MWXALfKB1UinJKU3F9oHGV65qBjlwVVXGc5xV2MypqE5URncMKS5BOfugkfripbaHy4YUkwcKBk1V1CUSahbwEKSULHgdAwJz+QFWm2MMDe7f7POP6Cl1G0Rs6/anYCMeXGBxySWJwP0FR3EYhgJZy0gBZsDjNMiWQ3M9w4DfMEUMeAAAP55ouZS6FecBWLYXjAHr+IoFYz7uJ5I94WOZQpBRl4ZCOQR/npVGMzWswCG48phuQhg4UHngN1XGMY5rftwp2qNxKgdOh4qFrdA7W0qhInzJCwO0qQclR7jqPakUpWKdp50omQzwyqW3KrIR8rDI56dc9u1Sm3ePBMBmI/h+0cfrUGiySRukdw+25MO5+4fnIYe3zfhWqRk53R4HPrmgUlYzvtM4UK9rBEp5yZCf0Uc/nQZnKYluHQH+GFAB+uasOuZQdw46Y6UxY/3xK7VB684zQGhm3727WjlYZJEGGDSjOSDwcGpbeZ3JkETFWPGWxwOOKnltGcqknltEpDBT1OOgPNRiNFiXIH3cfKOlFh3RjalLIt7x+6ILn5ec7go/+JrTSKAKCAXkC9yTjiq16uLxeWaAoFPy4wdwOfocY/ClaSS2sJDsOEDbQW+96U1oPfYz47iP7a07sp3fKm0Y+UHA/qfxrXhkiGx5GAYtjczZxVCWzTczeWkbK21Fz0AwKsR24UcspwD8wyAT6ZoQ5WZnXlw72r+SQShPzOeMBj0HpVhRLdQkCQyKQMrjg9zipZLVWjYMwUbyCE5yPr3qaBvLt14yVA6djTFzKxkQeZb5iB/dn7ufvAd+O/0qv4hl26e8EJP2i7BjiDnrkfMfoAOau67d2v8AZ8rXLnCrlWTquO475rz/AMLSy6vrVzJfzXE8lsNiAyEAKxyMn1x1pJ2LtfXsdbaRRSWSmBmMUgDGU/ekJ6ke3arwgRQNzqiqBhRWZYQ7S8cLyI0TnJLErg8gfkauHzmP7wnjhQveqbJZJI0YQiFWUfTiqc1wI0GVExJwwY5GDU8hKjBPz5zxxVYpGHLKu4gcknqaRJgvp9pJdtPHE8S9I0jYqp9Wx07AfhVZIYI9Qiiu5b5rOVi0gjYFgR/dzx+dbUpyBuYDHb2qtDYPqN/FaWzA3DuBGWOAD1BPt1zWiVhOQ9LDwqFIE/iIHPTEP+FZ/im6hv8AVUlsUla0gtY7ZfOwJDsXGSBx27VvyaboYwJNeYykcslm5j/A5zj8KwPEGnDTb94HlSRSgljlQ5WVGXIYcUyU02fTeCrYBA6Dp1pjRLtKggA80qsWAIIPA61XF1DNLttwZnz8zL9wfVun4DNIRI8q26NM7BY+h9cnsB3NVMvLJ++ymGyq5/1fuf8AbP6U8W8rzmWST5hwAg+77L6fXrTJZl2mO2baEJy4Gdv+6O59+g96GBPJdLBlAN0m3KRr1A9T6D3NM2sQbiVwZiNvA4HsP8ahgiHl5AIHU5OSx9Se5p5kbgj/AFuOM9FHrSvcBz3AfZhWMpH+rXqPc+grOuNRnjlMFukTyqMuDllX2yOrewqa4AUuIDtc4LNjJ57/AF9Kmgs0SIbQFwCR9aT7DM2Q3BhkuLgzOqDJ2ttXPYbByM9OSau6ZY21taLGsZMijLtvOWY8kk59TUkkXmXMEL/eU+axBxwv3f1x+VV5ZXsXkkaRfKIJwRg5Gc1Pwha5BKjW8lzMJ8BWBKyeuOgPX8OarQ6/b6oji3trm5ZeCI7fdtPQ5Y8CotNhuNUnkvL9E+dv3dushKxp2J4yWPU+la/2Y2+FjXbGTgIpwPzpb7FaIxoLOG+ugPMSEJyVUnzGPoc4Ax6gfjU2p6RbW9qJhe6hGVkQgC4Zi53DAA9TWzPB5nllwAU5XA+7VUKtxqBLcrbkIg7Zxlj+oH4UNDUjDnh1eJ/Mu7h57EceRCwD/iwwX+g4ra002xXbBFFFx93YQ/41oNEszcqcA9c4zVG5sZROrwHIU5HPNS00PmI7zz4bhWKrJFnLshwyj1IP+NR61dQRQR+ccRO4eR167R2x3zwMDn2qzHcY8xrmNgHYptx17AD8qxhaebe/aJdoiTbsVTkRg9h+AyT70bE+bGzvqMkTLYI1tZqm6Rn+SU/7IOTtz+Lc9qpwNDJeLaHBd2LSqvGzAw2B29M9ST7VZ1O/BY24kWO2gdXuMd3K5VfoPvH6Ad6dY6XbWsa3EtqRcSN8iRt8xAHC59upPqTSNFtqSzWlnBpTSs3kASSFPLT7p3YAXuMAAcYrk9Rs9Uu57JbxUuLZJ0ZgW2lYR8xd1xgsSoHHYHit2VXF3LbvmSRpGeFF/iJ5bn+6h4J9615Yoz9mjkIfzWDTMRjIHTp0GcAe2apq7uCdtyvpqm1t5LQxN5wlLsQOGLjcT+JzRFJbvc4zmdOhh+Zl/LP68UzUNLiE5u4Y5pgEKNCHJLKDn5cnHHp9QKl0mdHhR4VRYGzjaNpU+jDsfY0t2To9SWTUJDG4e1uVdep2r8w7Hk9KWG5juVCFTGT2K4/Xv+Bq1fqBEsuMgZDHse/8xWXqF1LPaBLYhVcgLI2AQCOoHbjJzVEqzIreNbvU7mcKrIgFvExOMhT8x/76JH/Aa1JJHghXepIHC+hPpVMGCyCKdixRxhVHXvx9SasxFiPNlyikHah7D6+tJDeohKRWpDBWVRy7NjJNZU+pL5sUSxzSPITFlIzgHGepwOgNa6/OqySEPJ1VMcKP6fWqV9Ft2zNsZxnc+OMZz+h/rQJWuJNcGGUlbW4cf9M0Bx+tVrjU45kaNIrhZQwZS8LKFx3JPGMZFXg6ld8eUKnDoRyp9P8A69F2gaArGy7pBtHuD1J+gzQGiKksEly1lLBF++iUlATjcMDKH2PH4gVaWcPEjoqiNh17/iP0qLbIl1AUl2ny2A2n6VWIMF8Vb5YbnLKWz8sg5IwPUc/XNFwZfdWxlAjZ6ACoRuLFWVsZxnFNblcF1C4/hHNNMceMYbI55bk0CY+Qqcck8Y+XnFQSTGJcBDkD71SeWdwwGQDj0pt0qBX2nYD/ABbcmmJFJds8rOXLgcYHQfj+dQ6msMVlMz7VJTkA9cn26VaK+XGoQrs6D5c8fSs3Uoo/scpJZyw9cA8igtMsWZErl1jGNxJAGc81NKQVzvUY6Hrz6YqhCjInG5Ex2O3P40MywFnPzsT06igGtS6h3AnDMp9eMUHmMlskAcdQBVOa8MLYSIBicZLf5xUZlnlJDXG5T/Cv3fxpia7nP3dlBdJIrLkyNwAxAJP07AUaHpNtZI4gQ8nqSSSfU/rWh9nUD7yhQoRc8nJHJ/TH51YUJa2ySPIiAn5V3fMaDS+mhWBH2+chWVAiFufqKssVCqrYAxxgcj2qmkyvdXLoQWUqmO3Az/WoZZ3aXBVcjuD0/CmRZksmwLjeFDZyR2rOubtUjKxRuzdOfT1qeRmYDemMKeKollkwQSQcgHsaCrEFzLNjYsa528Etwfypmn3V5Z30U9sEFxG4eMKpfJ9Md/pU0jbUJJGcevtUMVw1uyT2szR3MOGV0PzBu3NWjM2Hv4ZY1eXwpG0pUFtjTrGTjn5e351z3iKS61C+E95BHBIsYVIREUEaAYCqD0AH51213L41vrgXUUGrQI6LuRHbDNjlgvUA9cVxOr3tzdai51FriS5U7GM2SwxwAc8imTE+jI9PUbRI5kJAPIwpP0H9c1YKPGyqpwAOMdPyqYgtGpY8YHSkQKSOCAR160uULlSZJJ32hmVCcSEHBx6CnmEQp8qgKFxkdsVLBuEag4+bLH8aJWxG2QMUmgKp4O4hgPb0pGl2W/mhcyOcInTcew+n/wBelmyAB64z9KrRMTLNL96OHKJj+91Y/wAh+BpIZFFG8MoJzIAT5kh6s3r/AEA9K1Ipt8wAGVK5xTEAEZPQkBuneoY38lrh2HMahsfQZpLQB8f7ye4nBAGdiH/ZXr+pP5VUvx9oti0g+ZwSOP4AM4/HipclNLCA4fYAc+rdf1JqLUkMW7GTG8MowD0O0UMEM0hBGHdcrk/gRmtGV8REjGxfvHpis3RX22USOcNhVbnJDAYP65q/elWs5w4I+QgkDrST0G9xrTSMQ0DoiEYDFdxOeOAKoM0ltdTGWVWw24/LtO0gc4zjqDViKQqxhJyQdyH+8KS7iS5YM7CPyB8zjnJ/ukdwP50m7gTLdO0YZLZnj7ncAx9wD/8AWp8U6yKxVmGP4TwR9azY2v1by5kMUZ6fZ8M2PfPI+gHHqaJGYXiPHK5boUmXBP6DIo1GEpkuJrlAzBo38lR/vYZm/LA/A1HeuttBcmUfvFxnYOAMAZb0wKqQ3M0ht3t4/wB826SQFsqFZicfXGMVX8ZXEsegS2dorJdX7x20e/BY7slz15OwN7VKdy2Ymj3Bvbu0aePHmTNdsEziSVxlF+irtz9BXUmdmmaK0TfeFcPMPuQp3/8A1daxNL0pl08SM6qx2NHAp7rxgnqcDr07nvXS6b9njtHZVRVGWfjqe/09vahIJNdDPWyFr5s0JDPbqMM33mxywz6EHGP606OYym8DIPkwgwMkY+bOfxFPvHaG0W1QBprkkAL/AAg8sx9gDVyzjXypyDjfI+fwGB/Kn1JvoL5qMigoMnn5jg81m6rFbxP9sCMsjYRxGcFvQnI5x3z2+lW5XXy0MgDJsy+F7Dr+NZM6PIGPmENJGz7JRu8sfwgHI7Hv3NCQloLbzTrcRx3Su+3JRj8q7u4RT0IHryah0/Uo7i7kWNTJtH+jxEbSIs/fb057+gFGrW1xOiaeboRxTA+YyKdyoOuCTwSeM49aqWumzhfMRkluYG+bZldxwMjI5wR/SgtRizYjgVrtZJVWSQqMEnAAycgf49TVq6Ajtpdq5G0kZOR09KZZSJI3mhdoaNcEfj1q0xVlJyBnPGMZoIbGRumMbyD3xxmop0XHzBQp4PzdjUPn+QrI43NDwT0yOxqdboXCAodynlSB6igRnkSxyeW8e6WMDY4fBMfTrUkJiLPv8ze3VS2StT3MLSx5UbGTlWxnHrmqy7Z+UVYbmPr82Sv+Kmhj3J7or5YKD50O8DIyfb8RVS7ia7syIQQ7YMbkn5WByMj9Pzq8k4eMMQA2eehx61Tu1Cky27BX/iTor/X0PuKLCW5FaSC5gWQIqEcMMjKsOq/nU3nhTgNyD0UZNZJuVh1MNEpRJjtlVxysgAxx6MB19q0A6uNqEAdyqjimVKPUlMoOdyPknIZjxTXmd3IYggYxjufpSRBUbAdueOgIJpDHuwUDd8npSIKt28xCgIFTqSDgn2NUL5GktLhHUk7CVXdjkcjgfStSaPK/MmwY7D/Oagdoos70VehwOTjNMpMz7ZUmWJ0Ks4TcpZcgcVMknmCN8bz2Hp78VA0yRO3kxyfZmyQWGfLPp9KdF8wyjh42+bHmYwe5z6UFW6iTxjzScR4zjB+9UdxK0VsxQr5jAhQfX1x2HSmyykJ8iqiKDhpOf5c1UadHYsd77BnJXlyP1x7Uw33GmP5kjCn5RtyeST3bH1plzbxFyZBznr6Yp0TqSzDOXwc+tR6iwRhAwIklAOO4T1P8qA8kVLXcLZZMlWkZnOR0BPH6YpcBGJJyxPPv9ambaSFY9PTtUDKDITuAIzzQUmVL4PMBuO1x0KnFQ5OzOPmAwc96llmA3fN908Cq53EK0gbHTd0H0q0rkttlSaWUKyKoVePer+gXEemazY3k6GRIpA5UAEge3uOtVZCok3DJ+6ffmrugy20fiHT/ALcFFoJh5pf7o9Mj0zjPtTJk9C3c6bYS3MlyPFcYDZcmWOUS+vI9foaz/Fl5DqGqLNA8zxRQxxGWVdr3G1cb2HvW/eai19e3GkeKJLffk+TeRhT9nY8ryvDRngEdutZPj9Ps+qwRbkkMdhbqXjYMhIQdMdaZC3PoBJFIAU5GQPpUsTAAkduOKr7WyjKB0wfenSJJwcgc5bFAD4HBVVYEFMofw/8ArU25C7SAOT61E2/zh8y4kBY4GOR3/WpiTIBjAzS3AqzybYgzdUBJ/Af/AFqrwxtFYIr9Sg3EdyeT+pqfUkY2UwVskITyOKdKGT5cbV4281LQDbcnZsI4Bxk1DfDMNy2B88TDn+8oPH5Z/KrUsJeNWUkP3xzmmuglheInG4H5h1GadgK2qEJb79wVd6An0G4VU1AveRLjLiJw7IucYHVSR3I7U27f7dai1mDRtFGJrhVPcNwPocE1pJCsKxmPCo3QCo6jRlT2yQbri0RfImAZ9vY/3/p0z+dasM5kVUl+WQDPT2puFiiLAYTJJGMhfU/SquBbyLEuChYGIjouf4c+np+VLYe4+8UW0Y3AFU+aBiOT/s/57CqplkiuoIbj/VMfMYjj5vQ/ic/hVzU9ktuqSk7cqxyMEMWABH61BdNsnm+0bW/dpGRtzv6nAH4ikVFmjE+6STcOGOf8moL8o8E0YxINhOG/gPb8fSshtSe13h0lS3I4ncgBfbJPWoY9UAMVvY2011vbzD/CCo56n3xTuHKy5YWbWBW3DtI0CKCx+84Pc+/BFZOrSPeeKbuZbpRb2VisUcRXG2eVgS/PfYMfifWtezm1OQs8y2EMkpGEQvMVA7E/KM1y80WqfYbu686zlkvb+QplCoVVIVSeT8oCY9s0thpXZ1enTxsYSCp8oBMD1Yc/0FZmq3kUd/Ha2/70OwacqRthGeAx6cnGPb8Kw4TPpk13HNCLiR4o7mPZMSq5+XcykA43Aep54rqraFLeBYpUSTzlJlYgYlJ6n/AelK42kmPgs5N0j3C77gDBZV7dgPSlspjho33Kxd+Mc/eNOsFmW1EUcrOEJj8uQ5PB7MORxjrmsYTTR3kwktWBEuwEyjacgHIb8e9VsRual2CodF3hSGzx+dZV7dOkyCWFwI8NLKql12ehA5BOAcEdjzVy6S4kOXmW3GCAY8u2CMfePT8BUFs5gtoxayr5pGSAmSzd8jqfrQCI4dStbiS6uI54mTdgtkYCLx3991WbWRY50digaeMllDjIIOfzwf0rK8PqTbRtfR7Y9zMI3IOxs5O49xk8ema0NTht1MPlRIJJHKjCrwCpyenajzKdr2F0uVYr28w0ZhnbzIwpyBjgj8+fxrUl2yAbtoXBIIODWctnCn2YER+WpKlTGPT/AOtUzRQKyefB5YB+V8DA/HtSRLFuEKLvTDBeHPcqf8DzVe2j+zTz2+1gMh0B7Buo/PNT3PlCGRlySQVBz1z2x3qm9w0F7ljhhCBwTzzQNGgrkjad3tVe5t4bhlZnPmD7rpwR/iPY06K/jkBxMOeMFuaGfcpBYD0z3piaaMtUkgeQSwSOnmH5oh6gH7vUfrThcWxXBaRCOiNGw/pV1kycxn5jwyg43f4VE+PvfXIc5x+FIdzE161N9ZSiyEiXC/Mk0ny4K8jA6tzVjSXWSyt5YldkdQ23pknrmtAMUA2EALz0/QVz/h2VmjurZiV+z3EiKOo2k7h+QahFLVHQ+YxIVIiq9xjj8KiZ5HJRRggfeHQe1IhRTgEuy9ARwaJHzlVB39TnoKZFirKZAGQu29uCQOAPxpkkS7izKDznOc1M8RLB5EVm6gen1pjOm3hNxP8AkmgbGyZZV+UblJxwePwqpLp8UjFnVAxGTtJB/SrTskZ34YuTjGM4/pVcy5nZcMir0BAyaBFOfT7c8AkHr1JzUflqp2iIQsOcgctVyZ24C7xk44HWsq5ncyGKBC8/cY4Qep/w60Fq5Xu5fLYDYXeT7iLxn/Ae9RRW/lkNMQ0snzMw6ewHsKsC38vO5vMlkGGkP9PSpAsYLYBYgY46UxWKjeYHYqoI5/Oqsfm7mMsZ5PO3BrSbB4Xk46VTuFbcdzjJGMjp9KaFexRZdzHEbnnP3ePfvUUqBpc4fMZzgjAPv9asTfKNgO0nPOaQRYVsj5WIOc1YMpSRtlTjHPB/+tTBE88ioqGaRyFVR1Yk4AxWi2GY5AyAf5dqdoNxFBrVk8riJVyu/H3CwIDH6Eg0ITdhG0C2if7NNqVol2ODFhyFPoZANo+vT3rD1KznsZ5LeVGV4uHRznnrwe4rvTC0WuWU7STpLbwrCbFLdmMgVcFUIGxkbk5z/Ec1yHiu4jF/DHuSRre2igkdGypkUcjd3A+7n2pkqTZ9JhsjaQMBeKSNskZUHjvRRQIZkGeNSq4G7H5CnsRuYbQBnHFFFAipenbZSMByEY0XPO09O/5iiipYE6fdX2pJsKu4D5sUUUDMtAJZ9TLDDDkMOowgGPpUkDfaNOgkkA3GMNxkYOKKKhgPspm2jgcgH+dVJW26qloAPs86sWTspA6r6UUUmUivaTyTXEsUp3q8nJPX7gP82Ncnca9fz69FZRyLbi5mdJJol/ebVwMDdkDj2oooHHc6Q6Bp1vexymAzzlMGWdy7dO2ThfwAqhaM0092oZo1WTylCHGFAH+JooqGbHQ2DkW+3jghc/jiuW0id4vDjXICtMrzIpYZwPOaiiqXwmZn+LQdG0zTr6xZhKl2XKscq52k4PfGccAgcCuksrl5NocK3yFxkdDuooqRy6F3R53lWUuFy0jE4GOmBTrFmM1wCxw0zZHboKKKp7GXUW7gh5xEg78Cq9igjhBj+TLNnaAP4jRRTB7ENgWAcbiQWY4Prkj+VVJiRraAEhEhyq9lJPJH5CiioezKXxF95WZrfnHz4/Q08TMo38E8jnkdcUUVXQBMRq5dYIg3XIWq8kubi4JRPlVQOO3NFFALcjWGPy1YIMscmi3uGWeaLClVXcCeoooo6jkMMrPknHTPFQPEjPvYFm2jBJPHtRRQxFgqsecKDwCM9s1iW0hGt6im1drGFyMdypz/ACFFFJFLqaUZLMSWPy8ikuJGi2hD1bBoopollWYt5bHe/HbPBqrFO7KcnjYCR6896KKYyZiI5VRQACOah4CzcZx+v1oooAq6rPIpjRGKhjjI6gY7VmwgecIgNqA9AaKKC1sE3yyMykg4B46UkRyhfoxHJFFFMQ9AMcADjPHFZV0T5pXJ5xzk5HFFFVEhlF3YRRnOcuRzV5XPlA+1FFUORVncxRHYBksFyapyM3AyeKKKESOTU75ozafbblbY5BiWVguOO2cVQMabBxyd3P04FFFMuJ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple pedunculated papules are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irritated skin tag",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37546=[""].join("\n");
var outline_f36_42_37546=null;
var title_f36_42_37547="Compression stockings in chronic venous disorders";
var content_f36_42_37547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Compression stockings in chronic venous disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Class",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pressure",
"      </td>",
"      <td class=\"subtitle1\">",
"       Level of support",
"      </td>",
"      <td class=\"subtitle1\">",
"       Indication",
"      </td>",
"      <td class=\"subtitle1\">",
"       CEAP*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       OTC&bull;",
"      </td>",
"      <td>",
"       &lt;15 mmHg",
"      </td>",
"      <td>",
"       Minimal",
"      </td>",
"      <td>",
"       Asymptomatic individuals as needed for comfort",
"      </td>",
"      <td>",
"       0,1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       15-20 mmHg",
"      </td>",
"      <td>",
"       Mild",
"      </td>",
"      <td>",
"       Minor varicosities, tired aching legs, minor ankle, leg or foot swelling",
"      </td>",
"      <td>",
"       1,2,3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II",
"      </td>",
"      <td>",
"       20-30 mmHg",
"      </td>",
"      <td>",
"       Moderate",
"      </td>",
"      <td>",
"       Moderate to severe varicosities, moderate swelling, phlebitis, following vein ablation",
"      </td>",
"      <td>",
"       3,4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       30-40 mmHg",
"      </td>",
"      <td>",
"       Firm",
"      </td>",
"      <td>",
"       Severe varicosities, severe swelling, management of active ulceration, following DVT, post-surgery",
"      </td>",
"      <td>",
"       4,5,6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       &gt;40 mmHg",
"      </td>",
"      <td>",
"       Extra firm",
"      </td>",
"      <td>",
"       Lymphedema",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Clinical-Etiologic-Anatomic-Physiologic classification of chronic venous disorders.",
"     <br>",
"      &bull; OTC: Over-the-counter, no prescription needed.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37547=[""].join("\n");
var outline_f36_42_37547=null;
var title_f36_42_37548="Headache triggers";
var content_f36_42_37548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Headache triggers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Diet",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chocolate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aged cheeses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Monosodium glutamate (MSG)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspartame (Nutrasweet)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nuts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrites, Nitrates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hormones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ovulation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hormone replacement (progesterone)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Sensory stimuli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Strong light",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flickering lights",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Odors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sounds, noise",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Stress",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Let-down periods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Times of intense activity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Loss or change (death, separation, divorce, job change)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Moving",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crisis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Changes of environment or habits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Weather",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Travel (crossing time zones)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seasons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Altitude",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Schedule changes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sleeping patterns",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dieting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Skipping meals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irregular physical activity",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37548=[""].join("\n");
var outline_f36_42_37548=null;
var title_f36_42_37549="TNM stage hypopharynx";
var content_f36_42_37549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the hypopharynx",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades more than one subsite of hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a lymph node more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.",
"     <br>",
"      &bull; Metastases at level VII are considered regional lymph node metastases.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37549=[""].join("\n");
var outline_f36_42_37549=null;
var title_f36_42_37550="Bone markers and bone loss";
var content_f36_42_37550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    High bone turnover is predictive of rapid bone loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 353px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The probability of rapid loss was calculated from the corresponding logistic regression equation for each marker. At each level, from left to right, the markers were: BAP (red bars), OC (blue bars), DPD (green bars), and PYD (orange bars). The means and SDs were based on all 199 samples.",
"    <div class=\"footnotes\">",
"     BAP: bone specific alkaline phosphatase; OC: osteocalcin; DPD: free deoxypyridinoline; PYD: free pyridinolines.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ross, PD, Knowlton, W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998; 13:297. Copyright &copy;1998 American Society for Bone and Mineral Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37550=[""].join("\n");
var outline_f36_42_37550=null;
var title_f36_42_37551="Cystic renal cell carcinoma CT";
var content_f36_42_37551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan demonstrating cystic renal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single axial contrast-enhanced CT scan through the right kidney demonstrates a large, multiloculated cystic mass containing irregular septations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_42_37551=[""].join("\n");
var outline_f36_42_37551=null;
